<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Molecules</journal-id><journal-id journal-id-type="iso-abbrev">Molecules</journal-id><journal-id journal-id-type="pmc-domain-id">3416</journal-id><journal-id journal-id-type="pmc-domain">molecules</journal-id><journal-id journal-id-type="publisher-id">molecules</journal-id><journal-title-group><journal-title>Molecules</journal-title></journal-title-group><issn pub-type="epub">1420-3049</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11313463</article-id><article-id pub-id-type="pmcid-ver">PMC11313463.1</article-id><article-id pub-id-type="pmcaid">11313463</article-id><article-id pub-id-type="pmcaiid">11313463</article-id><article-id pub-id-type="pmid">39124859</article-id><article-id pub-id-type="doi">10.3390/molecules29153453</article-id><article-id pub-id-type="publisher-id">molecules-29-03453</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Recent Advances on Pt-Based Compounds for Theranostic Applications</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0006-2516-437X</contrib-id><name name-style="western"><surname>Ferrari</surname><given-names initials="G">Giulia</given-names></name><xref rid="af1-molecules-29-03453" ref-type="aff">1</xref><xref rid="fn1-molecules-29-03453" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0006-9057-6047</contrib-id><name name-style="western"><surname>Lopez-Martinez</surname><given-names initials="I">Ines</given-names></name><xref rid="af2-molecules-29-03453" ref-type="aff">2</xref><xref rid="af3-molecules-29-03453" ref-type="aff">3</xref><xref rid="fn1-molecules-29-03453" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0404-4452</contrib-id><name name-style="western"><surname>Wanek</surname><given-names initials="T">Thomas</given-names></name><xref rid="af3-molecules-29-03453" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5988-1434</contrib-id><name name-style="western"><surname>Kuntner</surname><given-names initials="C">Claudia</given-names></name><xref rid="af3-molecules-29-03453" ref-type="aff">3</xref><xref rid="af4-molecules-29-03453" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1034-9623</contrib-id><name name-style="western"><surname>Montagner</surname><given-names initials="D">Diego</given-names></name><xref rid="af1-molecules-29-03453" ref-type="aff">1</xref><xref rid="af5-molecules-29-03453" ref-type="aff">5</xref><xref rid="c1-molecules-29-03453" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Lucaciu</surname><given-names initials="RL">Roxana Liana</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Hangan</surname><given-names initials="AC">Adriana Corina</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-molecules-29-03453"><label>1</label>Department of Chemistry, Maynooth University, W23 F2H6 Maynooth, Ireland</aff><aff id="af2-molecules-29-03453"><label>2</label>Division of Nuclear Medicine, Department of Biomedical Imaging and Image&#8211;Guided Therapy, Medical University of Vienna, 1090 Vienna, Austria</aff><aff id="af3-molecules-29-03453"><label>3</label>Preclinical Imaging Lab (PIL), Department of Biomedical Imaging and Image&#8211;Guided Therapy, Medical University of Vienna, 1090 Vienna, Austria; <email>thomas.wanek@meduniwien.ac.at</email> (T.W.); <email>claudia.kuntner@meduniwien.ac.at</email> (C.K.)</aff><aff id="af4-molecules-29-03453"><label>4</label>Medical Imaging Cluster (MIC), Medical University of Vienna, 1090 Vienna, Austria</aff><aff id="af5-molecules-29-03453"><label>5</label>Kathleen Londsdale Institute for Human Health Research, Maynooth University, W23 F2H6 Maynooth, Ireland</aff><author-notes><corresp id="c1-molecules-29-03453"><label>*</label>Correspondence: <email>diego.montagner@mu.ie</email></corresp><fn id="fn1-molecules-29-03453"><label>&#8224;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>23</day><month>7</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>8</month><year>2024</year></pub-date><volume>29</volume><issue>15</issue><issue-id pub-id-type="pmc-issue-id">468570</issue-id><elocation-id>3453</elocation-id><history><date date-type="received"><day>02</day><month>7</month><year>2024</year></date><date date-type="rev-recd"><day>19</day><month>7</month><year>2024</year></date><date date-type="accepted"><day>20</day><month>7</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>23</day><month>07</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>10</day><month>08</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-08-28 18:25:13.523"><day>28</day><month>08</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="molecules-29-03453.pdf"/><abstract><p>Since the discovery of cisplatin&#8217;s antitumoral activity and its approval as an anticancer drug, significant efforts have been made to enhance its physiological stability and anticancer efficacy and to reduce its side effects. With the rapid development of targeted and personalized therapies, and the promising theranostic approach, platinum drugs have found new opportunities in more sophisticated systems. Theranostic agents combine diagnostic and therapeutic moieties in one scaffold, enabling simultaneous disease monitoring, therapy delivery, response tracking, and treatment efficacy evaluation. In these systems, the platinum core serves as the therapeutic agent, while the functionalized ligand provides diagnostic tools using various imaging techniques. This review aims to highlight the significant role of platinum&#8211;based complexes in theranostic applications, and, to the best of our knowledge, this is the first focused contribution on this type of platinum compounds. This review presents a brief introduction to the development of platinum chemotherapeutic drugs, their limitations, and resistance mechanisms. It then describes recent advancements in integrating platinum complexes with diagnostic agents for both tumor treatment and monitoring. The main body is organized into three categories based on imaging techniques: fluorescence, positron emission tomography (PET), single&#8211;photon emission computed tomography (SPECT), and magnetic resonance imaging (MRI). Finally, this review outlines promising strategies and future perspectives in this evolving field.</p></abstract><kwd-group><kwd>platinum chemotherapy</kwd><kwd>theranostic</kwd><kwd>molecular imaging</kwd><kwd>cancer therapy</kwd><kwd>therapy monitoring</kwd></kwd-group><funding-group><award-group><funding-source>STRIKE project HORIZON-MSCA-2021-DN-01</funding-source><award-id>101072462</award-id></award-group><funding-statement>This research was funded by the STRIKE project HORIZON-MSCA-2021-DN-01, grant number 101072462.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-molecules-29-03453"><title>1. Introduction</title><p>Cis-dichlorodiammine platinum(II), commonly known as cisplatin, is one of the most known and worldwide used chemotherapy agent for the treatment of several kinds of cancers in adults. The fortunate and accidental discovery of anticancer properties in 1965 by B. Rosenberg, followed by the Food and Drug Administration (FDA) approval (1978), triggered extensive research in this field, leading to the development of novel therapeutics based on a metallic scaffold. As a result, platinum(II) complexes have emerged as the most successful category of metal&#8211;based anticancer drugs, receiving enormous attention for over half a century [<xref rid="B1-molecules-29-03453" ref-type="bibr">1</xref>,<xref rid="B2-molecules-29-03453" ref-type="bibr">2</xref>].</p><p>Unfortunately, the use of cisplatin is limited due to severe dose-limiting side effects which arise from the drug&#8217;s indiscriminate uptake by all rapidly dividing cells, coupled with the body&#8217;s attempt to eliminate the exogenous drug through the kidneys. These adverse effects include nephrotoxicity, neurotoxicity, ototoxicity, myelosuppression, intrinsic/acquired therapy resistance, and the inconvenient intravenous administration route [<xref rid="B3-molecules-29-03453" ref-type="bibr">3</xref>,<xref rid="B4-molecules-29-03453" ref-type="bibr">4</xref>].</p><sec id="sec1dot1-molecules-29-03453"><title>1.1. Mechanism of Action of Cisplatin and Resistance Mechanisms</title><p>The action mechanism of cisplatin is nowadays well known (<xref rid="molecules-29-03453-f001" ref-type="fig">Figure 1</xref>). Cellular absorption relies on a combination of passive diffusion through the plasma membrane and active transport facilitated by membrane proteins, specifically copper transporter ions and organic cation transporters. Notably, transmembrane copper transport protein 1 (CTR1) is involved in copper homeostasis and cisplatin uptake. Indeed, downregulation of CTR1 is frequently observed in cisplatin-resistant cells, contributing to poor therapeutic responses in non&#8211;small cell lung cancer (NSCLC) patients [<xref rid="B5-molecules-29-03453" ref-type="bibr">5</xref>].</p><p>On the other hand, copper-extruding P-type ATPases (ATP7A and ATP7B) regulate cisplatin export [<xref rid="B6-molecules-29-03453" ref-type="bibr">6</xref>]. These transporters are observed to be upregulated in cisplatin-resistant cancer cells and high levels of ATP7A and ATP7B are associated with significantly poorer overall survival in patients with ovarian cancer and ovarian carcinoma, respectively [<xref rid="B7-molecules-29-03453" ref-type="bibr">7</xref>,<xref rid="B8-molecules-29-03453" ref-type="bibr">8</xref>]. Following intravenous administration of cisplatin, its intracellular activation relies on the drug&#8217;s high tendency to undergo aquation where one or both chloride ligand(s) are replaced by one or two molecules of water. This reaction is facilitated by the square planar geometry of cisplatin and is further promoted by the lower chloride concentration in the cytoplasm (4&#8211;20 mM) compared to the bloodstream (100 mM). These reactive cisplatin species (mono-aquo and di-aquo complexes) are then prone to bind to cytoplasmic S-containing nucleophiles, such as glutathione (GSH), metallothioneins and other cysteine-rich proteins. Indeed, high levels of glutathione, glutathione-S-transferase or &#947;-glutamyl cysteine synthetase have been observed in cisplatin-resistant cells [<xref rid="B9-molecules-29-03453" ref-type="bibr">9</xref>,<xref rid="B10-molecules-29-03453" ref-type="bibr">10</xref>,<xref rid="B11-molecules-29-03453" ref-type="bibr">11</xref>]. The activated platinum complexes, carrying positive charges, will also establish interactions with negatively charged DNA. Through this mechanism, cisplatin covalently binds preferentially to the N7 position of guanine nucleobase and to a lesser extent, adenine. Several DNA-Pt adducts have been identified, with the major ones being the cross-links between two adjacent guanines, (intrastrand DNA) and between two guanine bases from different DNA strands (interstrand adducts). These adducts induce a distortion in the DNA structure ranging from 10 to 60 degrees towards the major groove and unwind the helix by up to 23 degrees [<xref rid="B12-molecules-29-03453" ref-type="bibr">12</xref>,<xref rid="B13-molecules-29-03453" ref-type="bibr">13</xref>], hindering both replication and transcription, ultimately leading to apoptotic cell death. Several protein families are involved in the recognition of Pt-DNA adducts that finally lead to cisplatin-resistant mechanisms, including nucleotide excision repair (NER) proteins, mismatch repair (MMR) proteins and non-histone chromosomal high-mobility group protein 1 (HMGB1). Cisplatin resistance mechanisms can be classified as pre-target (alterations in cisplatin transport before DNA binding), on-target (repair of Pt-DNA lesions), post-target (cellular events occurring after formation of DNA-Pt adducts) and off-target (alterations in signaling pathways indirectly hindering cisplatin-induced proapoptotic events) [<xref rid="B14-molecules-29-03453" ref-type="bibr">14</xref>]. <xref rid="molecules-29-03453-t001" ref-type="table">Table 1</xref> reports the major resistance mechanisms associated with cisplatin chemotherapy.</p><p>To circumvent clinical cisplatin resistance and side effects, several platinum analogues with diverse structural motifs have been developed and explored for their antitumor properties. While some exhibit promising in vitro and in vivo biological activity, the translation to clinic for most of these species has been hindered by various challenges [<xref rid="B1-molecules-29-03453" ref-type="bibr">1</xref>].</p><p>Besides cisplatin, two more platinum(II)-based anticancer drugs received approval by FDA, carboplatin and oxaliplatin, called the &#8220;second generation of Pt chemotherapeutics&#8221;, which showed a higher physiological stability due to the chelate ligand(s) (<xref rid="molecules-29-03453-f002" ref-type="fig">Figure 2</xref>) [<xref rid="B36-molecules-29-03453" ref-type="bibr">36</xref>]. In addition, four more platinum(II) complexes have received approval for human use (<xref rid="molecules-29-03453-f002" ref-type="fig">Figure 2</xref>). Nedaplatin, a second-generation drug, has been approved in Japan for the treatment of NSCLC, small cell lung cancer (SCLC), esophageal cancer, and head and neck cancers. It demonstrates higher activity than carboplatin and comparable efficacy to cisplatin. Heptaplatin is approved in South Korea for the treatment of gastric cancer. More recently, in 2009, Miriplatin was approved in Japan for treating hepatocellular carcinoma [<xref rid="B37-molecules-29-03453" ref-type="bibr">37</xref>,<xref rid="B38-molecules-29-03453" ref-type="bibr">38</xref>], and Lobaplatin was approved in China for the treatment of chronic myelogenous leukemia, inoperable metastatic breast cancer and SCLC. Most of the previously mentioned drugs offer advantages over cisplatin, such as drug resistance alleviation, toxicity and side effects mitigation, and water solubility improvement.</p></sec><sec id="sec1dot2-molecules-29-03453"><title>1.2. Pt(IV) Complexes to Improve Cytotoxicity and to Overcome Resistance</title><p>In the last two decades, a lot of scientific interest has moved toward the synthesis and application of Pt(IV) species. These complexes are prodrugs because they must be intracellularly activated by reduction, releasing the active Pt(II) scaffold and restoring their latent cytotoxic activity [<xref rid="B39-molecules-29-03453" ref-type="bibr">39</xref>]. Pt(IV) complexes are prepared by oxidative addition of the square planar Pt(II) complexes to yield the octahedral complex while retaining the original Pt(II) equatorial coordination sphere. The major advantage of Pt(IV) species is their higher stability and lower reactivity toward S-containing nucleophiles, as a result of the octahedral geometry (d<sup>6</sup> low-spin electronic configuration) compared to the square planar Pt(II) counterparts (d<sup>8</sup>). The combination of two extra axial ligands to fine-tune chemical properties and high kinetic inertness to substitution reactions have turned Pt(IV) complexes into promising anticancer drug candidates. To date, three Pt(IV) compounds (tetraplatin, iproplatin and satraplatin) have undergone clinical trials, but none have gained clinical approval yet (<xref rid="molecules-29-03453-f003" ref-type="fig">Figure 3</xref>). Tetraplatin was abandoned due to severe neurotoxicity, while iproplatin demonstrated lower activity compared with carboplatin and cisplatin. Satraplatin, the first orally administered platinum(IV) complex, exhibited documented efficacy and acceptable safety in patients with hormone-refractory prostate cancer and small-cell lung cancer. Despite this, it failed to gain FDA approval due to the low convincing benefits in terms of overall survival [<xref rid="B4-molecules-29-03453" ref-type="bibr">4</xref>,<xref rid="B40-molecules-29-03453" ref-type="bibr">40</xref>].</p><p>The axial ligands of the Pt(IV) complexes can be viewed as cargos that the cytotoxic Pt(II) moiety unloads inside the cell. These ligands can play various roles, serving as passive uptake enhancers (lipophilic moieties) on cancer cells or subcellular targeting agents. Additionally, they can be designed to tether the prodrug to delivery system like polymers or nanoparticles. They can also be bioactive moieties such as other drugs, enzyme inhibitors, pathway activators or suppressor, epigenetic modifiers, and antimetabolites. The integration of these ligands aims to synergistically enhance the pharmacological properties in conjunction with the Pt(II) moiety [<xref rid="B2-molecules-29-03453" ref-type="bibr">2</xref>].</p></sec><sec id="sec1dot3-molecules-29-03453"><title>1.3. Translation to Theranostics</title><p>Besides the therapeutic properties, an appropriate functionalization of the Pt-based species can play an important role in the diagnostic detection of cancer. Through modification with biocompatible nanomaterials or appropriate functional ligands, the therapeutic units may have the potential to evolve into theranostic agents, offering simultaneously therapeutic and diagnostic applications [<xref rid="B41-molecules-29-03453" ref-type="bibr">41</xref>].</p><p>The term &#8220;theranostic&#8221; (syn: theragnostic) has been coined to describe platforms that serve dual roles as diagnostic and therapeutic agents. A broader definition has also been proposed, referring to an integrated therapeutic system, which can diagnose, deliver targeted therapy, and track the response to therapy. Indeed, the idea is that theranostic agents could provide the ability to simultaneously monitor the disease and the efficacy of the treatment [<xref rid="B42-molecules-29-03453" ref-type="bibr">42</xref>]. This combination promises to create a paradigm shift in individual patient care through an appropriate diagnostic methodology with an optimized treatment strategy to personalize a separate therapeutic intervention [<xref rid="B43-molecules-29-03453" ref-type="bibr">43</xref>].</p><p>This emerging field in personalized medicine is guided by ligands targeting malfunctioning cells. In the realm of cancer theranostics, diverse strategies involving nanomaterials, metal complexes or small molecules have been developed. As an example, metallic, lipidic and polymer nanoparticles exhibit a variety of biological characteristics that can be used for theranostic purposes. While clinical approval for the use of nanomaterials as transport vehicles has been longstanding, clinical translation of nanomaterial-based theranostic systems from bench to bedside has faced major hurdles [<xref rid="B44-molecules-29-03453" ref-type="bibr">44</xref>].</p><p>In this review, our primary focus lies in exploring different strategies for the integration of Pt complexes with diagnostic probes to obtain theranostic systems. According to the design goals, we divided them into three categories depending on the main imaging techniques used in combination with the anticancer drug: (i) optical imaging (fluorescence), (ii) positron emission tomography (PET) and single-photon emission computed tomography (SPECT) and (iii) magnetic resonance imaging (MRI). The applications, advantages, and disadvantages of these commonly used imaging techniques are summarized in <xref rid="molecules-29-03453-t002" ref-type="table">Table 2</xref>. Every imaging modality will be discussed in more detail in the subsequent sections and their application as Pt-based theranostic agents.</p></sec></sec><sec id="sec2-molecules-29-03453"><title>2. Illuminating Disease through Fluorescence Imaging</title><p>Fluorescence imaging is a non-invasive technique that allows for the monitoring of the dynamics of luminescent molecules within cells or small animals, offering high sensitivity and excellent temporal resolution. A targeted biological compound is exposed to a specific radiation (absorption) and the subsequent emitted light (emission) is captured for analysis. Utilizing standard infrastructure like a charged-couple device (CCD) camera and a light source, fluorescence imaging proves to be a cost-effective method (<xref rid="molecules-29-03453-f004" ref-type="fig">Figure 4</xref>) [<xref rid="B47-molecules-29-03453" ref-type="bibr">47</xref>]. Additionally, its remarkable sensitivity capable of detecting concentrations as low as picomolar to femtomolar levels enables the visualization of individual molecules and facilitates the tracking of biological processes. Unlike imaging techniques involving the detection of high-energy gamma rays such as PET and SPECT, fluorescence imaging operates with low-energy photons, ensuring its safety for both samples and operators. However, a significant limitation of this technique lies in its restricted tissue penetration, thereby impeding optical imaging of probes in deep tissues or large subjects, consequently hindering its clinical translation [<xref rid="B48-molecules-29-03453" ref-type="bibr">48</xref>].</p><p>A persisting challenge when studying Pt-based drugs in vitro and/or in vivo is that there are a few spectroscopic techniques available for detecting their faith. The main techniques employed to measure and quantify the cellular internalization of Pt-based samples in cells are Graphite Furnace Atomic Absorption Spectrometry (GFAAS) and Inductively Coupled Plasma Mass Spectrometry (ICP-MS) analysis [<xref rid="B49-molecules-29-03453" ref-type="bibr">49</xref>,<xref rid="B50-molecules-29-03453" ref-type="bibr">50</xref>] but, unfortunately, no information regarding speciation and cellular localization could be obtained. To address these challenges, several Pt complexes containing tethered fluorophores have been generated to evaluate its pharmacokinetic behavior. This assessment covers organ accumulation, systemic circulation time, intracellular target, and excretion patterns.</p><p>Most of these compounds retained the traditional structure&#8211;activity requirements for Pt(II) anticancer compounds (square planar complexes with leaving groups and amines in <italic toggle="yes">cis</italic> orientation) [<xref rid="B51-molecules-29-03453" ref-type="bibr">51</xref>]. Initial investigations involved linking cisplatin with fluorophores such as fluorescein (<bold>1</bold>) [<xref rid="B52-molecules-29-03453" ref-type="bibr">52</xref>] carboxyfluorescein diacetate (CFDA), (<bold>2</bold>), 6-(2,4-dinitrophenyl)aminohexanoic acid (DNP), (<bold>3</bold>) [<xref rid="B53-molecules-29-03453" ref-type="bibr">53</xref>], and Alexa [<xref rid="B54-molecules-29-03453" ref-type="bibr">54</xref>] (<xref rid="molecules-29-03453-f005" ref-type="fig">Figure 5</xref>). These complexes have been used to monitor the distribution of cisplatin in human ovarian carcinoma, human osteosarcoma, and human cervical carcinoma cells, respectively. Remarkably, they demonstrated swift accumulation of fluorophore-cisplatin analogues in the nucleus, succeeded by sequestration within Golgi vesicles. More recent works described a series of Pt-based complexes tethered to boron-dipyrromethene (BODIPY) [<xref rid="B55-molecules-29-03453" ref-type="bibr">55</xref>,<xref rid="B56-molecules-29-03453" ref-type="bibr">56</xref>,<xref rid="B57-molecules-29-03453" ref-type="bibr">57</xref>] (<xref rid="molecules-29-03453-f005" ref-type="fig">Figure 5</xref>). This family of fluorophores has gained considerable interest in bioimaging because of their high absorption coefficients, sharp emission, high fluorescence quantum yields and excellent chemical and photostability. Both <bold>4</bold> and <bold>5</bold> showed primarily cytosolic localization, with nuclear distribution observed only at higher concentrations [<xref rid="B55-molecules-29-03453" ref-type="bibr">55</xref>]. Regarding compound <bold>6</bold>, colocalization experiments with commercially available mitochondria-specific dye (MitoTracker) revealed its predominantly localization in the mitochondria, while nuclear colocalization remained indiscernible [<xref rid="B56-molecules-29-03453" ref-type="bibr">56</xref>]. Moreover, in vivo pharmacokinetics studies of these compounds have also been conducted. Using a window chamber tumor model, which enables simultaneous time-course fluorescence microscopy of the fluorescent drug in both mouse vasculature and tumor tissue, <bold>7</bold> showed plasma kinetics comparable to cisplatin. Furthermore, high-resolution intravital imaging was employed to monitor DNA damage in individual tumor cells following administration. The study focused on the fluorescence signal of 53BP1 puncta, which are markers of DNA damage response within the cells. No linear correlation was observed between the fluorescence signal of these 53BP1 puncta and the accumulation of the drug CP11, indicating potential heterogeneity in the cells&#8217; drug response [<xref rid="B57-molecules-29-03453" ref-type="bibr">57</xref>].</p><p>Nevertheless, incorporating a fluorophore into a small inorganic complex can significantly modify its physicochemical properties and biological activity. Such an approach must consider the organelle selectivity of the fluorophore, which may vary depending on parameters such as molecular weight, partition coefficient, amphiphilic character and pK<sub>a</sub> values [<xref rid="B58-molecules-29-03453" ref-type="bibr">58</xref>]. Thus, it is uncertain if fluorescent analogues accurately model cisplatin&#8217;s cellular behavior, and, likewise, bulky fluorophores may interfere with DNA binding mechanisms of platinum. Furthermore, some of them, and in particular BODIPY, can generate ROS (Reactive Oxygen Species) under irradiation that can potentially interfere with the cell damage mechanism. Notably, none of the previous Pt-fluorophore complexes showed significant nuclear localization.</p><p>To address these limitations and to allow for a &#8220;label-free&#8221; study of Pt drug fate, several exogeneous fluorophores have been synthesized to investigate the speciation of platinum anticancer drugs. For example, FCDPt1 (<xref rid="molecules-29-03453-f006" ref-type="fig">Figure 6</xref>) is a fluorescein-based probe linked to dithiocarbamic acid moiety which selectively identifies platinum species [<xref rid="B59-molecules-29-03453" ref-type="bibr">59</xref>]. Similarly, RPt1, a rhodamine-based probe incorporating phenyl isothiocyanate, has been developed for studying metabolism of trans-Pt complexes [<xref rid="B60-molecules-29-03453" ref-type="bibr">60</xref>]. Furthermore, Rho-DDTC was the first rhodamine-based fluorescent turn-on probe designed to distinguish between Pt(II) and Pt(IV) complexes upon intracellular reduction [<xref rid="B61-molecules-29-03453" ref-type="bibr">61</xref>,<xref rid="B62-molecules-29-03453" ref-type="bibr">62</xref>]. Following this discovery, numerous analogues were developed to enhance fluorescence intensity and sensitivity of these probe [<xref rid="B63-molecules-29-03453" ref-type="bibr">63</xref>,<xref rid="B64-molecules-29-03453" ref-type="bibr">64</xref>]. Probe RD640-TC was developed as the first tool for in vivo tracking of cisplatin due to its remarkable characteristics such as high fluorescence quantum yield (&#934; = 0.68), two-photon absorption properties (enabling greater penetration depth) and high photostability (<xref rid="molecules-29-03453-f006" ref-type="fig">Figure 6</xref>) [<xref rid="B65-molecules-29-03453" ref-type="bibr">65</xref>].</p><p>More examples of turn-on probes include the work by Lippard et al. [<xref rid="B66-molecules-29-03453" ref-type="bibr">66</xref>], who synthesized two analogues of fluorescein conjugated to cisplatin Pt(IV) prodrugs, <bold>8</bold> and <bold>9</bold>, and that of Bin Liu et al. [<xref rid="B39-molecules-29-03453" ref-type="bibr">39</xref>], who developed a cisplatin Pt(IV) prodrug conjugated to an aggregation-induced emission (AIE) luminogen (<bold>10</bold>). In both cases, the reduction of Pt(IV) to Pt(II) within the cellular environment was monitored by the release of fluorescein ligands and luminogen, respectively. Additionally, Bin Liu et al. incorporated a short hydrophilic peptide to ensure water solubility and a cyclic arginine-glycine-aspartic acid (cRGD) tripeptide as a targeting ligand (<xref rid="molecules-29-03453-f007" ref-type="fig">Figure 7</xref>).</p><p>To promote the clinical translation of fluorophores, both near infrared NIR-I (700&#8211;900 nm) and NIR-II dyes (1000&#8211;1700 nm) have emerged as imaging tools to afford precise dynamic actions in vivo with high spatiotemporal resolution, deeper penetration and decreasing light absorption and scattering (<xref rid="molecules-29-03453-t003" ref-type="table">Table 3</xref>) [<xref rid="B67-molecules-29-03453" ref-type="bibr">67</xref>,<xref rid="B68-molecules-29-03453" ref-type="bibr">68</xref>].</p><p>Among these, gold nanoclusters (AuNCs) stand out for their remarkable properties: excellent biocompatibility, size below the renal excretion threshold, robust photostability, facile modification, and excellent photothermal activity [<xref rid="B69-molecules-29-03453" ref-type="bibr">69</xref>]. In a study conducted by Li et al., AuNCs were coupled with Pt(IV)-cisplatin and folic acid (FA), enabling not only fluorescence imaging but also targeted chemotherapy for breast cancer (<xref rid="molecules-29-03453-f008" ref-type="fig">Figure 8</xref>). Biodistribution analysis revealed that FA-modified AuNC-Pt nanoparticles demonstrated high tumor uptake, effectively evaded reticuloendothelial system (RES) capture, and facilitated renal clearance [<xref rid="B70-molecules-29-03453" ref-type="bibr">70</xref>].</p><p>Similar studies were carried out by Zhiqiang Yu et al., who reported a cisplatin delivery platform based on AuNCs. The results showed that not only AuNCs-Pt does effectively bind glutathione (GSH) via Au-S bonds, scavenging intracellular GSH and thereby facilitating increased internalization of cisplatin, leading to enhanced anticancer activity, but also that the unique NIR-II imaging capability of AuNCs-Pt enables precise visualization of Pt transport in both ovarian and hepatocellular carcinoma tumor models. Importantly, in vivo NIR-II imaging revealed that AuNCs-Pt exhibited significantly superior tumor growth inhibition compared to cisplatin while inducing minimal systemic toxicity, underscoring its potential as a highly effective theranostic agent [<xref rid="B71-molecules-29-03453" ref-type="bibr">71</xref>].</p><p>Another class of NIR-I fluorescent probes are conjugated polymers, which are promising for their high brightness and low toxicity. Bin Liu et al. employed conjugated polyelectrolytes (CPE) grafted with polyethylene glycol (PEG) chains to load cisplatin for targeted in vitro and in vivo NIR imaging. These nanoparticles enable sustained cisplatin release, enhancing internalization. While these nanoparticles hold potential for liver cancer applications due to their high accumulation in RES, further optimization of their physical and chemical properties is needed for broader cancer imaging and chemotherapy applications [<xref rid="B72-molecules-29-03453" ref-type="bibr">72</xref>].</p><p>It has been well known that Pt(II) metallacycles-based supramolecular coordination complexes can act as anticancer agents; however, poor photostability, low tumor uptake and penetration depth limited the in vivo antitumor applications [<xref rid="B73-molecules-29-03453" ref-type="bibr">73</xref>]. Recently, Stang et al. designed a NIR-II theranostic nanoprobe that incorporates a Pt(II) metallacycle and an organic molecular dye (benzobisthiadiazole) into DSPE-mPEG500 to enhance stability and biocompatibility of the theranostic agent in vivo (<xref rid="molecules-29-03453-f009" ref-type="fig">Figure 9</xref>). Compared to cisplatin, this NIR-II theranostic agent displayed better efficiency of tumor growth inhibition and prolonged blood circulation, as well as reduced systemic toxicity [<xref rid="B74-molecules-29-03453" ref-type="bibr">74</xref>].</p><p>In a parallel investigation, Han et al. employed a benzobisthidiazole-based NIR II imaging probe (TQTPA) to synthesize multimodal nanoparticles loaded with both TQTPA and cisplatin using hyaluronic acid, enabling active targeting and enhanced accumulation in tumor tissue. The therapeutic efficacy of this chemo-photothermal synergistic approach was assessed in a mouse model. Upon irradiation, the tumor site temperatures significantly exceeded those of the negative control. Moreover, after 13 days of treatment, tumor volume decreased by 83% compared to the untreated control group [<xref rid="B75-molecules-29-03453" ref-type="bibr">75</xref>].</p><p>BODIPY fluorophores can also be used for NIR imaging by implementing &#960;-conjugated structures (red-shifted absorbance), (<xref rid="molecules-29-03453-f010" ref-type="fig">Figure 10</xref>). In this way, Zhigang Xie et al. synthesized compound <bold>11</bold> (&#955;<sub>abs</sub> = 645 nm, &#955;<sub>em</sub> = 674 nm), demonstrating its internalization in HepG2 cells and localization within mitochondria. Through MTT assays, <bold>11</bold> showed comparable cytotoxicity to cisplatin in HepG2 and HeLa cells. Through NIR imaging, <bold>11</bold> was localized at tumor sites four hours post-injection [<xref rid="B76-molecules-29-03453" ref-type="bibr">76</xref>]. Following this work, Minhuan Lan et al. further enhanced NIR imaging capabilities by synthesizing a NIR cisplatin-appended BODIPY fluorophore (<bold>12</bold>) with greater red-shifted absorption (&#955;<sub>abs</sub> = 748 nm, &#955;<sub>em</sub> = 947 nm) through the incorporation of N,N-dimethylaniline into BODIPY (<xref rid="molecules-29-03453-f010" ref-type="fig">Figure 10</xref>) [<xref rid="B77-molecules-29-03453" ref-type="bibr">77</xref>].</p><p>Quantum dots (QDs) are renowned for their distinct optical features like good photostability, large Stokes shift, and high fluorescence quantum yields. In a study by Rylander et al., a novel hybrid system was developed, comprising self-assembled single-walled carbon nanohorns (SWNHs) loaded with cisplatin and adorned with CdSe/ZnS quantum dots on their exterior. Through fluorescence imaging, SWNHs&#8211;QD+cis hybrids were tracked in rat bladder transitional carcinoma cells after 72 h incubation. These images helped to validate the mechanism of continued cell death over 72 h as well as the compound&#8217;s internalization and cisplatin delivery on the nucleus over time [<xref rid="B78-molecules-29-03453" ref-type="bibr">78</xref>]. However, a significant drawback of metal-based quantum dots lies in their inherent toxicity. Indeed, the previous work assessed cell viability using SWNHs as a negative control but did not include evaluation with SWNHs+QDs. Consequently, graphene quantum dots (GQDs) have emerged as alternative, non-toxic nanocarriers with superior biocompatibility and fluorescent properties. As an example, Sierin Lim et al. designed GQDs functionalized with anti-epidermal growth factor receptor antibodies and loaded with cisplatin, achieving targeted delivery of cisplatin in breast cancer cells, as validated through fluorescence imaging [<xref rid="B79-molecules-29-03453" ref-type="bibr">79</xref>]. Moreover, GQDs offer the possibility to fine-tune their optical properties, enabling the development of NIR-II imaging QDs for in vivo NIR imaging-guided photothermal therapy [<xref rid="B80-molecules-29-03453" ref-type="bibr">80</xref>]. This platform could also be coupled with cisplatin/Pt(IV) prodrugs delivery for multimodal therapeutic applications. <xref rid="molecules-29-03453-t003" ref-type="table">Table 3</xref> highlights the advantages, disadvantages, applications and future research on the NIR-fluorophores mentioned in this section [<xref rid="B81-molecules-29-03453" ref-type="bibr">81</xref>,<xref rid="B82-molecules-29-03453" ref-type="bibr">82</xref>].</p><table-wrap position="anchor" id="molecules-29-03453-t003" orientation="portrait"><object-id pub-id-type="pii">molecules-29-03453-t003_Table 3</object-id><label>Table 3</label><caption><p>Summary of the advantages, disadvantages, applications and future research on the NIR-fluorophores mentioned in this chapter [<xref rid="B81-molecules-29-03453" ref-type="bibr">81</xref>,<xref rid="B82-molecules-29-03453" ref-type="bibr">82</xref>].</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">NIR <break/>Fluorophores</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Advantages</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Disadvantages</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Applications</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Future Research</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AuNCs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Easy surface <break/>modification.<break/>High biocompatibility.<break/>Large Stokes shift.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Photobleaching.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bioimaging and <break/>therapeutic <break/>applications.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Escaping recognition by<break/>immune system.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Conjugated <break/>polymers</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High brightness.<break/>Low toxicity.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Limitation of excitation and emission wavelengths (&lt;900 nm).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Photoacoustic <break/>imaging.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increase polymer&#8217;s conjugation degree to shift spectra towards NIR-II window.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Benzobisthiadizole</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Large Stokes shifts.<break/>High imaging quality.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Photobleaching.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Probes for clinical<break/>translation.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Design of new materials for NIR-II imaging.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BODIPYs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High quantum yields.<break/>Excellent photostability.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Poor water solubility.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vivo visualization<break/>of tumors.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reducing bandgap of fluorophores to bathochromic shift wavelength enhancing <break/>hydrolytic stability.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">QDs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High quantum yield.<break/>Good photostability.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Toxicity.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro evaluation.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Design of non-toxic QDs for in vivo NIR imaging.</td></tr></tbody></table></table-wrap></sec><sec id="sec3-molecules-29-03453"><title>3. Pioneering Platinum-Radiopharmaceuticals for SPECT and PET Imaging</title><p>SPECT/PET are radionuclide molecular imaging modalities that allow for the real-time monitoring of drugs&#8217; distribution within the body as well as non-invasive monitoring of their therapeutic efficacy [<xref rid="B83-molecules-29-03453" ref-type="bibr">83</xref>]. The fundamental principle of SPECT is the administering of a radiotracer-containing imaging agent (such as a peptide, protein, or nanoparticle) with a gamma-emitting radioisotope (Technetium-99m, Iodine-123, Thallium-201) to the patient. Subsequently, gamma rays emitted by the tracer are captured by a rotating gamma camera, which collects data from various angles to facilitate tomographic reconstruction. On the other hand, PET employs positron-emitting radioisotopes, such as fluorine-18, Gallium-68, Copper-64, Zirconium-89. Positrons emitted by the tracer will then collide with electrons in the surrounding tissues, a phenomenon known as annihilation, which results in the creation of two gamma rays, each with an energy of 511 keV, moving in opposite directions. The PET detector detects these gamma rays which determine the location of annihilation event. The resulting electrical signals are then converted into sinograms, which are further reconstructed into detailed tomographic images (<xref rid="molecules-29-03453-f011" ref-type="fig">Figure 11</xref>) [<xref rid="B47-molecules-29-03453" ref-type="bibr">47</xref>]. While both techniques are similar, PET exhibits significantly higher sensitivity, typically ranging from two to three orders of magnitude greater than that of SPECT [<xref rid="B84-molecules-29-03453" ref-type="bibr">84</xref>].</p><p>The development of smart molecules, possessing both therapeutic and diagnostic properties, holds the potential to revolutionize cancer therapy by enhancing efficiency and safety. The simplest examples of such theranostics are the radioactive forms of cisplatin (<bold>CDDP</bold>) and carboplatin (<bold>CP</bold>) such as <sup>191</sup>Pt/<sup>195m</sup>Pt-CDDP, <sup>195m</sup>Pt-CP, <sup>18</sup>F-FCP (a derivative of carboplatin) and <sup>13</sup>N-CDDP (<xref rid="molecules-29-03453-f012" ref-type="fig">Figure 12</xref>).</p><p>Among the four radioactive isotopes of Pt (Platinum-191, Platinum-193m, Platinum-195m, Platinum-197), Platinum-195m has gained special attention over the years due to its ease of production, ideal gamma energy spectrum (similar toThallium-201) and appropriate half-life (4 days) for efficient synthesis, quality control and in vivo radio-imaging (<xref rid="molecules-29-03453-t004" ref-type="table">Table 4</xref>).</p><p>The synthesis of Platinum-195m has been well established [<xref rid="B85-molecules-29-03453" ref-type="bibr">85</xref>,<xref rid="B86-molecules-29-03453" ref-type="bibr">86</xref>], and relies on the thermal neutron irradiation of <sup>194</sup>Pt with yields ranging from 60 to 90%. More recently, an alternative preparation method has been introduced to enhance the specific activity of Platinum-195m. This method involves irradiating <sup>197</sup>Au with breaking radiation. Notably, this novel approach has demonstrated a remarkable 37,000-fold increase in specific activity over a span of 25 years [<xref rid="B87-molecules-29-03453" ref-type="bibr">87</xref>].</p><p>Platinum-195m is not a pure gamma emitter, as each disintegration also releases 36 auger electrons that deposit large amounts of energy (around 25 keV) within nanometer-micrometer distances in tissues. Therefore, integration of cisplatin to Platinum-195m emerges as a versatile platform, offering the potential for both enhanced therapeutic effects and tumor imaging. For this reason, several studies were conducted with <bold>14</bold>, also known as (CISSPECT<sup>&#174;</sup>). Using <bold>14</bold> and <bold>15</bold>, Wolf et al. studied non-invasive in vivo pharmacokinetics of these compounds in Walker 526 solid tumors bearing rats [<xref rid="B88-molecules-29-03453" ref-type="bibr">88</xref>]. In a more recent study, <bold>14</bold> proved to be a safe radiopharmaceutical, highlighting its potential for optimizing dosage in patients undergoing cisplatin chemotherapy. Moreover, the radiopharmaceutical presented a favorable biodistribution profile in which the kidneys received the highest dose accounting for a clearance half-life of 40 h [<xref rid="B89-molecules-29-03453" ref-type="bibr">89</xref>]. Later, the first preclinical SPECT images of <bold>14</bold> were conducted, showing its potential as a tracer to image the biodistribution of platinum-based compounds in vivo [<xref rid="B90-molecules-29-03453" ref-type="bibr">90</xref>]. In addition, <bold>14</bold> has proven to be more effective than regular cisplatin due to its enhanced toxicity after incubation in the Chinese hamster V79 cell line [<xref rid="B91-molecules-29-03453" ref-type="bibr">91</xref>]. Its enhanced toxicity needs to be further validated in in vivo models [<xref rid="B92-molecules-29-03453" ref-type="bibr">92</xref>].</p><p>Given the inherent therapeutic efficacy of the Platinum-195m radioisotope, there is a current trend in the development of radio-therapeutically active compounds. An illustrative example is the development of <sup>195m</sup>Pt-biphosphonates (BP) complex <bold>18</bold> (<xref rid="molecules-29-03453-f013" ref-type="fig">Figure 13</xref>). The bisphosphonate ligand was chosen to specifically target bone cancers due to high affinity for Ca<sup>2+</sup>.</p><p>This complex (<bold>18</bold>) has demonstrated a specific accumulation in bone sites exhibiting high metabolic activity, resulting in an impressive 11-fold increase in DNA damage within metastatic tumor cells when compared to non-radioactive Pt-BP. Furthermore, the biodistribution of these compounds can be precisely monitored through SPECT imaging, revealing minimal systemic toxicity. This opens a promising avenue for further research in the field of radiopharmaceuticals, particularly for the treatment of bone cancer [<xref rid="B93-molecules-29-03453" ref-type="bibr">93</xref>,<xref rid="B94-molecules-29-03453" ref-type="bibr">94</xref>]. On the other hand, earlier studies used <bold>13</bold> to examine biodistribution and kinetics in patients undergoing cisplatin treatment [<xref rid="B95-molecules-29-03453" ref-type="bibr">95</xref>,<xref rid="B96-molecules-29-03453" ref-type="bibr">96</xref>], following the demonstration of its enhanced antitumor effect in both in vitro and in vivo models compared to non-radioactive cisplatin [<xref rid="B97-molecules-29-03453" ref-type="bibr">97</xref>,<xref rid="B98-molecules-29-03453" ref-type="bibr">98</xref>,<xref rid="B99-molecules-29-03453" ref-type="bibr">99</xref>].</p><p>However, the further application of this radioisotope for human imaging studies is hindered by certain drawbacks. Above all, its high energy &#947;-photons (539 keV) are not ideal for high-contrast radio imaging using modern gamma cameras. Moreover, unlike Platinum-195m, which decays to <sup>195</sup>Pt, Platinum-191 decays to <sup>191</sup>Ir which is a different element with different pharmacokinetics leading to regulatory challenges in human imaging studies. Little research has been carried out regarding Platinum-193m and <sup>197</sup>Platinum-197 radioisotopes [<xref rid="B100-molecules-29-03453" ref-type="bibr">100</xref>].</p><p>The synthesis of <bold>17</bold> has also been reported through several methods [<xref rid="B101-molecules-29-03453" ref-type="bibr">101</xref>,<xref rid="B102-molecules-29-03453" ref-type="bibr">102</xref>] to investigate the pharmacokinetics of cisplatin in both mice and brain tumor patients [<xref rid="B103-molecules-29-03453" ref-type="bibr">103</xref>]. However, its clinical use is constrained by its very short half-life (t<sub>1/2</sub> = 10 min).</p><p>A different approach was taken by Zweit et al., who developed compound <bold>16</bold>, a feasible PET tracer for assessing the biodistribution of carboplatin [<xref rid="B104-molecules-29-03453" ref-type="bibr">104</xref>]. Fluorine-18 is widely used and is the preferred radioisotope for PET imaging due to its favorable characteristics such as half-life of 109 min, high positron emission (97%), suitable positron energy (0.634 MeV) and being easily produced by cyclotron (<xref rid="molecules-29-03453-t005" ref-type="table">Table 5</xref>) [<xref rid="B105-molecules-29-03453" ref-type="bibr">105</xref>].</p><p>Compared to Platinum-195m, Fluorine-18 offers several advantages for clinical use. The routine production and supply of Platinum-195m face significant challenges due to its high cost and logistical difficulties. On the other hand, <sup>18</sup>F has high availability, versatile chemistry, and compatibility with a wide range of biomolecules.</p><p>In this way, <bold>16</bold> demonstrated its capability to assess the drug distribution across various tumor types, showcasing its potential to enhance the overall efficacy of platinum-based chemotherapy on an individual patient basis. Following this discovery, a versatile platform consisting of <bold>16</bold> encapsulated in <sup>111</sup>In-labeled liposomes was synthesized for image-guided drug delivery [<xref rid="B107-molecules-29-03453" ref-type="bibr">107</xref>]. This study proves the dual-tracer imaging feasibility of SPECT and PET probes in vivo, aiming to enhance the precision of drug tracing within the body.</p><p>In more recent studies, supramolecular structures were developed that can encapsulate Pt drugs while incorporating radionuclides for in vivo PET imaging. An example is the work by Casini et al. [<xref rid="B108-molecules-29-03453" ref-type="bibr">108</xref>], who developed a palladium-based metallo-cage scaffold to encapsulate cisplatin while incorporating Fluorine-18. Although very promising outcomes were obtained, further investigation is needed to refine the kinetic stability of these supramolecular structures, ensuring optimal biodistribution profiles for future clinical applications. Despite the synthesis of numerous Pt(II)-metallo-assemblies, their potential as imaging-assisted cancer diagnosis agents is still in an early stage of exploration [<xref rid="B109-molecules-29-03453" ref-type="bibr">109</xref>].</p><p>Terpyridine (TP) platinum-based complexes have been developed as theranostic platforms with a specific focus on targeting G-quadruplexes to overcome platinum drug resistance (<xref rid="molecules-29-03453-f014" ref-type="fig">Figure 14</xref>). These complexes are conjugated with <sup>64</sup>Cu-NOTA (NOTA = 1,4,7-Triazacyclononane-1,4,7-triacetic acid) for targeted radiotherapy. This radioisotope (t<sub>1/2</sub> = 12.8 h; EC, [43.1%], &#946;+, 0.653 MeV [18%]; &#946;-, 0.579 MeV [38.4%]) not only possesses PET imaging properties via &#946;+ emission but also holds potential for cancer therapy via auger electron emission. Gu&#233;rin et al. synthesized two <sup>64</sup>Cu-NOTA-TP conjugates (<bold>19</bold> and <bold>20</bold>), each featuring a unique TP-NOTA linker, with the aim of investigating their cytotoxic effects in both human colorectal tumor cells and a normal fibroblast cell line (<xref rid="molecules-29-03453-f014" ref-type="fig">Figure 14</xref>). Notably, the use of a flexible linker in <bold>20</bold> demonstrated superior selectivity towards cancer cells, a higher percentage of nucleus internalization, and comparable cytotoxicity to cisplatin with an activity of 4.0 MBq/nmol [<xref rid="B110-molecules-29-03453" ref-type="bibr">110</xref>,<xref rid="B111-molecules-29-03453" ref-type="bibr">111</xref>]. Following the promising results obtained in vitro, the stability and the biodistribution profile of <bold>20</bold> through PET imaging was analyzed in vivo. It showed a promising tumor uptake ranging from 1.8 &#177; 0.4 to 3.0 &#177; 0.2% ID/g over 48 h. Furthermore, it demonstrated the ability to retard tumor growth with any observable signs of toxicity [<xref rid="B112-molecules-29-03453" ref-type="bibr">112</xref>].</p><p>Another example is <bold>21</bold>, which was developed to target G-quadruplexes. Here, the Pt scaffold was functionalized with a <sup>111</sup>In-DOTA moiety to assess its in vivo biodistribution via SPECT imaging [<xref rid="B113-molecules-29-03453" ref-type="bibr">113</xref>]. Unfortunately, the complex exhibited limited cell permeability, highlighting the necessity for further research in this field (<xref rid="molecules-29-03453-f014" ref-type="fig">Figure 14</xref>).</p><p>Gallium-68 is a promising radioisotope for PET imaging, offering a suitable half-life (68 min) for rapid imaging and reduced patient exposure. Moreover, standard radiolabeling protocols are already established for this radioisotope. Notably, Sadler et al. conducted a pioneering in vivo imaging study using dynamic PET imaging to observe the whole-body distribution of a photoactivable Pt(IV) azido complex (<bold>22</bold>). The findings demonstrated a promising pharmacokinetic profile, indicating the potential for advancing <sup>68</sup>Ga-DFO (DFO = deferoxamine) complexes in the image-guided treatment of therapeutic Pt(IV) prodrugs [<xref rid="B114-molecules-29-03453" ref-type="bibr">114</xref>].</p><p>As a conclusion of this section, it needs to be highlighted that the design of novel theranostic platforms featuring both therapeutic (Pt-based complexes) and imaging modalities is still in its infancy and therefore further research needs to be carried out.</p></sec><sec id="sec4-molecules-29-03453"><title>4. Magnetic Resonance Imaging (MRI) Contrast Agent-Pt Conjugates for Detecting and Treating Solid Tumors</title><p>MRI is indeed the most efficient technique for tumor imaging. It is non-invasive with excellent tissue contrast and spatial resolution (10&#8211;100 &#181;m), and it is applicable in whole body with precise 3D localization. It employs radiofrequency radiation in the presence of carefully controlled magnetic fields, producing high-quality cross-sectional images of the body [<xref rid="B115-molecules-29-03453" ref-type="bibr">115</xref>,<xref rid="B116-molecules-29-03453" ref-type="bibr">116</xref>]. While the image resolution of MRI is superior to other tissue-penetrating imaging techniques such as PET or SPECT, its use is still limited in detecting disparities in the magnetic properties of tissues and organs in clinical practice [<xref rid="B117-molecules-29-03453" ref-type="bibr">117</xref>].</p><p>Contrast-enhanced MRI plays an increasingly key role in diagnostic medicine. Its usefulness originates from its capability to provide more detailed diagnostic information that cannot be obtained with other non-invasive techniques. The contrast agent is administered while the patient is in the scanner, and the diagnostic images appear within minutes (<xref rid="molecules-29-03453-f015" ref-type="fig">Figure 15</xref>).</p><p>The basis for an MRI signal is the precession of water hydrogen nuclei with respect to an applied magnetic field, and MRI contrast agents can be used to shorten the relaxation times of water molecules. They accumulate tissue-specifically and therefore enhance contrast in this specific organ, allowing for faster imaging (higher throughput) and for imaging that is less sensitive to artifacts caused by motion (better-quality images). Two different relaxation times are analyzed: longitudinal (spin&#8211;lattice relaxation time, T1) and the transversal (spin&#8211;spin relaxation time, T2). The rate constants corresponding to the T1 or T2 relaxation times are defined as 1/T1 and 1/T2. Contrast agents with higher relaxivities [r1 (=1/T1) and r2 (=1/T2)] give stronger contrast enhancement [<xref rid="B118-molecules-29-03453" ref-type="bibr">118</xref>].</p><p>The contrast agents are small, such as hydrophilic gadolinium(III)-based chelates, but gadolinium is not the only element that can be used to generate MRI contrast. Indeed, iron oxide nanoparticles and manganese(II) complexes have been approved for liver imaging, although they are still not commercially successful. Paramagnetic elements such as gadolinium(III) and high&#8211;spin manganese(II) are for T1-weighted because of their shorter T1 time, while superparamagnetic contrast agents such as iron-oxide nanoparticles are for T2-weighted, for the same reason [<xref rid="B119-molecules-29-03453" ref-type="bibr">119</xref>,<xref rid="B120-molecules-29-03453" ref-type="bibr">120</xref>,<xref rid="B121-molecules-29-03453" ref-type="bibr">121</xref>].</p><p>Gadolinium may also play an important role in therapeutic techniques, such as synchrotron stereotactic radiotherapy, in which the selective delivery of gadolinium to the cell nucleus would significantly enhance the efficacy of the treatment [<xref rid="B122-molecules-29-03453" ref-type="bibr">122</xref>,<xref rid="B123-molecules-29-03453" ref-type="bibr">123</xref>]. Gadolinium(III) complexes have also been explored as potential agents in an experimental anti-cancer treatment known as gadolinium neutron-capture therapy, which is closely related to the boron neutron-capture therapy [<xref rid="B124-molecules-29-03453" ref-type="bibr">124</xref>,<xref rid="B125-molecules-29-03453" ref-type="bibr">125</xref>]. When looking at the design of new small theranostic molecules, one common approach is that the therapeutic component (i.e., Pt-based scaffold) is covalently linked to the diagnostic component (i.e., Gd contrast agent) [<xref rid="B117-molecules-29-03453" ref-type="bibr">117</xref>]. More recent studies showed the development of hybrid Gd-Pt theranostic agents incorporated into micelles [<xref rid="B126-molecules-29-03453" ref-type="bibr">126</xref>,<xref rid="B127-molecules-29-03453" ref-type="bibr">127</xref>] or nanoparticles instead [<xref rid="B128-molecules-29-03453" ref-type="bibr">128</xref>,<xref rid="B129-molecules-29-03453" ref-type="bibr">129</xref>]. All these approaches aim to mitigate the inherent cytotoxicity of the drug carrier [<xref rid="B130-molecules-29-03453" ref-type="bibr">130</xref>].</p><sec id="sec4dot1-molecules-29-03453"><title>4.1. Pt-Based Gd (III) Conjugates as Theranostic Contrast Agents</title><p>In 2010, Crossley et al. [<xref rid="B131-molecules-29-03453" ref-type="bibr">131</xref>] reported the pioneering work of gadolinium transport to a tumor cell nucleus via conjugation with a platinum complex. This innovative approach involved the functionalization of Gd&#8211;DTPA (DTPA = diethylenetriaminepentaacetic acid) with two Pt(II) (terpy) (terpy = 2,2&#8242;:6&#8242;,2&#8243;-terpyridine) units <bold>23</bold>. It was shown to function as a potent DNA intercalator of lung tumor cells. The tumor cells exhibited an enhanced accumulation capacity of both Pt and Gd with respect to the control, suggesting the presence of a tumor-selective uptake mechanism for the complex and the integrity of the complex in vitro. However, despite these observations, the Gd-Pt complex displayed significant cytotoxicity towards both normal and tumor cells, preventing its use as a potential theranostic agent (<xref rid="molecules-29-03453-f016" ref-type="fig">Figure 16</xref>).</p><p>Fenton et al. [<xref rid="B132-molecules-29-03453" ref-type="bibr">132</xref>] presented a next generation of DNA metal-intercalators that addressed a few unfavorable key factors associated with the previous prototype. By replacing the acyclic DTPA ligand with the macrocycle DOTA (DOTA = 2,2&#8242;,2&#8243;,2&#8244;-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid), the amide hydrolytic stability was enhanced. Moreover, by employing only a single Pt(II)-terpy unit, the cytotoxicity decreased with a concomitant increase in the cellular uptake while retaining an excellent DNA targeting ability (<bold>24</bold>).</p><p>Zhu et al. [<xref rid="B133-molecules-29-03453" ref-type="bibr">133</xref>] developed two bifunctional Pt&#8211;Gd complexes (<bold>25</bold> and <bold>26</bold>) to monitor the temporal distribution of Pt drugs in vivo and to assess the therapeutic response in situ. These complexes partially dissociate in the tumor environment releasing the cytostatic Pt scaffold and the residual Gd moiety for imaging. The incorporation of Pt units significantly enhances the cellular uptake of Gd complexes, while the proton relaxivities of the Pt&#8211;Gd complexes surpassed those of Gd&#8211;DTPA under physiological conditions. Also, these complexes exhibit prolonged retention in mice kidneys, presenting an opportunity for non-invasive diagnosis of acute renal injury induced by nephrotoxic platinum drugs in mice models (<xref rid="molecules-29-03453-f016" ref-type="fig">Figure 16</xref>).</p><p>A different approach was developed through the conjugation of a gadolinium(III) texaphyrin to platinum-based scaffolds as a strategy for selective targeting tumoral tissues and overcoming mechanisms associated with cisplatin resistance. Metallotexaphyrins, a class of expanded porphyrins (e.g., motexafin gadolinium [MGd]), demonstrated notable accumulation in both primary and metastatic tumors [<xref rid="B134-molecules-29-03453" ref-type="bibr">134</xref>,<xref rid="B135-molecules-29-03453" ref-type="bibr">135</xref>] and possess intrinsic anticancer activity attributed to their macrocyclic ligand-centered redox activity [<xref rid="B136-molecules-29-03453" ref-type="bibr">136</xref>,<xref rid="B137-molecules-29-03453" ref-type="bibr">137</xref>]. Since 2004, Sessler&#8217;s group has focused its interest on the development of texaphyrin drug conjugates as promising candidates for tumor localization [<xref rid="B138-molecules-29-03453" ref-type="bibr">138</xref>,<xref rid="B139-molecules-29-03453" ref-type="bibr">139</xref>,<xref rid="B140-molecules-29-03453" ref-type="bibr">140</xref>,<xref rid="B141-molecules-29-03453" ref-type="bibr">141</xref>,<xref rid="B142-molecules-29-03453" ref-type="bibr">142</xref>,<xref rid="B143-molecules-29-03453" ref-type="bibr">143</xref>] and on the combination of Motexafin gadolinium drug (MGd, <xref rid="molecules-29-03453-f017" ref-type="fig">Figure 17</xref>) to mediate the cancer-specific reduction of Pt(IV) agents [<xref rid="B144-molecules-29-03453" ref-type="bibr">144</xref>]. Magda et al. [<xref rid="B138-molecules-29-03453" ref-type="bibr">138</xref>] reported the first generation of texaphyrin-type drugs (<bold>27</bold> and <bold>28</bold>), where established anticancer agents such as cisplatin were covalently conjugated to a tumor-localizing texaphyrin core. Unfortunately, this initial study faced limitations in in vitro evaluation due to poor solubility and hydrolytic instability (<xref rid="molecules-29-03453-f017" ref-type="fig">Figure 17</xref>).</p><p>More recently, a novel gadolinium texaphyrinmalonate-Pt conjugate <bold>29</bold> was reported by Arambula et al. [<xref rid="B139-molecules-29-03453" ref-type="bibr">139</xref>], which showed anti-proliferative activity in vitro comparable to that of carboplatin. The inclusion of the malonate chelating group, analogous to that present in carboplatin, was strategically designed to facilitate Pt release under physiological conditions (<xref rid="molecules-29-03453-f018" ref-type="fig">Figure 18</xref>). Furthermore, working with an ovarian cancer cell model, an enhanced intracellular platinum accumulation was observed, as well as a greater number of Pt&#8211;DNA adducts compared to the controls (i.e., methilmalonatoplatinum, carboplatin). Despite these findings, the DNA damage repair induced by the conjugate remained comparable to that of cisplatin, suggesting the persistence of other molecular mechanisms of resistance, such as failure to reactivate the tumor suppressor factor p53 [<xref rid="B140-molecules-29-03453" ref-type="bibr">140</xref>].</p><p>To overcome key platinum pharmacological and molecular resistance mechanisms in vitro, a novel texaphyrin-oxaliplatin-like conjugate <bold>30</bold> was synthesized and biologically screened (<xref rid="molecules-29-03453-f018" ref-type="fig">Figure 18</xref>). While very effective in terms of anticancer activity, it was observed that the Pt moieties were hydrolytically unstable in aqueous environments, resulting in slow, uncontrolled release of the Pt(II) core. Therefore, difficulties were encountered in terms of formulating this generation conjugate for in vivo applications [<xref rid="B141-molecules-29-03453" ref-type="bibr">141</xref>].</p><p>In order to develop a targeting Pt-texaphyrin system capable of controlled Pt release, a second generation of platinum(IV)-texaphyrin conjugates was synthetized later by the same group. The presence of a Pt(IV) core increased the hydrolytic stability relative to the first-generation Pt(II) systems, and Pt(IV) conjugates were able to release the Pt(II) scaffold in a controlled fashion upon exposure to light or a reducing environment. The asymmetric Pt(IV) based on cisplatin scaffold was chosen as the platinum precursor for <bold>31</bold> and <bold>32</bold> (<xref rid="molecules-29-03453-f019" ref-type="fig">Figure 19</xref>, first-generation). Both conjugates demonstrated a very good anti-proliferative activity in vitro against both wild-type and cisplatin-resistant ovarian cancer cell lines, showing improvements in the IC<sub>50</sub> values for both cell lines, as well a decrease in the resistance factor (the resistance factor is calculated as the ratio between the IC<sub>50</sub> values of cisplatin-resistant ovarian cancer and wild-type cell lines) [<xref rid="B142-molecules-29-03453" ref-type="bibr">142</xref>].</p><p>A combination of both in vitro and in vivo studies on the latest generation of Pt(IV)-based texaphyrin conjugates (<bold>33</bold>&#8211;<bold>36</bold>
<xref rid="molecules-29-03453-f019" ref-type="fig">Figure 19</xref>) showed promising results in overcoming platinum-resistant ovarian and colon cancers. In this case, the 1,2-diaminocyclohexane (DACH) ligand environment around the platinum center (oxalilplatin scaffold) is believed to be crucial in producing agents capable of overcoming p53-based platinum resistance. Texaphyrin conjugates based on a Pt(IV)&#8211;DACH complex were designed to deliver an active Pt(II), analogue to oxaliplatin, in the reducing environments characteristic of many solid tumors and to overcome common p53-related cisplatin resistance mechanisms. Among the four different complexes shown in <xref rid="molecules-29-03453-f019" ref-type="fig">Figure 19</xref>, <bold>34</bold> demonstrated a superior efficacy in retarding/inhibiting tumor growth in mouse models, including those with clinically relevant Pt-resistant mouse models, outperforming the most closely related current platinum-based standards of care. These findings suggest that this complex could play a promising role in clinical applications [<xref rid="B143-molecules-29-03453" ref-type="bibr">143</xref>].</p><p>Inspired by this promising work of Sessler and coworkers, who demonstrated how Gd(III) complexes can be used synergistically with Pt(IV) prodrugs, Adams et al. took the opportunity to investigate Gd(III)&#8211;Pt(IV) mixed-metal complexes as theranostic agents [<xref rid="B145-molecules-29-03453" ref-type="bibr">145</xref>,<xref rid="B146-molecules-29-03453" ref-type="bibr">146</xref>]. Firstly, two Gd(III)&#8211;Pt(IV) conjugates (<bold>37</bold> and <bold>38</bold>, <xref rid="molecules-29-03453-f020" ref-type="fig">Figure 20</xref>) were synthesized by coupling a Gd(III) MRI contrast agent in the axial position of a cisplatin and carboplatin-based scaffold forming novel Pt(IV) complexes [<xref rid="B145-molecules-29-03453" ref-type="bibr">145</xref>]. Unlike the typical Gd(III) contrast agents, which are confined to the extracellular space surrounding tumors, these complexes are tailored for intracellular contrast enhancement of cancer cells due to the presence of the more lipophilic platinum moiety. Among the two agents, <bold>37</bold> emerged as the most promising, displaying greater cellular toxicity, higher intracellular accumulation of Gd(III), and superior MR contrast enhancement in vitro. Cellular accumulation analyses between in vitro and in vivo studies highlighted the variations in MR contrast enhancement, offering a potential strategy for imaging Pt in resistance cell lines. This platform could potentially be applied across various chemotherapeutics, particularly in cases where decreased drug accumulation is a dominant mechanism of chemoresistance [<xref rid="B146-molecules-29-03453" ref-type="bibr">146</xref>].</p></sec><sec id="sec4dot2-molecules-29-03453"><title>4.2. Multifunctional Nanodevices Combining Platinum Complexes and Magnetic Resonance (MRI)</title><p>Nanotechnology is one of the fast-moving areas in the medicinal field and it contributes significantly to the progress of medicinal science, with an increasing role in diagnostics, in vivo imaging, and improved treatment of disease [<xref rid="B146-molecules-29-03453" ref-type="bibr">146</xref>,<xref rid="B147-molecules-29-03453" ref-type="bibr">147</xref>]. The usefulness of nanoparticles is mainly derived from their small size and large surface area for in vivo drug delivery [<xref rid="B148-molecules-29-03453" ref-type="bibr">148</xref>]. Nanoscale carriers as drug delivery systems can maximize the therapeutic efficacy and minimize the side effects of loaded drugs. Indeed, they can be accumulated selectively in solid tumors exploiting the enhanced permeability and retention effect [<xref rid="B149-molecules-29-03453" ref-type="bibr">149</xref>,<xref rid="B150-molecules-29-03453" ref-type="bibr">150</xref>,<xref rid="B151-molecules-29-03453" ref-type="bibr">151</xref>]. Engineered nanodevices can target cancer cells, release their cargo in response to a stimulus, and selectively deliver drugs to the final target, and this approach can enhance the pharmacological activity of the drugs and improve the pharmacokinetics [<xref rid="B152-molecules-29-03453" ref-type="bibr">152</xref>,<xref rid="B153-molecules-29-03453" ref-type="bibr">153</xref>,<xref rid="B154-molecules-29-03453" ref-type="bibr">154</xref>]. In oncology, nanotechnology finds application as nanoscale Trojan horses to bypass drug inactivation pathways in the cytoplasm and deliver drugs efficiently to the target nuclei, overcoming multidrug resistance in cancer cells [<xref rid="B155-molecules-29-03453" ref-type="bibr">155</xref>]. In the last decade, several families of nanoparticle therapeutics platforms have been developed to selectively deliver Pt-based anticancer drugs to tumor sites, including inorganic nanoparticles [<xref rid="B156-molecules-29-03453" ref-type="bibr">156</xref>,<xref rid="B157-molecules-29-03453" ref-type="bibr">157</xref>] and polymeric micelles [<xref rid="B118-molecules-29-03453" ref-type="bibr">118</xref>,<xref rid="B158-molecules-29-03453" ref-type="bibr">158</xref>].</p><p>Recent advances in nanomedicine include the functionalization of the surface of nanodevices with targeting ligands [<xref rid="B159-molecules-29-03453" ref-type="bibr">159</xref>], as well as imaging and therapeutic moieties [<xref rid="B160-molecules-29-03453" ref-type="bibr">160</xref>], or the loading of drugs with an integration of various imaging elements that allows for multimodal and multifunctional nano-agents.</p><p>MRI stands out as one of the most extensively utilized imaging techniques for nanostructures, as MRI contrast agents are mainly paramagnetic complexes or magnetic nanoparticles. As previously mentioned, the direct conjugation of imaging contrast agents to therapeutic entities, such as Pt-complexes, has been found to compromise both the biodistribution and biological activity of the drug [<xref rid="B138-molecules-29-03453" ref-type="bibr">138</xref>,<xref rid="B139-molecules-29-03453" ref-type="bibr">139</xref>,<xref rid="B140-molecules-29-03453" ref-type="bibr">140</xref>,<xref rid="B141-molecules-29-03453" ref-type="bibr">141</xref>]. Nevertheless, the integration of imaging functionality into nanoscale drug carriers preserved these important attributes while potentially enhancing the targeting properties towards diseased sites and improving both diagnostic and therapeutic effectiveness [<xref rid="B161-molecules-29-03453" ref-type="bibr">161</xref>,<xref rid="B162-molecules-29-03453" ref-type="bibr">162</xref>]. Specific examples of how nanodevices have been exploited to enhance T1 and T2 contrast agents are described in <xref rid="sec4dot3-molecules-29-03453" ref-type="sec">Section 4.3</xref> and <xref rid="sec4dot4-molecules-29-03453" ref-type="sec">Section 4.4</xref>.</p></sec><sec id="sec4dot3-molecules-29-03453"><title>4.3. T1-Enhanced Contrast Agents</title><p>Regarding T1-enhanced contrast agents like paramagnetic molecules, such as gadolinium and manganese, higher relaxivity gives a stronger contrast enhancement. A strategy aimed at enhancing the relaxivity of Gd contrast agents involves reducing the mobility of the metal complex. This is achieved by conjugation/loading them onto nanoscale platforms such as micelles, thereby slowing molecular reorientation [<xref rid="B163-molecules-29-03453" ref-type="bibr">163</xref>,<xref rid="B164-molecules-29-03453" ref-type="bibr">164</xref>]. Polymeric micelles have been considered one of the most promising drug delivery systems in the field of cancer therapy and have revealed a reduction in side effects and high effectiveness against various intractable tumors. The development of micelles with both imaging and therapeutic functions has enabled real-time visualization of their distribution inside the body, facilitating the optimization of treatment protocols [<xref rid="B160-molecules-29-03453" ref-type="bibr">160</xref>,<xref rid="B165-molecules-29-03453" ref-type="bibr">165</xref>,<xref rid="B166-molecules-29-03453" ref-type="bibr">166</xref>].</p><p>Kaida et al. [<xref rid="B127-molecules-29-03453" ref-type="bibr">127</xref>] developed a self-assembly polymeric micelle that integrates both MRI functionality and cancer therapeutic capacity (<xref rid="molecules-29-03453-f021" ref-type="fig">Figure 21</xref>). This was achieved by incorporating gadolinium-diethylenetriaminepentaacetic acid (Gd&#8211;DTPA) as a contrast agent and the complex (1,2-diaminocyclohexane)platinum(II) (DACHPt), based on the DTPA anticancer drug oxaliplatin scaffold. In vitro and in vivo studies on pancreatic tumor models showed an enhanced tumor accumulation of the micelles, along with improved drug release, leading to enhanced efficacy and decreased toxicity. Additionally, real-time monitoring of drug distribution and tracking of tumor size were achieved. Gd&#8211;DTPA/DACHPt-loaded micelles also revealed an outstanding contrast enhancement attributed to the accumulation and to the increase in the relaxivity, suggesting a great potential of this modality for the clear detection of the tumor. In a more recent study [<xref rid="B167-molecules-29-03453" ref-type="bibr">167</xref>], the same group examined the feasibility of using these Gd&#8211;DTPA/DACHPt-loaded micelles to simultaneously diagnose and treat a clinically rat model of hepatocellular carcinoma (HCC) and demonstrated the safety and the enhanced efficacy of these micelles for the selective imaging and treatment of HCC.</p><p>An alternative approach was described by Feng et al. [<xref rid="B126-molecules-29-03453" ref-type="bibr">126</xref>] with the conjugation of Gd(III) and cisplatin on the surface of DOTA functionalized cross-linked small molecular micelles, as seen in <xref rid="molecules-29-03453-f022" ref-type="fig">Figure 22</xref>. The in vivo evaluation showed that the new theranostic nanoplatform exhibited not only a stronger and longer-lasting contrast enhancement efficacy but also a greater tumor growth inhibition rate with lower side effects. Due to the toxicity associated with the use of paramagnetic chelates for T1-weighted MRI, there is a demanding need to explore alternative transition-metal oxides [<xref rid="B168-molecules-29-03453" ref-type="bibr">168</xref>].</p><p>More recently, manganese dioxide (MnO<sub>2</sub>) nanostructures have emerged as a novel responsive MRI-T1 contrast agent [<xref rid="B169-molecules-29-03453" ref-type="bibr">169</xref>]. In these nanoparticles, manganese presents a 4+ oxidation state, displaying weak paramagnetism. However, in the presence of biologically relevant concentrations of GSH or other redox-active species, MnO<sub>2</sub> nanostructures undergo reduction to form free aqueous Mn(II) and O<sub>2</sub>. Mn in its 2+ oxidation state has two unpaired electrons and exhibits strong paramagnetism, leading to an enhanced MRI signal [<xref rid="B170-molecules-29-03453" ref-type="bibr">170</xref>]. In this context, Hao et al. [<xref rid="B169-molecules-29-03453" ref-type="bibr">169</xref>] reported a very promising approach by developing a tumor-targeted theranostic delivery system comprising degradable MnO<sub>2</sub> nanosheets functionalized with hyaluronic acid (HA) and loaded with cisplatin, as shown in <xref rid="molecules-29-03453-f023" ref-type="fig">Figure 23</xref>. Here, HA was used as a delivery molecule, as overexpression of its receptors has been found in various tumors. Once the tumor is reached, controlled drug release is achieved by the tumor-microenvironment-responsive degradation of MnO<sub>2</sub> nanosheets.</p><p>However, the preparation of these theranostic agents required challenging multistep reactions. A few years later, Brito et al. [<xref rid="B171-molecules-29-03453" ref-type="bibr">171</xref>] described a MnO<sub>2</sub>&#8211;Pt (IV) nanostructure synthesized through a simplified one-pot facile ultrasonication reaction, significantly reducing the time and complexity of the materials. These nanoparticles demonstrated a robust off/on MRI behavior both in vitro and in vivo in response to the reducing agents. They also exhibited efficiency in inducing cell death, comparable to that of cisplatin. However, further systemic imaging and therapeutic studies are still required to fully assess their potential.</p><p>In the same year, Zhang et al. [<xref rid="B172-molecules-29-03453" ref-type="bibr">172</xref>] presented a promising strategy aimed at overcoming the primary limitation associated with polymeric micelles as drug delivery vehicles such as premature release, and drug binding with plasma proteins before reaching tumor cells. They developed poly(glycolic acid)/cisplatin (PGA/CDDP) NPs via electrostatic interaction, which were further coated with MnO<sub>2</sub> to prevent premature leakage and augment the therapeutic effect of cisplatin in tumor cells. Additionally, the MnO<sub>2</sub> shells can react with high concentration of GSH, H<sub>2</sub>O<sub>2</sub> and H<sup>+</sup> for a multi-responsive controlled drug release (<xref rid="molecules-29-03453-f024" ref-type="fig">Figure 24</xref>). This innovative approach led to a significant enhancement in the toxic effect of pure cisplatin of approximately 2&#8211;3 times, upon coupling with MnO<sub>2</sub>. Furthermore, serving as a multi-functional nanoplatform, PGA/CDDP@MnO<sub>2</sub> NPs holds considerable promise for imaging and diagnosing various tumors.</p></sec><sec id="sec4dot4-molecules-29-03453"><title>4.4. T2-Enhanced Contrast Agents</title><p>The most studied T2-enhanced contrast agents are superparamagnetic iron-oxide (Fe<sub>3</sub>O<sub>4</sub>) nanoparticles. In this case, the value of T2 is inversely proportional to its cross-sectional area, meaning that the same amount of magnetized material is more effective when dispersed as fewer large aggregates rather than numerous smaller ones [<xref rid="B173-molecules-29-03453" ref-type="bibr">173</xref>]. Mn-doped Fe<sub>3</sub>O<sub>4</sub> nanoparticles may be used as simultaneous dual-modal probes for T1/T2 MRI, providing complementary imaging information for an early and precise diagnosis [<xref rid="B174-molecules-29-03453" ref-type="bibr">174</xref>].</p><p>SPIONs (Super Paramagnetic Iron Oxide Nanoparticles) possess some excellent properties, such as biocompatibility, hydrophilicity, nontoxicity, and no immunogenicity and as a result, they have garnered significant attention in recent years as both drug carriers and diagnostic agents [<xref rid="B175-molecules-29-03453" ref-type="bibr">175</xref>,<xref rid="B176-molecules-29-03453" ref-type="bibr">176</xref>]. Based on this idea, Xing et al. [<xref rid="B177-molecules-29-03453" ref-type="bibr">177</xref>] synthesized superparamagnetic magnetite nanocrystal clusters. Sodium carboxymethylcellulose (Na-CMC SPMNC) was chosen as a biocompatible and biodegradable polymer for external coating. The platinum drug (monochlorinated CDDP, CMDP) was loaded onto the clusters, forming a conjugate of CMDP&#8211;CMC&#8211;SPMNC magnetic drug carriers that were able to transport platinum drug preferentially to its biological target by making use of a magnetic field (<xref rid="molecules-29-03453-f025" ref-type="fig">Figure 25</xref>). In addition to the benefits of simplicity in preparation and high loading capacity, the system significantly enhances the cellular uptake of platinum drugs. The cytotoxicity towards the human cervical cancer HeLa cells and the human hepatocarcinoma HepG2 cells of the drug carrier conjugate are higher than or at least comparable to those of cisplatin.</p><p>In subsequent work, Wang et al. [<xref rid="B128-molecules-29-03453" ref-type="bibr">128</xref>] reported a study where an analog of cisplatin (CMDP) was tethered to modified maghemite nanoparticles (OTPBA&#8211;SPION) for targeted cancer theranostics under the influence of an external magnetic field. This approach offered several advantages, including particle size conducive to tumor cell entry, straight-forward preparation, high drug-loading capacity, nontoxic degradation of the core, and more importantly, and specific accumulation in cancer tissues under an external magnetic field. However, there was a concern that Pt(II) moieties could react during delivery, potentially posing toxic effects on normal tissues.</p><p>To overcome these limitations, Zhu et al. [<xref rid="B178-molecules-29-03453" ref-type="bibr">178</xref>] proposed a novel strategy involving the substitution of the previous Pt(II) pharmacophore with a Pt(IV) prodrug complex that is more inert and more stable than Pt(II) complexes as described earlier, thereby mitigating undesirable side reactions in the blood plasma. In this study, SPIONs were retained to construct a targeted Pt prodrug system, with polyethylene glycol (PEG) coating applied to enhance in vivo stability. A functionalized prodrug of cisplatin (HSPt) was loaded onto the surface of the PEGylated SPIONs. The system produced a significant negative contrast in MRI, suggesting its potential as a theranostic agent for chemotherapy. Cytotoxicity was enhanced in the presence of GSH, facilitating controlled drug release within the tumor microenvironment.</p><p>Cheng et al. [<xref rid="B174-molecules-29-03453" ref-type="bibr">174</xref>] designed and developed an innovative Pt-FMO nanoplatform (where FMO stands for manganese deposited iron oxide, Fe&#8211;Mg composite oxide) that served as a simultaneous dual-modal probe for T1/T2 MRI while also enabling mutual beneficial cascade reactions to promote ferroptosis and apoptosis in combination with its utilization as an MRI agent. A cisplatin prodrug Pt(IV) containing a carboxylic acid in the axial position was covalently conjugated to the surface of FMO via amide bond formation and was activated through endogenous GSH to generate the Pt(II) drug (<xref rid="molecules-29-03453-f026" ref-type="fig">Figure 26</xref>). In vitro and in vivo essays demonstrate that a remarkably lower Pt dose (8.89%) of Pt-FMO was able to achieve a significant in vivo antitumor effect of cisplatin. The combination effect on tumor cells through cisplatin-induced apoptosis and Fenton-reaction-promoted ferroptosis is crucial to achieve such promising results.</p></sec></sec><sec sec-type="conclusions" id="sec5-molecules-29-03453"><title>5. Conclusions</title><p>The overview provided in this review about recent advancements in the use of Pt-based drugs coupled with various imaging techniques showed a huge potential in future translation to clinical studies. Nevertheless, further studies are needed to overcome the limitations of the different imaging techniques involved and to improve the activity of the anticancer agent.</p><p>Regarding fluorescence imaging, coupling Pt compounds with fluorophores to study their spatial-temporal distribution in cells poses a challenge because the fluorophore&#8217;s structure can alter the original Pt-based compound&#8217;s physicochemical properties. To address this issue, various exogenous turn-on probes have been developed. Among the different NIR-fluorescent probes mentioned before, AuNCs have the highest potential for in vivo tumor imaging due to their small size, tunable emissions from the visible to the NIR range, excellent biocompatibility, easy surface functionalization with peptides/proteins/antibodies for active cell-targeting, and enhanced EPR effect.</p><p>Regarding SPECT imaging, CISSPECT<sup>&#174;</sup> was the most efficient theranostic agent developed to predict chemotherapy treatment efficacy of cisplatin, external radio beam therapy optimization and reduction in side effects such as severe kidney toxicity. While CISSPECT<sup>&#174;</sup> shows promising results, PET imaging offers distinct advantages, including higher sensitivity, superior resolution, and the use of shorter-half-life radiotracers that reduce radiation exposure. Notably, we highlight the promising outcomes of terpyridine platinum-based complexes conjugated with <sup>64</sup>Cu-NOTA as an innovative theranostic platform aimed at overcoming platinum drug resistance. Although PET imaging of Pt-theranostic compounds is still a rare technique, recent developments, such as the <sup>68</sup>Ga-Pt(IV)azido complex (<bold>22</bold>), demonstrate significant potential for image-guided treatment of therapeutic Pt(IV) prodrugs.</p><p>In the field of MRI imaging, significant efforts have been made in the development of Pt-Gd complexes. While first-generation Gd-Pt complexes encountered challenges such as cytotoxicity and stability concerns, ongoing research has led to substantial advancements in their design and efficacy. Particularly noteworthy are texaphyrin-based and Pt(IV) conjugates, which hold promise for overcoming platinum resistance through targeted therapeutic action. Notably, complex <bold>34</bold> has demonstrated superior efficacy in inhibiting tumor growth, underscoring its potential for clinical applications. Moreover, nanotechnology has highly promoted MRI contrast agents research, thus offering versatile platforms that decrease the toxicity of Gd-based probes and achieve a stronger contrast enhancement. However, we believe SPIONs have a huge potential as both MRI contrast agents and drug delivery platforms due to their high biocompatibility, low toxicity, decreased immunogenicity, extended imaging windows, and easy surface functionalization with ligands or therapeutic agents.</p><p>For the future of molecular medicine, developing dual-modality molecular imaging probes will be pivotal, as no single imaging modality can provide all the necessary information. For example, PET offers excellent sensitivity and metabolic functionality but suffers from poor spatial resolution. Conversely, MRI provides supremely high-resolution anatomic information in the sub-millimeter range. By synergistically combining these modalities, we can achieve comprehensive diagnostic capabilities. Several current strategies are already moving in this direction [<xref rid="B179-molecules-29-03453" ref-type="bibr">179</xref>,<xref rid="B180-molecules-29-03453" ref-type="bibr">180</xref>].</p><p>Therefore, our future contribution in this field will be to develop SPION-based platforms with Pt-derivatives coupled to radio-chelators to create MRI/PET imaging theranostic probes for both cancer diagnosis and treatment. We aim to evaluate these probes both in vitro and in vivo to assess their potential for clinical translation.</p><p>In conclusion, the use of Pt-based complexes in a theranostic scenario emerges as a strategy to solve current issues of one of the widest-used anticancer drugs and to design an individual therapeutic intervention in combination with an appropriate diagnostic methodology. We are confident that this direction is a promising approach so that personalized molecular medicine may soon become a clinical reality.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, D.M. and T.W.; writing&#8212;original draft preparation, G.F. and I.L.-M.; writing&#8212;review and editing, D.M., T.W. and C.K.; visualization, G.F. and I.L.-M.; supervision, D.M. and T.W.; project administration, D.M. and C.K.; funding acquisition, D.M. and C.K. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Data sharing is not applicable.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-molecules-29-03453"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>K.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>B.B.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>Z.W.</given-names></name></person-group><article-title>What Blocks More Anticancer Platinum Complexes from Experiment to Clinic: Major Problems and Potential Strategies from Drug Design Perspectives</article-title><source>Coord. Chem. Rev.</source><year>2021</year><volume>449</volume><elocation-id>214210</elocation-id><pub-id pub-id-type="doi">10.1016/j.ccr.2021.214210</pub-id></element-citation></ref><ref id="B2-molecules-29-03453"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gibson</surname><given-names>D.</given-names></name></person-group><article-title>Multi&#8211;Action Pt(IV) Anticancer Agents; Do We Understand How They Work?</article-title><source>J. Inorg. Biochem.</source><year>2019</year><volume>191</volume><fpage>77</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.jinorgbio.2018.11.008</pub-id><pub-id pub-id-type="pmid">30471522</pub-id></element-citation></ref><ref id="B3-molecules-29-03453"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wheate</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>S.</given-names></name><name name-style="western"><surname>Craig</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Oun</surname><given-names>R.</given-names></name></person-group><article-title>The Status of Platinum Anticancer Drugs in the Clinic and in Clinical Trials</article-title><source>Dalton Trans.</source><year>2010</year><volume>39</volume><fpage>8113</fpage><lpage>8127</lpage><pub-id pub-id-type="doi">10.1039/c0dt00292e</pub-id><pub-id pub-id-type="pmid">20593091</pub-id></element-citation></ref><ref id="B4-molecules-29-03453"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Theiner</surname><given-names>S.</given-names></name><name name-style="western"><surname>Varbanov</surname><given-names>H.P.</given-names></name><name name-style="western"><surname>Galanski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Egger</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Berger</surname><given-names>W.</given-names></name><name name-style="western"><surname>Heffeter</surname><given-names>P.</given-names></name><name name-style="western"><surname>Keppler</surname><given-names>B.K.</given-names></name></person-group><article-title>Comparative In Vitro and In Vivo Pharmacological Investigation of Platinum(IV) Complexes as Novel Anticancer Drug Candidates for Oral Application</article-title><source>J. Biol. Inorg. Chem.</source><year>2015</year><volume>20</volume><fpage>89</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1007/s00775-014-1214-6</pub-id><pub-id pub-id-type="pmid">25413442</pub-id><pub-id pub-id-type="pmcid">PMC4351919</pub-id></element-citation></ref><ref id="B5-molecules-29-03453"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>X.M.</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Kilari</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chow</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Fujimoto</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kalhor</surname><given-names>N.</given-names></name><name name-style="western"><surname>Swisher</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Wistuba</surname><given-names>I.I.</given-names></name><etal/></person-group><article-title>Copper Transporter CTR1 Expression and Tissue Platinum Concentration in Non-Small Cell Lung Cancer</article-title><source>Lung Cancer</source><year>2014</year><volume>85</volume><fpage>88</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2014.04.005</pub-id><pub-id pub-id-type="pmid">24792335</pub-id><pub-id pub-id-type="pmcid">PMC4090351</pub-id></element-citation></ref><ref id="B6-molecules-29-03453"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lasorsa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Natile</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rosato</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tadini&#8211;Buoninsegni</surname><given-names>F.</given-names></name><name name-style="western"><surname>Arnesano</surname><given-names>F.</given-names></name></person-group><article-title>Monitoring Interactions Inside Cells by Advanced Spectroscopies: Overview of Copper Transporters and Cisplatin</article-title><source>Curr. Med. Chem.</source><year>2018</year><volume>25</volume><fpage>462</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.2174/0929867324666171110141311</pub-id><pub-id pub-id-type="pmid">29121854</pub-id></element-citation></ref><ref id="B7-molecules-29-03453"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Samimi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Varki</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Wilczynski</surname><given-names>S.</given-names></name><name name-style="western"><surname>Safaei</surname><given-names>R.</given-names></name><name name-style="western"><surname>Alberts</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Howell</surname><given-names>S.B.</given-names></name></person-group><article-title>Increase in Expression of the Copper Transporter ATP7A during Platinum Drug-Based Treatment Is Associated with Poor Survival in Ovarian Cancer Patients</article-title><source>Clin. Cancer Res.</source><year>2003</year><volume>9</volume><fpage>5853</fpage><lpage>5859</lpage><pub-id pub-id-type="pmid">14676106</pub-id></element-citation></ref><ref id="B8-molecules-29-03453"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Samimi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Safaei</surname><given-names>R.</given-names></name><name name-style="western"><surname>Katano</surname><given-names>K.</given-names></name><name name-style="western"><surname>Holzer</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Rochdi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tomioka</surname><given-names>M.</given-names></name><name name-style="western"><surname>Goodman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Howell</surname><given-names>S.B.</given-names></name></person-group><article-title>Increased Expression of the Copper Efflux Transporter ATP7A Mediates Resistance to Cisplatin, Carboplatin, and Oxaliplatin in Ovarian Cancer Cells</article-title><source>Clin. Cancer Res.</source><year>2004</year><volume>10</volume><fpage>4661</fpage><lpage>4669</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-0137</pub-id><pub-id pub-id-type="pmid">15269138</pub-id></element-citation></ref><ref id="B9-molecules-29-03453"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iida</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mori</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mori</surname><given-names>K.</given-names></name><name name-style="western"><surname>Goto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Urata</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Oka</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kohno</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kondo</surname><given-names>T.</given-names></name></person-group><article-title>Co-Expression of Gamma-Glutamylcysteine Synthetase Sub-Units in Response to Cisplatin and Doxorubicin in Human Cancer Cells</article-title><source>Int. J. Cancer.</source><year>1999</year><volume>82</volume><fpage>405</fpage><lpage>411</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(SICI)1097-0215(19990730)82:3&amp;#x0003c;405::AID-IJC14&amp;#x0003e;3.0.CO;2-M</pub-id><pub-id pub-id-type="pmid">10399958</pub-id></element-citation></ref><ref id="B10-molecules-29-03453"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Iida</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>S.</given-names></name><name name-style="western"><surname>Oka</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kohno</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kondo</surname><given-names>T.</given-names></name></person-group><article-title>Overexpression of Glutathione S-Transferase &#960; Enhances the Adduct Formation of Cisplatin with Glutathione in Human Cancer Cells</article-title><source>Free Rad. Res.</source><year>1999</year><volume>31</volume><fpage>549</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1080/10715769900301121</pub-id><pub-id pub-id-type="pmid">10630679</pub-id></element-citation></ref><ref id="B11-molecules-29-03453"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hutter</surname><given-names>K.-J.</given-names></name><name name-style="western"><surname>Zeller</surname><given-names>W.J.</given-names></name></person-group><article-title>Positive Correlation between Cellular Glutathione and Acquired Cisplatin Resistance in Human Ovarian Cancer Cells</article-title><source>Cell Biol. Toxicol.</source><year>1995</year><volume>11</volume><fpage>273</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1007/BF00757625</pub-id><pub-id pub-id-type="pmid">8608408</pub-id></element-citation></ref><ref id="B12-molecules-29-03453"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lippard</surname><given-names>S.J.</given-names></name></person-group><article-title>Cellular Processing of Platinum Anticancer Drugs</article-title><source>Nat. Rev. Durg Discov.</source><year>2005</year><volume>4</volume><fpage>307</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1038/nrd1691</pub-id><pub-id pub-id-type="pmid">15789122</pub-id></element-citation></ref><ref id="B13-molecules-29-03453"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kelland</surname><given-names>L.</given-names></name></person-group><article-title>The Resurgence of Platinum-Based Cancer Chemotherapy</article-title><source>Nat. Rev. Cancer</source><year>2007</year><volume>7</volume><fpage>573</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1038/nrc2167</pub-id><pub-id pub-id-type="pmid">17625587</pub-id></element-citation></ref><ref id="B14-molecules-29-03453"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dilruba</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kalayda</surname><given-names>G.V.</given-names></name></person-group><article-title>Platinum&#8211;Based Drugs: Past, Present and Future</article-title><source>Cancer Chemother. Pharmacol.</source><year>2016</year><volume>77</volume><fpage>1103</fpage><lpage>1124</lpage><pub-id pub-id-type="doi">10.1007/s00280-016-2976-z</pub-id><pub-id pub-id-type="pmid">26886018</pub-id></element-citation></ref><ref id="B15-molecules-29-03453"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holzer</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Samimi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Katano</surname><given-names>K.</given-names></name><name name-style="western"><surname>Naerdemann</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Safaei</surname><given-names>R.</given-names></name><name name-style="western"><surname>Howell</surname><given-names>S.B.</given-names></name></person-group><article-title>The Copper Influx Transporter Human Copper Transport Protein 1 Regulates the Uptake of Cisplatin in Human Ovarian Carcinoma Cells</article-title><source>Mol. Pharmacol.</source><year>2004</year><volume>66</volume><fpage>817</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1124/mol.104.001198</pub-id><pub-id pub-id-type="pmid">15229296</pub-id></element-citation></ref><ref id="B16-molecules-29-03453"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoshizawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nozaki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kitahara</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ohara</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kawashiri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>E.</given-names></name></person-group><article-title>Copper Efflux Transporter (ATP7B) Contributes to the acquisition of Cisplatin-Resistance in Human Oral Squamous Cell Lines</article-title><source>Oncol. Rep.</source><year>2007</year><volume>18</volume><fpage>987</fpage><lpage>991</lpage><pub-id pub-id-type="doi">10.3892/or.18.4.987</pub-id><pub-id pub-id-type="pmid">17786364</pub-id></element-citation></ref><ref id="B17-molecules-29-03453"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakayama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kanzaki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Terada</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mutoh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ogawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sugiyama</surname><given-names>T.</given-names></name><name name-style="western"><surname>Takenoshita</surname><given-names>S.</given-names></name><name name-style="western"><surname>Itoh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yaegashi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Miyazaki</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Prognostic Value of the Cu-Transporting ATPase in Ovarian Carcinoma Patients Receiving Cisplatin-Based Chemotherapy</article-title><source>Clin. Cancer Res.</source><year>2004</year><volume>10</volume><fpage>1804</fpage><lpage>2811</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-03-0454</pub-id><pub-id pub-id-type="pmid">15102688</pub-id></element-citation></ref><ref id="B18-molecules-29-03453"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ueda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shirabe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Morita</surname><given-names>K.</given-names></name><name name-style="western"><surname>Umeda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kayashima</surname><given-names>H.</given-names></name><name name-style="western"><surname>Uchiyama</surname><given-names>H.</given-names></name><name name-style="western"><surname>Soejima</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Taketomi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Maehara</surname><given-names>Y.</given-names></name></person-group><article-title>Evaluation of ERCC1 Expression for Cisplatin Sensitivity in Human Hepatocellular Carcinoma</article-title><source>Ann. Surg. Oncol.</source><year>2011</year><volume>18</volume><fpage>1204</fpage><lpage>1211</lpage><pub-id pub-id-type="doi">10.1245/s10434-010-1414-4</pub-id><pub-id pub-id-type="pmid">21076943</pub-id></element-citation></ref><ref id="B19-molecules-29-03453"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Britten</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tessier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hutchison</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Murray</surname><given-names>D.</given-names></name></person-group><article-title>ERCC1 Expression as a Molecular Marker of Cisplatin Resistance in Human Cervical Tumor Cells</article-title><source>Int. J. Cancer</source><year>2000</year><volume>89</volume><fpage>453</fpage><lpage>457</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1097-0215(20000920)89:5&amp;#x0003c;453::AID-IJC9&amp;#x0003e;3.0.CO;2-E</pub-id><pub-id pub-id-type="pmid">11008208</pub-id></element-citation></ref><ref id="B20-molecules-29-03453"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steffensen</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Waldstr&#248;m</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jakobsen</surname><given-names>A.</given-names></name></person-group><article-title>The Relationship of Platinum Resistance and ERCC1 Protein Expression in Epithelial Ovarian Cancer</article-title><source>Int. J. Gynecol. Cancer</source><year>2009</year><volume>19</volume><fpage>820</fpage><lpage>825</lpage><pub-id pub-id-type="doi">10.1111/IGC.0b013e3181a12e09</pub-id><pub-id pub-id-type="pmid">19574766</pub-id></element-citation></ref><ref id="B21-molecules-29-03453"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ulker</surname><given-names>M.</given-names></name><name name-style="western"><surname>Duman</surname><given-names>B.B.</given-names></name><name name-style="western"><surname>Sahin</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gumurdulu</surname><given-names>D.</given-names></name></person-group><article-title>ERCC1 and RRM1 as a Predictive Parameter for Non-Small Cell Lung, Ovarian or Pancreas Cancer Treated with Cisplatin and/or Gemcitabine</article-title><source>Contemp. Oncol.</source><year>2015</year><volume>19</volume><fpage>207</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.5114/wo.2015.52656</pub-id><pub-id pub-id-type="pmid">26557761</pub-id><pub-id pub-id-type="pmcid">PMC4631284</pub-id></element-citation></ref><ref id="B22-molecules-29-03453"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kishi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Doki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yasuda</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fujiwara</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Takiguchi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Higuchi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Monden</surname><given-names>M.</given-names></name></person-group><article-title>Reduced MLH1 Expression after Chemotherapy Is an Indicator for Poor Prognosis in Esophageal Cancers</article-title><source>Clin. Cancer Res.</source><year>2003</year><volume>9</volume><fpage>4368</fpage><lpage>4375</lpage><pub-id pub-id-type="pmid">14555508</pub-id></element-citation></ref><ref id="B23-molecules-29-03453"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawashima</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>H.</given-names></name><name name-style="western"><surname>Miwa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fujiwara</surname><given-names>K.</given-names></name></person-group><article-title>MLH1 Is a Prognostic Biomarker for Serous Ovarian Cancer Treated with Platinum- and Taxane-Based Chemotherapy</article-title><source>Anticancer Res.</source><year>2019</year><volume>39</volume><fpage>5505</fpage><lpage>5513</lpage><pub-id pub-id-type="doi">10.21873/anticanres.13743</pub-id><pub-id pub-id-type="pmid">31570444</pub-id></element-citation></ref><ref id="B24-molecules-29-03453"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chavez&#8211;Dominguez</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Perez&#8211;Medina</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Lopez&#8211;Gonzalez</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Galicia&#8211;Velasco</surname><given-names>M.</given-names></name><name name-style="western"><surname>Matias&#8211;Florentino</surname><given-names>M.</given-names></name><name name-style="western"><surname>Avila&#8211;Rios</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rumbo&#8211;Nava</surname><given-names>U.</given-names></name><name name-style="western"><surname>Salgado&#8211;Aguayo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gonzalez&#8211;Gonzalez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Aguilar&#8211;Cazares</surname><given-names>D.</given-names></name></person-group><article-title>Role of HMGB1 in Cisplatin-Persistent Lung Adenocarcinoma Cell Lines</article-title><source>Front. Oncol.</source><year>2021</year><volume>11</volume><elocation-id>750677</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2021.750677</pub-id><pub-id pub-id-type="pmid">34966671</pub-id><pub-id pub-id-type="pmcid">PMC8710495</pub-id></element-citation></ref><ref id="B25-molecules-29-03453"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Song</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name></person-group><article-title>Inhibiting the Cytoplasmic Location of HMGB1 Reverses Cisplatin Resistance in Human Cervical Cancer Cells</article-title><source>Mol. Med. Rep.</source><year>2017</year><volume>15</volume><fpage>488</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.3892/mmr.2016.6003</pub-id><pub-id pub-id-type="pmid">27959427</pub-id></element-citation></ref><ref id="B26-molecules-29-03453"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Han</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Z.</given-names></name></person-group><article-title>Elevated HMGB1 Promotes the Malignant Progression and Contributes to Cisplatin Resistance of Non-Small Cell Lung Cancer</article-title><source>Hereditas</source><year>2023</year><volume>160</volume><fpage>33</fpage><pub-id pub-id-type="doi">10.1186/s41065-023-00294-9</pub-id><pub-id pub-id-type="pmid">37518006</pub-id><pub-id pub-id-type="pmcid">PMC10388484</pub-id></element-citation></ref><ref id="B27-molecules-29-03453"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nishiguchi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Oue</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fujiwara&#8211;Tani</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sasaki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ohmori</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kishi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mori</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mori</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>N.</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Role of Metastasis-Related Genes in Cisplatin Chemoresistance in Gastric Cancer</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><elocation-id>254</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21010254</pub-id><pub-id pub-id-type="pmid">31905926</pub-id><pub-id pub-id-type="pmcid">PMC6981396</pub-id></element-citation></ref><ref id="B28-molecules-29-03453"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Timmerman</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Eleveld</surname><given-names>T.F.</given-names></name><name name-style="western"><surname>Gillis</surname><given-names>A.J.M.</given-names></name><name name-style="western"><surname>Friedrichs</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Hillenius</surname><given-names>S.</given-names></name><name name-style="western"><surname>Remmers</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Sriram</surname><given-names>S.</given-names></name><name name-style="western"><surname>Looijenga</surname><given-names>L.H.J.</given-names></name></person-group><article-title>The Role of Tp53 in Cisplatin Resistance in Mediastinal and Testicular Germ Cell Tumors</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>11774</elocation-id><pub-id pub-id-type="doi">10.3390/ijms222111774</pub-id><pub-id pub-id-type="pmid">34769213</pub-id><pub-id pub-id-type="pmcid">PMC8583723</pub-id></element-citation></ref><ref id="B29-molecules-29-03453"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castedo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Coquelle</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vivet</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vitale</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kauffmann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dessen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pequignot</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Casares</surname><given-names>N.</given-names></name><name name-style="western"><surname>Valent</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mouhamad</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Apoptosis Regulation in Tetraploid Cancer Cells</article-title><source>EMBO J.</source><year>2006</year><volume>25</volume><fpage>2584</fpage><lpage>2595</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7601127</pub-id><pub-id pub-id-type="pmid">16675948</pub-id><pub-id pub-id-type="pmcid">PMC1478174</pub-id></element-citation></ref><ref id="B30-molecules-29-03453"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>Le Teuff</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lacas</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tsao</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Graziano</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pignon</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Douillard</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Le Chevalier</surname><given-names>T.</given-names></name><name name-style="western"><surname>Seymour</surname><given-names>L.</given-names></name><name name-style="western"><surname>Filipits</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis</article-title><source>J. Thorac. Oncol.</source><year>2016</year><volume>11</volume><fpage>850</fpage><lpage>861</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2016.02.002</pub-id><pub-id pub-id-type="pmid">26899019</pub-id></element-citation></ref><ref id="B31-molecules-29-03453"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Z.F.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Shao</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>R.Y.</given-names></name></person-group><article-title>Hypoxia-Induced Autophagy Mediates Cisplatin Resistance in Lung Cancer Cells</article-title><source>Sci. Rep.</source><year>2015</year><volume>5</volume><fpage>12291</fpage><pub-id pub-id-type="doi">10.1038/srep12291</pub-id><pub-id pub-id-type="pmid">26201611</pub-id><pub-id pub-id-type="pmcid">PMC4511870</pub-id></element-citation></ref><ref id="B32-molecules-29-03453"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>G.S.</given-names></name></person-group><article-title>Role of Autophagy in Cisplatin Resistance in Ovarian Cancer Cells</article-title><source>J. Biol. Chem.</source><year>2014</year><volume>289</volume><fpage>17163</fpage><lpage>17173</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.558288</pub-id><pub-id pub-id-type="pmid">24794870</pub-id><pub-id pub-id-type="pmcid">PMC4059157</pub-id></element-citation></ref><ref id="B33-molecules-29-03453"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>He</surname><given-names>W.-S.</given-names></name><name name-style="western"><surname>Nong</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Q.-Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R.-G.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.-L.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>G.</given-names></name></person-group><article-title>Acquired Cisplatin Resistance in Human Lung Adenocarcinoma Cells Is Associated with Enhanced Autophagy</article-title><source>Cancer Biother. Radiophar.</source><year>2010</year><volume>25</volume><fpage>75</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1089/cbr.2009.0701</pub-id><pub-id pub-id-type="pmid">20187799</pub-id></element-citation></ref><ref id="B34-molecules-29-03453"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ru</surname><given-names>G.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shou</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z.</given-names></name></person-group><article-title>Cisplatin Resistance in Gastric Cancer Cells Is Associated with HER2 Upregulation-Induced Epithelial-Mesenchymal Transition</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>20502</fpage><pub-id pub-id-type="doi">10.1038/srep20502</pub-id><pub-id pub-id-type="pmid">26846307</pub-id><pub-id pub-id-type="pmcid">PMC4742832</pub-id></element-citation></ref><ref id="B35-molecules-29-03453"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Calikusu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yildirim</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Akcali</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sakalli</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bal</surname><given-names>N.</given-names></name><name name-style="western"><surname>Unal</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ozyilkan</surname><given-names>O.</given-names></name></person-group><article-title>The Effect of HER2 Expression on Cisplatin-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer Patients</article-title><source>J. Exp. Clin. Cancer Res.</source><year>2009</year><volume>28</volume><fpage>97</fpage><pub-id pub-id-type="doi">10.1186/1756-9966-28-97</pub-id><pub-id pub-id-type="pmid">19575783</pub-id><pub-id pub-id-type="pmcid">PMC2717055</pub-id></element-citation></ref><ref id="B36-molecules-29-03453"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gibson</surname><given-names>D.</given-names></name></person-group><article-title>Platinum(IV) Anticancer Prodrugs-Hypotheses and Facts</article-title><source>Dalton Trans.</source><year>2016</year><volume>45</volume><fpage>12983</fpage><lpage>12991</lpage><pub-id pub-id-type="doi">10.1039/C6DT01414C</pub-id><pub-id pub-id-type="pmid">27214873</pub-id></element-citation></ref><ref id="B37-molecules-29-03453"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Hyun</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.-K.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Song</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Do</surname><given-names>Y.R.</given-names></name><name name-style="western"><surname>Ryoo</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Zang</surname><given-names>D.Y.</given-names></name><etal/></person-group><article-title>Randomized, Multicenter, Phase III Trial of Heptaplatin 1-Hour Infusion and 5-Fluorouracil Combination Chemotherapy Comparing with Cisplatin and 5-Fluorouracil Combination Chemotherapy in Patients with Advanced Gastric Cancer</article-title><source>Cancer Res. Treat.</source><year>2009</year><volume>41</volume><fpage>12</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.4143/crt.2009.41.1.12</pub-id><pub-id pub-id-type="pmid">19688066</pub-id><pub-id pub-id-type="pmcid">PMC2699097</pub-id></element-citation></ref><ref id="B38-molecules-29-03453"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McKeage</surname><given-names>M.J.</given-names></name></person-group><article-title>Lobaplatin: A New Antitumour Platinum Drug</article-title><source>Expert. Opin. Investig. Drugs</source><year>2001</year><volume>10</volume><fpage>119</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1517/13543784.10.1.119</pub-id><pub-id pub-id-type="pmid">11116285</pub-id></element-citation></ref><ref id="B39-molecules-29-03453"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>B.Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name></person-group><article-title>A Targeted Theranostic Platinum(Iv) Prodrug Containing a Luminogen with Aggregation-Induced Emission (AIE) Characteristics for in Situ Monitoring of Drug Activation</article-title><source>Chem. Commun.</source><year>2014</year><volume>50</volume><fpage>3868</fpage><lpage>3870</lpage><pub-id pub-id-type="doi">10.1039/c3cc49516g</pub-id><pub-id pub-id-type="pmid">24589580</pub-id></element-citation></ref><ref id="B40-molecules-29-03453"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kelland</surname><given-names>L.</given-names></name></person-group><article-title>Broadening the Clinical Use of Platinum Drug-Based Chemotherapy with New Analogues: Satraplatin and Picoplatin</article-title><source>Expert. Opin. Investig. Drugs</source><year>2007</year><volume>16</volume><fpage>1009</fpage><lpage>1021</lpage><pub-id pub-id-type="doi">10.1517/13543784.16.7.1009</pub-id><pub-id pub-id-type="pmid">17594186</pub-id></element-citation></ref><ref id="B41-molecules-29-03453"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Z.</given-names></name></person-group><article-title>Functionalization of Platinum Complexes for Biomedical Applications</article-title><source>Acc. Chem. Res.</source><year>2015</year><volume>48</volume><fpage>2622</fpage><lpage>2631</lpage><pub-id pub-id-type="doi">10.1021/acs.accounts.5b00203</pub-id><pub-id pub-id-type="pmid">26247558</pub-id></element-citation></ref><ref id="B42-molecules-29-03453"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vivero-Escoto</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Huxford-Phillips</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>W.</given-names></name></person-group><article-title>Silica-Based Nanoprobes for Biomedical Imaging and Theranostic Applications</article-title><source>Chem. Soc. Rev.</source><year>2012</year><volume>41</volume><fpage>2673</fpage><lpage>2685</lpage><pub-id pub-id-type="doi">10.1039/c2cs15229k</pub-id><pub-id pub-id-type="pmid">22234515</pub-id><pub-id pub-id-type="pmcid">PMC3777230</pub-id></element-citation></ref><ref id="B43-molecules-29-03453"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Janib</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Moses</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>MacKay</surname><given-names>J.A.</given-names></name></person-group><article-title>Imaging and Drug Delivery Using Theranostic Nanoparticles</article-title><source>Adv. Drug Deliv. Rev.</source><year>2010</year><volume>62</volume><fpage>1052</fpage><lpage>1063</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2010.08.004</pub-id><pub-id pub-id-type="pmid">20709124</pub-id><pub-id pub-id-type="pmcid">PMC3769170</pub-id></element-citation></ref><ref id="B44-molecules-29-03453"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asif</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shahid</surname><given-names>S.</given-names></name></person-group><article-title>Emerging Trends in Nano-Theranostics: Platinum-Based Drug Delivery Systems for Cancer Treatment</article-title><source>Glob. Drug Des. Dev. Rev.</source><year>2022</year><volume>8</volume><fpage>15</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.31703/10.31703/gdddr.2023(VIII-II).03</pub-id></element-citation></ref><ref id="B45-molecules-29-03453"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Workman</surname><given-names>P.</given-names></name><name name-style="western"><surname>Aboagye</surname><given-names>E.O.</given-names></name><name name-style="western"><surname>Balkwill</surname><given-names>F.</given-names></name><name name-style="western"><surname>Balmain</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bruder</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chaplin</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Double</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Everitt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Farningham</surname><given-names>D.A.H.</given-names></name><name name-style="western"><surname>Glennie</surname><given-names>M.J.</given-names></name><etal/></person-group><article-title>Guidelines for the Welfare and Use of Animals in Cancer Research</article-title><source>Br. J. Cancer</source><year>2010</year><volume>102</volume><fpage>1555</fpage><lpage>1577</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6605642</pub-id><pub-id pub-id-type="pmid">20502460</pub-id><pub-id pub-id-type="pmcid">PMC2883160</pub-id></element-citation></ref><ref id="B46-molecules-29-03453"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cabral</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nishiyama</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kataoka</surname><given-names>K.</given-names></name></person-group><article-title>Supramolecular Nanodevices: From Design Validation to Theranostic Nanomedicine</article-title><source>Acc. Chem. Res.</source><year>2011</year><volume>44</volume><fpage>999</fpage><lpage>1008</lpage><pub-id pub-id-type="doi">10.1021/ar200094a</pub-id><pub-id pub-id-type="pmid">21755933</pub-id></element-citation></ref><ref id="B47-molecules-29-03453"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>James</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Gambhir</surname><given-names>S.S.</given-names></name></person-group><article-title>A Molecular Imaging Primer: Modalities, Imaging Agents, and Applications</article-title><source>Physiol. Rev.</source><year>2012</year><volume>92</volume><fpage>897</fpage><lpage>965</lpage><pub-id pub-id-type="doi">10.1152/physrev.00049.2010</pub-id><pub-id pub-id-type="pmid">22535898</pub-id></element-citation></ref><ref id="B48-molecules-29-03453"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schouw</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Huisman</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Janssen</surname><given-names>Y.F.</given-names></name><name name-style="western"><surname>Slart</surname><given-names>R.H.J.A.</given-names></name><name name-style="western"><surname>Borra</surname><given-names>R.J.H.</given-names></name><name name-style="western"><surname>Willemsen</surname><given-names>A.T.M.</given-names></name><name name-style="western"><surname>Brouwers</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>van Dijl</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Dierckx</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>van Dam</surname><given-names>G.M.</given-names></name><etal/></person-group><article-title>Targeted Optical Fluorescence Imaging: A Meta-Narrative Review and Future Perspectives</article-title><source>Eur. J. Nucl. Med. Mol. Imaging</source><year>2021</year><volume>48</volume><fpage>4272</fpage><lpage>4292</lpage><pub-id pub-id-type="doi">10.1007/s00259-021-05504-y</pub-id><pub-id pub-id-type="pmid">34633509</pub-id><pub-id pub-id-type="pmcid">PMC8566445</pub-id></element-citation></ref><ref id="B49-molecules-29-03453"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirin</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Ott</surname><given-names>I.</given-names></name><name name-style="western"><surname>Gust</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mier</surname><given-names>W.</given-names></name><name name-style="western"><surname>Weyherm&#252;ller</surname><given-names>T.</given-names></name><name name-style="western"><surname>Metzler&#8211;Nolte</surname><given-names>N.</given-names></name></person-group><article-title>Cellular Uptake Quantification of Metalated Peptide and Peptide Nucleic Acid Bioconjugates by Atomic Absorption Spectroscopy</article-title><source>Angew. Chem. Int. Ed.</source><year>2008</year><volume>47</volume><fpage>955</fpage><lpage>959</lpage><pub-id pub-id-type="doi">10.1002/anie.200703994</pub-id><pub-id pub-id-type="pmid">18092311</pub-id></element-citation></ref><ref id="B50-molecules-29-03453"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Egger</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Rappel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jakupec</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Hartinger</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Heffeter</surname><given-names>P.</given-names></name><name name-style="western"><surname>Keppler</surname><given-names>B.K.</given-names></name></person-group><article-title>Development of an Experimental Protocol for Uptake Studies of Metal Compounds in Adherent Tumor Cells</article-title><source>J. Anal. At. Spectrom.</source><year>2009</year><volume>24</volume><fpage>51</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1039/B810481F</pub-id><pub-id pub-id-type="pmid">22723721</pub-id><pub-id pub-id-type="pmcid">PMC3378211</pub-id></element-citation></ref><ref id="B51-molecules-29-03453"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hambley</surname><given-names>T.W.</given-names></name></person-group><article-title>The Influence of Structure on the Activity and Toxicity of Pt Anti-Cancer Drugs</article-title><source>Coord. Chem. Rev.</source><year>1997</year><volume>166</volume><fpage>181</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1016/S0010-8545(97)00023-4</pub-id></element-citation></ref><ref id="B52-molecules-29-03453"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Safaei</surname><given-names>R.</given-names></name><name name-style="western"><surname>Katano</surname><given-names>K.</given-names></name><name name-style="western"><surname>Larson</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Samimi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Holzer</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Naerdemann</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tomioka</surname><given-names>M.</given-names></name><name name-style="western"><surname>Goodman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Howell</surname><given-names>S.B.</given-names></name></person-group><article-title>Intracellular Localization and Trafficking of Fluorescein-Labeled Cisplatin in Human Ovarian Carcinoma Cells</article-title><source>Clin. Cancer Res.</source><year>2005</year><volume>11</volume><fpage>756</fpage><lpage>767</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.756.11.2</pub-id><pub-id pub-id-type="pmid">15701866</pub-id></element-citation></ref><ref id="B53-molecules-29-03453"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Molenaar</surname><given-names>C.</given-names></name><name name-style="western"><surname>Teuben</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Heetebrij</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Tanke</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Reedijk</surname><given-names>J.</given-names></name></person-group><article-title>New Insights in the Cellular Processing of Platinum Antitumor Compounds, Using Fluorophore-Labeled Platinum Complexes and Digital Fluorescence Microscopy</article-title><source>J. Biol. Inorg. Chem.</source><year>2000</year><volume>5</volume><fpage>655</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1007/s007750000153</pub-id><pub-id pub-id-type="pmid">11085656</pub-id></element-citation></ref><ref id="B54-molecules-29-03453"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>X.J.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K.G.</given-names></name><name name-style="western"><surname>Wincovitch</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Garfield</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Gottesman</surname><given-names>M.M.</given-names></name></person-group><article-title>Trafficking and Localization of Platinum Complexes in Cisplatin-Resistant Cell Lines Monitored by Fluorescence-Labeled Platinum</article-title><source>J. Cell. Physiol.</source><year>2005</year><volume>202</volume><fpage>635</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.1002/jcp.20253</pub-id><pub-id pub-id-type="pmid">15546142</pub-id></element-citation></ref><ref id="B55-molecules-29-03453"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jagodinsky</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Sulima</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Poprawski</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Blackman</surname><given-names>B.N.</given-names></name><name name-style="western"><surname>Lloyd</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Swenson</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Gottesman</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>M.D.</given-names></name></person-group><article-title>Evaluation of Fluorophore-Tethered Platinum Complexes to Monitor the Fate of Cisplatin Analogs</article-title><source>J. Biol. Inorg. Chem.</source><year>2015</year><volume>20</volume><fpage>1081</fpage><lpage>1095</lpage><pub-id pub-id-type="doi">10.1007/s00775-015-1290-2</pub-id><pub-id pub-id-type="pmid">26323351</pub-id><pub-id pub-id-type="pmcid">PMC5035150</pub-id></element-citation></ref><ref id="B56-molecules-29-03453"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>T.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jing</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Z.</given-names></name></person-group><article-title>Mitochondria-Localized Fluorescent BODIPY-Platinum Conjugate</article-title><source>ACS Med. Chem. Lett.</source><year>2015</year><volume>6</volume><fpage>430</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1021/acsmedchemlett.5b00041</pub-id><pub-id pub-id-type="pmid">25941554</pub-id><pub-id pub-id-type="pmcid">PMC4416427</pub-id></element-citation></ref><ref id="B57-molecules-29-03453"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Askevold</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Kohler</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Weissleder</surname><given-names>R.</given-names></name></person-group><article-title>Platinum Compounds for High-Resolution In Vivo Cancer Imaging</article-title><source>ChemMedChem</source><year>2014</year><volume>9</volume><fpage>1131</fpage><lpage>1135</lpage><pub-id pub-id-type="doi">10.1002/cmdc.201300502</pub-id><pub-id pub-id-type="pmid">24504646</pub-id><pub-id pub-id-type="pmcid">PMC4037345</pub-id></element-citation></ref><ref id="B58-molecules-29-03453"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wexselblatt</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yavin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>D.</given-names></name></person-group><article-title>Cellular Interactions of Platinum Drugs</article-title><source>Inorganica Chim. Acta</source><year>2012</year><volume>393</volume><fpage>75</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/j.ica.2012.07.013</pub-id></element-citation></ref><ref id="B59-molecules-29-03453"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>B.D.W.</given-names></name><name name-style="western"><surname>Dawson</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Charles</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Hambley</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>New</surname><given-names>E.J.</given-names></name></person-group><article-title>Fluorescent Sensing of Monofunctional Platinum Species</article-title><source>Chem. Comm.</source><year>2015</year><volume>51</volume><fpage>6312</fpage><lpage>6314</lpage><pub-id pub-id-type="doi">10.1039/C4CC08077G</pub-id><pub-id pub-id-type="pmid">25760940</pub-id></element-citation></ref><ref id="B60-molecules-29-03453"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kolanowski</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Dawson</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Graziotto</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Filipek</surname><given-names>W.K.</given-names></name><name name-style="western"><surname>Hambley</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>New</surname><given-names>E.J.</given-names></name></person-group><article-title>A Fluorescent Probe for Investigating Metabolic Stability of Active Transplatin Analogues</article-title><source>Sens. Actuators B Chem.</source><year>2018</year><volume>255</volume><fpage>2721</fpage><lpage>2724</lpage><pub-id pub-id-type="doi">10.1016/j.snb.2017.09.084</pub-id></element-citation></ref><ref id="B61-molecules-29-03453"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ong</surname><given-names>J.X.</given-names></name><name name-style="western"><surname>Yap</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Yap</surname><given-names>S.Q.</given-names></name><name name-style="western"><surname>Ang</surname><given-names>W.H.</given-names></name></person-group><article-title>Structure-Activity Relationship Studies on Rhodamine B-Based Fluorogenic Probes and Their Activation by Anticancer Platinum(II) Compounds</article-title><source>J. Inorg. Biochem.</source><year>2015</year><volume>153</volume><fpage>272</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1016/j.jinorgbio.2015.10.002</pub-id><pub-id pub-id-type="pmid">26518138</pub-id></element-citation></ref><ref id="B62-molecules-29-03453"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montagner</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yap</surname><given-names>S.Q.</given-names></name><name name-style="western"><surname>Ang</surname><given-names>W.H.</given-names></name></person-group><article-title>A Fluorescent Probe for Investigating the Activation of Anticancer Platinum(IV) Prodrugs Based on the Cisplatin Scaffold</article-title><source>Angew. Chem.</source><year>2013</year><volume>125</volume><fpage>12001</fpage><lpage>12005</lpage><pub-id pub-id-type="doi">10.1002/ange.201305734</pub-id><pub-id pub-id-type="pmid">24105908</pub-id></element-citation></ref><ref id="B63-molecules-29-03453"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ong</surname><given-names>J.X.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>C.S.Q.</given-names></name><name name-style="western"><surname>Le</surname><given-names>H.V.</given-names></name><name name-style="western"><surname>Ang</surname><given-names>W.H.</given-names></name></person-group><article-title>A Ratiometric Fluorescent Probe for Cisplatin: Investigating the Intracellular Reduction of Platinum(IV) Prodrug Complexes</article-title><source>Angew. Chem. Int. Ed.</source><year>2019</year><volume>58</volume><fpage>164</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1002/anie.201810361</pub-id><pub-id pub-id-type="pmid">30407697</pub-id></element-citation></ref><ref id="B64-molecules-29-03453"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ong</surname><given-names>J.X.</given-names></name><name name-style="western"><surname>Ang</surname><given-names>W.H.</given-names></name></person-group><article-title>Development of a Pre-Assembled Through-Bond Energy Transfer (TBET) Fluorescent Probe for Ratiometric Sensing of Anticancer Platinum(Ll) Complexes</article-title><source>Chem. Asian J.</source><year>2020</year><volume>15</volume><fpage>1449</fpage><lpage>1455</lpage><pub-id pub-id-type="doi">10.1002/asia.202000157</pub-id><pub-id pub-id-type="pmid">32144847</pub-id></element-citation></ref><ref id="B65-molecules-29-03453"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>G.</given-names></name></person-group><article-title>Using a High Quantum Yield Fluorescent Probe with Two-Photon Excitation to Detect Cisplatin in Biological Systems</article-title><source>ACS Sens.</source><year>2021</year><volume>6</volume><fpage>1400</fpage><lpage>1406</lpage><pub-id pub-id-type="doi">10.1021/acssensors.1c00161</pub-id><pub-id pub-id-type="pmid">33656320</pub-id></element-citation></ref><ref id="B66-molecules-29-03453"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Suntharalingam</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yeung</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Royzen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lippard</surname><given-names>S.J.</given-names></name></person-group><article-title>Synthesis and Characterization of Pt(Iv) Fluorescein Conjugates to Investigate Pt(Iv) Intracellular Transformations</article-title><source>Bioconjug. Chem.</source><year>2013</year><volume>24</volume><fpage>1733</fpage><lpage>1740</lpage><pub-id pub-id-type="doi">10.1021/bc400281a</pub-id><pub-id pub-id-type="pmid">23957697</pub-id><pub-id pub-id-type="pmcid">PMC3800427</pub-id></element-citation></ref><ref id="B67-molecules-29-03453"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>F.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F.</given-names></name></person-group><article-title>Beyond 1000 Nm Emission Wavelength: Recent Advances in Organic and Inorganic Emitters for Deep-Tissue Molecular Imaging</article-title><source>Adv. Healthc. Mater.</source><year>2019</year><volume>8</volume><fpage>1900260</fpage><pub-id pub-id-type="doi">10.1002/adhm.201900260</pub-id><pub-id pub-id-type="pmid">30983165</pub-id></element-citation></ref><ref id="B68-molecules-29-03453"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>G.</given-names></name><name name-style="western"><surname>Antaris</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>H.</given-names></name></person-group><article-title>Near-Infrared Fluorophores for Biomedical Imaging</article-title><source>Nat. Biomed. Eng.</source><year>2017</year><volume>1</volume><elocation-id>10</elocation-id><pub-id pub-id-type="doi">10.1038/s41551-016-0010</pub-id></element-citation></ref><ref id="B69-molecules-29-03453"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name></person-group><article-title>Regulating the Optical Properties of Gold Nanoclusters for Biological Applications</article-title><source>ACS Omega</source><year>2020</year><volume>5</volume><fpage>22702</fpage><lpage>22707</lpage><pub-id pub-id-type="doi">10.1021/acsomega.0c03218</pub-id><pub-id pub-id-type="pmid">32954117</pub-id><pub-id pub-id-type="pmcid">PMC7495455</pub-id></element-citation></ref><ref id="B70-molecules-29-03453"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>F.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Cisplatin Prodrug-Conjugated Gold Nanocluster for Fluorescence Imaging and Targeted Therapy of the Breast Cancer</article-title><source>Theranostics</source><year>2016</year><volume>6</volume><fpage>679</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.7150/thno.14556</pub-id><pub-id pub-id-type="pmid">27022415</pub-id><pub-id pub-id-type="pmcid">PMC4805662</pub-id></element-citation></ref><ref id="B71-molecules-29-03453"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Illuminating Platinum Transportation While Maximizing Therapeutic Efficacy by Gold Nanoclusters via Simultaneous Near-Infrared-I/II Imaging and Glutathione Scavenging</article-title><source>ACS Nano</source><year>2020</year><volume>14</volume><fpage>13536</fpage><lpage>13547</lpage><pub-id pub-id-type="doi">10.1021/acsnano.0c05541</pub-id><pub-id pub-id-type="pmid">32924505</pub-id></element-citation></ref><ref id="B72-molecules-29-03453"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Pu</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name></person-group><article-title>Conjugated Polyelectrolyte-Cisplatin Complex Nanoparticles for Simultaneous in Vivo Imaging and Drug Tracking</article-title><source>Nanoscale</source><year>2011</year><volume>3</volume><fpage>1997</fpage><lpage>2002</lpage><pub-id pub-id-type="doi">10.1039/c0nr00950d</pub-id><pub-id pub-id-type="pmid">21442097</pub-id></element-citation></ref><ref id="B73-molecules-29-03453"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saha</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Stang</surname><given-names>P.J.</given-names></name></person-group><article-title>Photophysical Properties of Organoplatinum(II) Compounds and Derived Self-Assembled Metallacycles and Metallacages: Fluorescence and Its Applications</article-title><source>Acc. Chem. Res.</source><year>2016</year><volume>49</volume><fpage>2527</fpage><lpage>2539</lpage><pub-id pub-id-type="doi">10.1021/acs.accounts.6b00416</pub-id><pub-id pub-id-type="pmid">27736060</pub-id></element-citation></ref><ref id="B74-molecules-29-03453"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Rhomboidal Pt(II) Metallacycle-Based NIR-II Theranostic Nanoprobe for Tumor Diagnosis and Image-Guided Therapy</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2019</year><volume>116</volume><fpage>1968</fpage><lpage>1973</lpage><pub-id pub-id-type="doi">10.1073/pnas.1817021116</pub-id><pub-id pub-id-type="pmid">30670648</pub-id><pub-id pub-id-type="pmcid">PMC6369813</pub-id></element-citation></ref><ref id="B75-molecules-29-03453"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Han</surname><given-names>W.</given-names></name></person-group><article-title>A Novel Multimodal NIR-II Nanoprobe for the Detection of Metastatic Lymph Nodes and Targeting Chemo-Photothermal Therapy in Oral Squamous Cell Carcinoma</article-title><source>Theranostics</source><year>2019</year><volume>9</volume><fpage>391</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.7150/thno.30268</pub-id><pub-id pub-id-type="pmid">30809282</pub-id><pub-id pub-id-type="pmcid">PMC6376191</pub-id></element-citation></ref><ref id="B76-molecules-29-03453"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Z.</given-names></name></person-group><article-title>Near Infrared BODIPY-Platinum Conjugates for Imaging, Photodynamic Therapy and Chemotherapy</article-title><source>Dye. Pigm.</source><year>2017</year><volume>141</volume><fpage>5</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.dyepig.2017.01.075</pub-id></element-citation></ref><ref id="B77-molecules-29-03453"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xing</surname><given-names>X.</given-names></name><name name-style="western"><surname>Pang</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Song</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lan</surname><given-names>M.</given-names></name></person-group><article-title>Cisplatin-Appended BODIPY for near Infrared II Fluorescent and Photoacoustic Imaging-Guided Synergistic Phototherapy and Chemotherapy of Cancer</article-title><source>Chin. Chem. Lett.</source><year>2024</year><volume>35</volume><fpage>108467</fpage><pub-id pub-id-type="doi">10.1016/j.cclet.2023.108467</pub-id></element-citation></ref><ref id="B78-molecules-29-03453"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Isaac</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Sabaraya</surname><given-names>I.V.</given-names></name><name name-style="western"><surname>Ghousifam</surname><given-names>N.</given-names></name><name name-style="western"><surname>Das</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pekkanen</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Romanovicz</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Long</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Saleh</surname><given-names>N.B.</given-names></name><name name-style="western"><surname>Rylander</surname><given-names>M.N.</given-names></name></person-group><article-title>Functionalization of Single-Walled Carbon Nanohorns for Simultaneous Fluorescence Imaging and Cisplatin Delivery In Vitro</article-title><source>Carbon</source><year>2018</year><volume>138</volume><fpage>309</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1016/j.carbon.2018.06.020</pub-id></element-citation></ref><ref id="B79-molecules-29-03453"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nasrollahi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Koh</surname><given-names>Y.R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Varshosaz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Khodadadi</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>S.</given-names></name></person-group><article-title>Targeting Graphene Quantum Dots to Epidermal Growth Factor Receptor for Delivery of Cisplatin and Cellular Imaging</article-title><source>Mater. Sci. Eng. C</source><year>2019</year><volume>94</volume><fpage>247</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1016/j.msec.2018.09.020</pub-id><pub-id pub-id-type="pmid">30423706</pub-id></element-citation></ref><ref id="B80-molecules-29-03453"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name></person-group><article-title>Magnetic-Induced Graphene Quantum Dots for Imaging-Guided Photothermal Therapy in the Second near-Infrared Window</article-title><source>Biomaterials</source><year>2020</year><volume>232</volume><elocation-id>119700</elocation-id><pub-id pub-id-type="doi">10.1016/j.biomaterials.2019.119700</pub-id><pub-id pub-id-type="pmid">31881379</pub-id></element-citation></ref><ref id="B81-molecules-29-03453"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>M.</given-names></name></person-group><article-title>Recent Advances in Second Near-Infrared Region (NIR-II) Fluorophores and Biomedical Applications</article-title><source>Front. Chem.</source><year>2021</year><volume>9</volume><elocation-id>750404</elocation-id><pub-id pub-id-type="doi">10.3389/fchem.2021.750404</pub-id><pub-id pub-id-type="pmid">34733821</pub-id><pub-id pub-id-type="pmcid">PMC8558517</pub-id></element-citation></ref><ref id="B82-molecules-29-03453"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gong</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.H.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.B.</given-names></name></person-group><article-title>Activatable NIR-II Fluorescent Probes Applied in Biomedicine: Progress and Perspectives</article-title><source>ChemMedChem</source><year>2021</year><volume>16</volume><fpage>2426</fpage><lpage>2440</lpage><pub-id pub-id-type="doi">10.1002/cmdc.202100142</pub-id><pub-id pub-id-type="pmid">33780139</pub-id></element-citation></ref><ref id="B83-molecules-29-03453"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cri&#537;an</surname><given-names>G.</given-names></name><name name-style="western"><surname>Moldovean-cioroianu</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Timaru</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Andrie&#537;</surname><given-names>G.</given-names></name><name name-style="western"><surname>C&#259;inap</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chi&#537;</surname><given-names>V.</given-names></name></person-group><article-title>Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>5023</elocation-id><pub-id pub-id-type="doi">10.3390/ijms23095023</pub-id><pub-id pub-id-type="pmid">35563414</pub-id><pub-id pub-id-type="pmcid">PMC9103893</pub-id></element-citation></ref><ref id="B84-molecules-29-03453"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahmim</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zaidi</surname><given-names>H.</given-names></name></person-group><article-title>PET versus SPECT: Strengths, Limitations and Challenges</article-title><source>Nucl. Med. Commun.</source><year>2008</year><volume>29</volume><fpage>193</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1097/MNM.0b013e3282f3a515</pub-id><pub-id pub-id-type="pmid">18349789</pub-id></element-citation></ref><ref id="B85-molecules-29-03453"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawai</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yukihiro</surname><given-names>N.</given-names></name></person-group><article-title>Synthesis of Platinum-195m Radiolabelled Cis-Diammine(l,l-Cyclobutanedicarboxylato) Platinum(L1) of High Radionuclidic Purity</article-title><source>J. Label. Compd. Radiopharm.</source><year>1995</year><volume>36</volume><fpage>65</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1002/jlcr.2580360108</pub-id></element-citation></ref><ref id="B86-molecules-29-03453"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anand</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>W.</given-names></name></person-group><article-title>A New, Semi-Automated System for the Micro-Scale Synthesis of [195mPt]Cisplatin Suitable for Clinical Studies</article-title><source>Int. J. Rad. Appl. Instr. A</source><year>1992</year><volume>43</volume><fpage>809</fpage><lpage>814</lpage><pub-id pub-id-type="doi">10.1016/0883-2889(92)90247-C</pub-id><pub-id pub-id-type="pmid">1319424</pub-id></element-citation></ref><ref id="B87-molecules-29-03453"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bodnar</surname><given-names>E.N.</given-names></name><name name-style="western"><surname>Dikiy</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Medvedeva</surname><given-names>E.P.</given-names></name></person-group><article-title>Photonuclear Production and Antitumor Effect of Radioactive Cisplatin (195mPt)</article-title><source>J. Radioanal. Nucl. Chem.</source><year>2015</year><volume>305</volume><fpage>133</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1007/s10967-015-4053-1</pub-id></element-citation></ref><ref id="B88-molecules-29-03453"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dowell</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Sancho</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Anand</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>W.</given-names></name></person-group><article-title>Noninvasive Measurements for Studying the Tumoral Pharmacokinetics of Platinum Anticancer Drugs in Solid Tumors</article-title><source>Adv. Drug Deliv. Rev.</source><year>2000</year><volume>41</volume><fpage>111</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1016/S0169-409X(99)00059-9</pub-id><pub-id pub-id-type="pmid">10699308</pub-id></element-citation></ref><ref id="B89-molecules-29-03453"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sathekge</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wagener</surname><given-names>J.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>Soni</surname><given-names>N.</given-names></name><name name-style="western"><surname>Marjanovic-Painter</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zinn</surname><given-names>C.</given-names></name><name name-style="western"><surname>Van de Wiele</surname><given-names>C.</given-names></name><name name-style="western"><surname>D&#8217;Asseler</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Perkins</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zeevaart</surname><given-names>J.R.</given-names></name></person-group><article-title>Biodistribution and Dosimetry of 195mPt-Cisplatin in Normal Volunteers. Imaging Agent for Single Photon Emission Computed Tomography</article-title><source>Nucl. Med.</source><year>2013</year><volume>52</volume><fpage>222</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.3413/Nukmed-0599-13-06</pub-id><pub-id pub-id-type="pmid">24108524</pub-id></element-citation></ref><ref id="B90-molecules-29-03453"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aalbersberg</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>de Wit van der Veen</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Zwaagstra</surname><given-names>O.</given-names></name><name name-style="western"><surname>van der Schilden</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Vegt</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>W.V.</given-names></name></person-group><article-title>Preclinical Imaging Characteristics and Quantification of Platinum-195m SPECT</article-title><source>Eur. J. Nucl. Med. Mol. Imaging</source><year>2017</year><volume>44</volume><fpage>1347</fpage><lpage>1354</lpage><pub-id pub-id-type="doi">10.1007/s00259-017-3643-2</pub-id><pub-id pub-id-type="pmid">28190123</pub-id></element-citation></ref><ref id="B91-molecules-29-03453"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Howell</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Kassis</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>James Adelstein</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>D.V.</given-names></name><name name-style="western"><surname>Wright</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Hamm</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Turner</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Sastry</surname><given-names>K.S.R.</given-names></name></person-group><article-title>Radiotoxicity of Platinum-195m-Labeled Trans-Platinum (II) in Mammalian Cells</article-title><source>Radiat. Res.</source><year>1994</year><volume>140</volume><fpage>55</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.2307/3578568</pub-id><pub-id pub-id-type="pmid">7938455</pub-id><pub-id pub-id-type="pmcid">PMC9319989</pub-id></element-citation></ref><ref id="B92-molecules-29-03453"><label>92.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Aalbersberg</surname><given-names>E.A.</given-names></name></person-group><source>Imaging Biomarker Development and Optimization of 195mPT-Cisplatin and 68Ga-DOTATATE</source><publisher-name>University of Utrecht</publisher-name><publisher-loc>Utrecht, The Netherlands</publisher-loc><year>2019</year></element-citation></ref><ref id="B93-molecules-29-03453"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nadar</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Farbod</surname><given-names>K.</given-names></name><name name-style="western"><surname>van der Schilden</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Schlatt</surname><given-names>L.</given-names></name><name name-style="western"><surname>Crone</surname><given-names>B.</given-names></name><name name-style="western"><surname>Asokan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Curci</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brand</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bornhaeuser</surname><given-names>M.</given-names></name><name name-style="western"><surname>Iafisco</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Targeting of Radioactive Platinum-Bisphosphonate Anticancer Drugs to Bone of High Metabolic Activity</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><fpage>5889</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-62039-2</pub-id><pub-id pub-id-type="pmid">32246003</pub-id><pub-id pub-id-type="pmcid">PMC7125202</pub-id></element-citation></ref><ref id="B94-molecules-29-03453"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nadar</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Franssen</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Van Dijk</surname><given-names>N.W.M.</given-names></name><name name-style="western"><surname>van der Schilden</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>de Weijert</surname><given-names>M.</given-names></name><name name-style="western"><surname>Oosterwijk</surname><given-names>E.</given-names></name><name name-style="western"><surname>Iafisco</surname><given-names>M.</given-names></name><name name-style="western"><surname>Margiotta</surname><given-names>N.</given-names></name><name name-style="western"><surname>Heskamp</surname><given-names>S.</given-names></name><name name-style="western"><surname>van den Beucken</surname><given-names>J.J.J.P.</given-names></name><etal/></person-group><article-title>Bone Tumor-Targeted Delivery of Theranostic 195mPt-Bisphosphonate Complexes Promotes Killing of Metastatic Tumor Cells</article-title><source>Mater. Today Bio</source><year>2021</year><volume>9</volume><elocation-id>100088</elocation-id><pub-id pub-id-type="doi">10.1016/j.mtbio.2020.100088</pub-id><pub-id pub-id-type="pmcid">PMC7809194</pub-id><pub-id pub-id-type="pmid">33490949</pub-id></element-citation></ref><ref id="B95-molecules-29-03453"><label>95.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Areberg</surname><given-names>J.</given-names></name></person-group><source>Studies of Radioactive Cisplatin (<sup>191</sup>Pt) for Tumour Imaging and Therapy</source><publisher-name>Lund University</publisher-name><publisher-loc>Malmo, Sweden</publisher-loc><year>2000</year></element-citation></ref><ref id="B96-molecules-29-03453"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Areberg</surname><given-names>J.</given-names></name><name name-style="western"><surname>Norrgren</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ren Mattsson</surname><given-names>S.</given-names></name></person-group><article-title>Absorbed Doses to Patients from 191 Pt-, 193m Pt-and 195m Pt-Cisplatin</article-title><source>Appl. Radiat. Isot.</source><year>1999</year><volume>51</volume><fpage>581</fpage><lpage>586</lpage><pub-id pub-id-type="doi">10.1016/S0969-8043(99)00082-2</pub-id><pub-id pub-id-type="pmid">10464923</pub-id></element-citation></ref><ref id="B97-molecules-29-03453"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Norrgren</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sj&#246;lin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bj&#246;rkman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Areberg</surname><given-names>J.</given-names></name><name name-style="western"><surname>Johnsson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Johansson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mattsson</surname><given-names>S.</given-names></name></person-group><article-title>Comparative Renal, Hepatic, and Bone Marrow Toxicity of Cisplatin and Radioactive Cisplatin (191 Pt) in Wistar Rats</article-title><source>Cancer Biother. Radiopharm.</source><year>2006</year><volume>21</volume><fpage>528</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1089/cbr.2006.21.528</pub-id><pub-id pub-id-type="pmid">17105425</pub-id></element-citation></ref><ref id="B98-molecules-29-03453"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Areberg</surname><given-names>J.</given-names></name><name name-style="western"><surname>Johnsson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wennerberg</surname><given-names>J.</given-names></name></person-group><article-title>In Vitro Toxicity of (191)Pt-Labeled Cisplatin to a Human Cervical Carcinoma Cell Line (ME-180)</article-title><source>Int. J. Radiat. Oncol. Biol. Phys.</source><year>2000</year><volume>46</volume><fpage>1275</fpage><lpage>1280</lpage><pub-id pub-id-type="doi">10.1016/S0360-3016(99)00543-X</pub-id><pub-id pub-id-type="pmid">10725641</pub-id></element-citation></ref><ref id="B99-molecules-29-03453"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Areberg</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wennerberg</surname><given-names>J.</given-names></name><name name-style="western"><surname>Johnsson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Norrgren</surname><given-names>K.</given-names></name><name name-style="western"><surname>S&#246;ren Mattsson</surname><given-names>S.</given-names></name></person-group><article-title>Antitumor Effect of Radioactive Cisplatin (191Pt) on Nude Mice</article-title><source>Int. J. Radiat. Oncol. Biol. Phys.</source><year>2001</year><volume>49</volume><fpage>827</fpage><lpage>832</lpage><pub-id pub-id-type="doi">10.1016/S0360-3016(00)01419-X</pub-id><pub-id pub-id-type="pmid">11172966</pub-id></element-citation></ref><ref id="B100-molecules-29-03453"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vaidya</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Gadre</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kamisetti</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Patra</surname><given-names>M.</given-names></name></person-group><article-title>Challenges and Opportunities in the Development of Metal-Based Anticancer Theranostic Agents</article-title><source>Biosci. Rep.</source><year>2022</year><volume>42</volume><elocation-id>BSR20212160</elocation-id><pub-id pub-id-type="doi">10.1042/BSR20212160</pub-id><pub-id pub-id-type="pmid">35420649</pub-id><pub-id pub-id-type="pmcid">PMC9109461</pub-id></element-citation></ref><ref id="B101-molecules-29-03453"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holschbach</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hamkens</surname><given-names>W.</given-names></name><name name-style="western"><surname>Steinbach</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hamacher</surname><given-names>K.</given-names></name><name name-style="western"><surname>Stocklin</surname><given-names>G.</given-names></name></person-group><article-title>[13N]Cisplatin: A Fast and Efficient On-Line Synthesis Using a Solid State Support</article-title><source>Appl. Radial. Isot.</source><year>1997</year><volume>48</volume><fpage>739</fpage><lpage>744</lpage><pub-id pub-id-type="doi">10.1016/S0969-8043(96)00323-5</pub-id></element-citation></ref><ref id="B102-molecules-29-03453"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Spiegeleer</surname><given-names>B.</given-names></name><name name-style="western"><surname>Slegers</surname><given-names>G.</given-names></name><name name-style="western"><surname>Vandecasteele</surname><given-names>C.</given-names></name><name name-style="western"><surname>Van den Bossche</surname><given-names>W.</given-names></name><name name-style="western"><surname>Schelstraete</surname><given-names>K.</given-names></name><name name-style="western"><surname>Claeys</surname><given-names>A.</given-names></name><name name-style="western"><surname>De Moerloose</surname><given-names>P.</given-names></name></person-group><article-title>Microscale Synthesis of Nitrogen-13-Labeled Cisplatin</article-title><source>J. Nucl. Med.</source><year>1986</year><volume>27</volume><fpage>399</fpage><lpage>403</lpage><pub-id pub-id-type="pmid">3712059</pub-id></element-citation></ref><ref id="B103-molecules-29-03453"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ginos</surname><given-names>J.Z.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>A.J.L.</given-names></name><name name-style="western"><surname>Dhawan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>J.C.K.</given-names></name><name name-style="western"><surname>Strother</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Alcock</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rottenberg</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Rottenberg</surname><given-names>D.A.</given-names></name></person-group><article-title>[13N]Cisplatin PET to Assess Pharmacokinetics of Intra-ArterialVersus Intravenous Chemotherapy for Malignant Brain Tumors</article-title><source>J. Nucl. Med.</source><year>1987</year><volume>28</volume><fpage>1844</fpage><lpage>1852</lpage><pub-id pub-id-type="pmid">3500286</pub-id></element-citation></ref><ref id="B104-molecules-29-03453"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lamichhane</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dewkar</surname><given-names>G.K.</given-names></name><name name-style="western"><surname>Sundaresan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jose</surname><given-names>P.</given-names></name><name name-style="western"><surname>Otabashi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Morelle</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Farrell</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zweit</surname><given-names>J.</given-names></name></person-group><article-title>18F-Labeled Carboplatin Derivative for PET Imaging of Platinum Drug Distribution</article-title><source>J. Nucl. Med.</source><year>2017</year><volume>58</volume><fpage>1997</fpage><lpage>2003</lpage><pub-id pub-id-type="doi">10.2967/jnumed.117.191965</pub-id><pub-id pub-id-type="pmid">28729428</pub-id></element-citation></ref><ref id="B105-molecules-29-03453"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pike</surname><given-names>V.W.</given-names></name></person-group><article-title>Chemistry with [18F]Fluoride Ion</article-title><source>Eur. J. Org. Chem.</source><year>2008</year><volume>2008</volume><fpage>2853</fpage><lpage>2873</lpage><pub-id pub-id-type="doi">10.1002/ejoc.200800114</pub-id></element-citation></ref><ref id="B106-molecules-29-03453"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holland</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>J.S.</given-names></name></person-group><article-title>Unconventional Nuclides for Radiopharmaceuticals</article-title><source>Mol. Imaging</source><year>2010</year><volume>9</volume><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.2310/7290.2010.00008</pub-id><pub-id pub-id-type="pmid">20128994</pub-id><pub-id pub-id-type="pmcid">PMC4962336</pub-id></element-citation></ref><ref id="B107-molecules-29-03453"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lamichhane</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dewkar</surname><given-names>G.K.</given-names></name><name name-style="western"><surname>Sundaresan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mahon</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Zweit</surname><given-names>J.</given-names></name></person-group><article-title>[18F]-Fluorinated Carboplatin and [111in]-Liposome for Image-Guided Drug Delivery</article-title><source>Int. J. Mol. Sci.</source><year>2017</year><volume>18</volume><elocation-id>1079</elocation-id><pub-id pub-id-type="doi">10.3390/ijms18051079</pub-id><pub-id pub-id-type="pmid">28524076</pub-id><pub-id pub-id-type="pmcid">PMC5454988</pub-id></element-citation></ref><ref id="B108-molecules-29-03453"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cosialls</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sim&#243;</surname><given-names>C.</given-names></name><name name-style="western"><surname>Borr&#243;s</surname><given-names>S.</given-names></name><name name-style="western"><surname>G&#243;mez-Vallejo</surname><given-names>V.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>C.</given-names></name><name name-style="western"><surname>Llop</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cuenca</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Casini</surname><given-names>A.</given-names></name></person-group><article-title>PET Imaging of Self-Assembled 18F-Labelled Pd2L4 Metallacages for Anticancer Drug Delivery</article-title><source>Chem. Eur. J.</source><year>2023</year><volume>29</volume><fpage>e202202604</fpage><pub-id pub-id-type="doi">10.1002/chem.202202604</pub-id><pub-id pub-id-type="pmid">36239701</pub-id><pub-id pub-id-type="pmcid">PMC10168593</pub-id></element-citation></ref><ref id="B109-molecules-29-03453"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>C.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>C.</given-names></name></person-group><article-title>Biomedical Applications of Multinuclear Pt(II)/Ru(II)/Ir(III) Metallo-Supramolecular Assemblies for Intensive Cancer Therapy</article-title><source>Coord. Chem. Rev.</source><year>2023</year><volume>495</volume><fpage>215366</fpage><pub-id pub-id-type="doi">10.1016/j.ccr.2023.215366</pub-id></element-citation></ref><ref id="B110-molecules-29-03453"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khosravifarsani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ait-Mohand</surname><given-names>S.</given-names></name><name name-style="western"><surname>Paquette</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sanche</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gu&#233;rin</surname><given-names>B.</given-names></name></person-group><article-title>High Cytotoxic Effect by Combining Copper-64 with a NOTA-Terpyridine Platinum Conjugate</article-title><source>J. Med. Chem.</source><year>2021</year><volume>64</volume><fpage>6765</fpage><lpage>6776</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.1c00039</pub-id><pub-id pub-id-type="pmid">33909440</pub-id></element-citation></ref><ref id="B111-molecules-29-03453"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khosravifarsani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ait-Mohand</surname><given-names>S.</given-names></name><name name-style="western"><surname>Paquette</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sanche</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gu&#233;rin</surname><given-names>B.</given-names></name></person-group><article-title>Design, Synthesis, and Cytotoxicity Assessment of [64cu]Cu-Nota-Terpyridine Platinum Conjugate: A Novel Chemoradiotherapeutic Agent with Flexible Linker</article-title><source>Nanomaterials</source><year>2021</year><volume>11</volume><elocation-id>2154</elocation-id><pub-id pub-id-type="doi">10.3390/nano11092154</pub-id><pub-id pub-id-type="pmid">34578470</pub-id><pub-id pub-id-type="pmcid">PMC8469169</pub-id></element-citation></ref><ref id="B112-molecules-29-03453"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gutfilen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mendes</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gu&#233;rin</surname><given-names>B.</given-names></name></person-group><article-title>In Vivo Behaviour of [64Cu]NOTA-Terpyridine Platinum, a Novel Chemo-Radio-Theranostic Agent for Imaging, and Theraphy of Colorectal Cancer</article-title><source>Front. Med.</source><year>2022</year><volume>9</volume><elocation-id>975213</elocation-id><pub-id pub-id-type="doi">10.3389/fmed.2022.975213</pub-id><pub-id pub-id-type="pmcid">PMC9549809</pub-id><pub-id pub-id-type="pmid">36226156</pub-id></element-citation></ref><ref id="B113-molecules-29-03453"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Majid</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fruhwirth</surname><given-names>G.O.</given-names></name><name name-style="western"><surname>Vilar</surname><given-names>R.</given-names></name></person-group><article-title>Radiolabelling Pt-Based Quadruplex DNA Binders via Click Chemistry</article-title><source>Bioorg. Med. Chem.</source><year>2022</year><volume>76</volume><elocation-id>117097</elocation-id><pub-id pub-id-type="doi">10.1016/j.bmc.2022.117097</pub-id><pub-id pub-id-type="pmid">36417789</pub-id></element-citation></ref><ref id="B114-molecules-29-03453"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Imberti</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lok</surname><given-names>J.</given-names></name><name name-style="western"><surname>Coverdale</surname><given-names>J.P.C.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>O.W.L.</given-names></name><name name-style="western"><surname>Fry</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Postings</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Firth</surname><given-names>G.</given-names></name><name name-style="western"><surname>Blower</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Sadler</surname><given-names>P.J.</given-names></name></person-group><article-title>Radiometal-Labeled Photoactivatable Pt(IV) Anticancer Complex for Theranostic Phototherapy</article-title><source>Inorg. Chem.</source><year>2023</year><volume>62</volume><fpage>20745</fpage><lpage>20753</lpage><pub-id pub-id-type="doi">10.1021/acs.inorgchem.3c02245</pub-id><pub-id pub-id-type="pmid">37643591</pub-id><pub-id pub-id-type="pmcid">PMC10731635</pub-id></element-citation></ref><ref id="B115-molecules-29-03453"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weissleder</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pittet</surname><given-names>M.J.</given-names></name></person-group><article-title>Imaging in the Era of Molecular Oncology</article-title><source>Nature</source><year>2008</year><volume>452</volume><fpage>580</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1038/nature06917</pub-id><pub-id pub-id-type="pmid">18385732</pub-id><pub-id pub-id-type="pmcid">PMC2708079</pub-id></element-citation></ref><ref id="B116-molecules-29-03453"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ara</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Katti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Shireen</surname><given-names>A.</given-names></name></person-group><article-title>Magnetic Resonance Imaging (MRI)&#8212;A Review</article-title><source>Int. J. Clin. Dent.</source><year>2011</year><volume>3</volume><fpage>65</fpage><lpage>70</lpage></element-citation></ref><ref id="B117-molecules-29-03453"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verwilst</surname><given-names>P.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.S.</given-names></name></person-group><article-title>Recent Advances in Gd-Chelate Based Bimodal Optical/MRI Contrast Agents</article-title><source>Chem. Soc. Rev.</source><year>2015</year><volume>44</volume><fpage>1791</fpage><lpage>1806</lpage><pub-id pub-id-type="doi">10.1039/C4CS00336E</pub-id><pub-id pub-id-type="pmid">25622561</pub-id></element-citation></ref><ref id="B118-molecules-29-03453"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cabral</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nishiyama</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kataoka</surname><given-names>K.</given-names></name></person-group><article-title>Optimization of (1,2-Diamino-Cyclohexane)Platinum(II)-Loaded Polymeric Micelles Directed to Improved Tumor Targeting and Enhanced Antitumor Activity</article-title><source>J. Control. Release</source><year>2007</year><volume>121</volume><fpage>146</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2007.05.024</pub-id><pub-id pub-id-type="pmid">17628162</pub-id></element-citation></ref><ref id="B119-molecules-29-03453"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wahsner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gale</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Rodr&#237;guez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Caravan</surname><given-names>P.</given-names></name></person-group><article-title>Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers</article-title><source>Chem. Rev.</source><year>2019</year><volume>119</volume><fpage>957</fpage><lpage>1057</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.8b00363</pub-id><pub-id pub-id-type="pmid">30350585</pub-id><pub-id pub-id-type="pmcid">PMC6516866</pub-id></element-citation></ref><ref id="B120-molecules-29-03453"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lohrke</surname><given-names>J.</given-names></name><name name-style="western"><surname>Frenzel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Endrikat</surname><given-names>J.</given-names></name><name name-style="western"><surname>Alves</surname><given-names>F.C.</given-names></name><name name-style="western"><surname>Grist</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Law</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Leiner</surname><given-names>T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Nikolaou</surname><given-names>K.</given-names></name><etal/></person-group><article-title>25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future Perspectives</article-title><source>Adv. Ther.</source><year>2016</year><volume>33</volume><fpage>1</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1007/s12325-015-0275-4</pub-id><pub-id pub-id-type="pmid">26809251</pub-id><pub-id pub-id-type="pmcid">PMC4735235</pub-id></element-citation></ref><ref id="B121-molecules-29-03453"><label>121.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>Medical Imaging Drugs Advisory Committee Meeting</collab></person-group><article-title>Gadolinium Retention after Gadolinium Based Contrast Magnetic Resonance Imaging in Patients with Normal Renal Function Briefing Document</article-title><year>2017</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/media/107133/download" ext-link-type="uri">https://www.fda.gov/media/107133/download</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-04-25">(accessed on 25 April 2024)</date-in-citation></element-citation></ref><ref id="B122-molecules-29-03453"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Nair</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Mcmurry</surname><given-names>T.J.</given-names></name></person-group><article-title>Gadolinium Meets Medicinal Chemistry: MRI Contrast Agent Development</article-title><source>Curr. Med. Chem.</source><year>2005</year><volume>12</volume><fpage>751</fpage><lpage>778</lpage><pub-id pub-id-type="doi">10.2174/0929867053507379</pub-id><pub-id pub-id-type="pmid">15853710</pub-id></element-citation></ref><ref id="B123-molecules-29-03453"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>William</surname><given-names>W.N.</given-names></name><name name-style="western"><surname>Zinner</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Karp</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>Y.W.</given-names></name><name name-style="western"><surname>Glisson</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Phan</surname><given-names>S.-C.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>D.J.</given-names></name></person-group><article-title>Phase I Trial of Motexafin Gadolinium in Combination with Docetaxel and Cisplatin for the Treatment of Non-Small Cell Lung Cancer</article-title><source>J. Thorac. Oncol.</source><year>2007</year><volume>2</volume><fpage>745</fpage><lpage>750</lpage><pub-id pub-id-type="doi">10.1097/JTO.0b013e31811f4719</pub-id><pub-id pub-id-type="pmid">17762342</pub-id></element-citation></ref><ref id="B124-molecules-29-03453"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brugger</surname><given-names>R.M.</given-names></name></person-group><article-title>Gadolinium as Xda Neutron Capture Therapy Agent</article-title><source>Med. Phys.</source><year>1992</year><volume>19</volume><fpage>733</fpage><lpage>744</lpage><pub-id pub-id-type="doi">10.1118/1.596817</pub-id><pub-id pub-id-type="pmid">1508113</pub-id></element-citation></ref><ref id="B125-molecules-29-03453"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salt</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lennox</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Takagaki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maguire</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Hosmane</surname><given-names>N.S.</given-names></name></person-group><article-title>Boron and Gadolinium Neutron Capture Therapy</article-title><source>Russ. Chem. Bull.</source><year>2004</year><volume>53</volume><fpage>1871</fpage><lpage>1888</lpage><pub-id pub-id-type="doi">10.1007/s11172-005-0045-6</pub-id></element-citation></ref><ref id="B126-molecules-29-03453"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name></person-group><article-title>DOTA Functionalized Cross-Linked Small-Molecule Micelles for Theranostics Combining Magnetic Resonance Imaging and Chemotherapy</article-title><source>Bioconjug. Chem.</source><year>2018</year><volume>29</volume><fpage>3402</fpage><lpage>3410</lpage><pub-id pub-id-type="doi">10.1021/acs.bioconjchem.8b00565</pub-id><pub-id pub-id-type="pmid">30200761</pub-id></element-citation></ref><ref id="B127-molecules-29-03453"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaida</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cabral</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kumagai</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kishimura</surname><given-names>A.</given-names></name><name name-style="western"><surname>Terada</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sekino</surname><given-names>M.</given-names></name><name name-style="western"><surname>Aoki</surname><given-names>I.</given-names></name><name name-style="western"><surname>Nishiyama</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tani</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kataoka</surname><given-names>K.</given-names></name></person-group><article-title>Visible Drug Delivery by Supramolecular Nanocarriers Directing to Single-Platformed Diagnosis and Therapy of Pancreatic Tumor Model</article-title><source>Cancer Res.</source><year>2010</year><volume>70</volume><fpage>7031</fpage><lpage>7041</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-0303</pub-id><pub-id pub-id-type="pmid">20685894</pub-id></element-citation></ref><ref id="B128-molecules-29-03453"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Z.</given-names></name></person-group><article-title>A Platinum Anticancer Theranostic Agent with Magnetic Targeting Potential Derived from Maghemite Nanoparticles</article-title><source>Chem. Sci.</source><year>2013</year><volume>4</volume><fpage>2605</fpage><lpage>2612</lpage><pub-id pub-id-type="doi">10.1039/c3sc50554e</pub-id></element-citation></ref><ref id="B129-molecules-29-03453"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rammohan</surname><given-names>N.</given-names></name><name name-style="western"><surname>MacRenaris</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Parigi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mastarone</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Manus</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Lilley</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Preslar</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Waters</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Filicko</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Nanodiamond-Gadolinium(III) Aggregates for Tracking Cancer Growth in Vivo at High Field</article-title><source>Nano Lett.</source><year>2016</year><volume>16</volume><fpage>7551</fpage><lpage>7564</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.6b03378</pub-id><pub-id pub-id-type="pmid">27960515</pub-id><pub-id pub-id-type="pmcid">PMC5482002</pub-id></element-citation></ref><ref id="B130-molecules-29-03453"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robertson</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Rendina</surname><given-names>L.M.</given-names></name></person-group><article-title>Gadolinium Theranostics for the Diagnosis and Treatment of Cancer</article-title><source>Chem. Soc. Rev.</source><year>2021</year><volume>50</volume><fpage>4231</fpage><lpage>4244</lpage><pub-id pub-id-type="doi">10.1039/D0CS01075H</pub-id><pub-id pub-id-type="pmid">33599224</pub-id></element-citation></ref><ref id="B131-molecules-29-03453"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crossley</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Aitken</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Vogt</surname><given-names>S.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Rendina</surname><given-names>L.M.</given-names></name></person-group><article-title>Selective Aggregation of a Platinum-Gadolinium Complex within a Tumor-Cell Nucleus</article-title><source>Angew. Chem. Int. Ed.</source><year>2010</year><volume>49</volume><fpage>1231</fpage><lpage>1233</lpage><pub-id pub-id-type="doi">10.1002/anie.200902309</pub-id><pub-id pub-id-type="pmid">20077549</pub-id></element-citation></ref><ref id="B132-molecules-29-03453"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fenton</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Busse</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rendina</surname><given-names>L.M.</given-names></name></person-group><article-title>Synthesis and DNA-Binding Studies of a Dinuclear Gadolinium(Iii)-Platinum(Ii) Complex</article-title><source>Aust. J. Chem.</source><year>2015</year><volume>68</volume><fpage>576</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1071/CH14572</pub-id></element-citation></ref><ref id="B133-molecules-29-03453"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name><name name-style="western"><surname>Aime</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sadler</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Z.</given-names></name></person-group><article-title>Platinum(II)-Gadolinium(III) Complexes as Potential Single-Molecular Theranostic Agents for Cancer Treatment</article-title><source>Angew. Chem. Int. Ed.</source><year>2014</year><volume>53</volume><fpage>13225</fpage><lpage>13228</lpage><pub-id pub-id-type="doi">10.1002/anie.201407406</pub-id><pub-id pub-id-type="pmid">25255766</pub-id></element-citation></ref><ref id="B134-molecules-29-03453"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenthal</surname><given-names>D.I.</given-names></name><name name-style="western"><surname>Nurenberg</surname><given-names>P.</given-names></name><name name-style="western"><surname>Becerra</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Frenkel</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Carbone</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Lum</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>R.</given-names></name><name name-style="western"><surname>Engel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Young</surname><given-names>S.</given-names></name><name name-style="western"><surname>Miles</surname><given-names>D.</given-names></name><etal/></person-group><article-title>A Phase I Single-Dose Trial of Gadolinium Texaphyrin (Gd-Tex), a Tumor Selective Radiation Sensitizer Detectable by Magnetic Resonance Imaging</article-title><source>Clin. Cancer Res.</source><year>1999</year><volume>5</volume><fpage>739</fpage><lpage>745</lpage><pub-id pub-id-type="pmid">10213207</pub-id></element-citation></ref><ref id="B135-molecules-29-03453"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pica</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rosenthal</surname><given-names>D.I.</given-names></name><name name-style="western"><surname>Koprowski</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schea</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ruckle</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tishler</surname><given-names>R.</given-names></name><name name-style="western"><surname>Larner</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Arwood</surname><given-names>D.</given-names></name><name name-style="western"><surname>Haie-Meder</surname><given-names>C.</given-names></name><name name-style="western"><surname>Young</surname><given-names>S.</given-names></name><etal/></person-group><article-title>A Phase Multi-Dose Trial of Gadolinium-Texaphyrin (Gd-Tex) as a Radiosensitizer in Patients with Brain Metastases Treated with Conventional Radiation Therapy: Preliminary Results</article-title><source>Int. J. Radiat. Oncol. Biol. Phys.</source><year>1997</year><volume>39</volume><elocation-id>270</elocation-id><pub-id pub-id-type="doi">10.1016/S0360-3016(97)80828-0</pub-id></element-citation></ref><ref id="B136-molecules-29-03453"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Woodburn</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Renschler</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Sessler</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Koutcher</surname><given-names>J.A.</given-names></name></person-group><article-title>In Vivo Animal Studies with Gadolinium (III) Texaphyrin as a Radiation Enhancer</article-title><source>Int. J. Radiat. Oncol. Biol. Phys.</source><year>1999</year><volume>45</volume><fpage>981</fpage><lpage>989</lpage><pub-id pub-id-type="doi">10.1016/S0360-3016(99)00274-6</pub-id><pub-id pub-id-type="pmid">10571206</pub-id></element-citation></ref><ref id="B137-molecules-29-03453"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mody</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Sessler</surname><given-names>J.L.</given-names></name></person-group><article-title>Texaphyrins: A New Approach to Drug Development</article-title><source>J. Porphyr. Phthalocyanines</source><year>2001</year><volume>5</volume><fpage>134</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1002/jpp.326</pub-id></element-citation></ref><ref id="B138-molecules-29-03453"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Magda</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gerasimchuk</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W.</given-names></name><name name-style="western"><surname>Anzenbacher</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sessler</surname><given-names>J.L.</given-names></name></person-group><article-title>Synthesis of Texaphyrin Conjugates</article-title><source>Pure Appl. Chem.</source><year>2004</year><volume>76</volume><fpage>365</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1351/pac200476020365</pub-id></element-citation></ref><ref id="B139-molecules-29-03453"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arambula</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Sessler</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Fountain</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W.</given-names></name><name name-style="western"><surname>Magda</surname><given-names>D.</given-names></name><name name-style="western"><surname>Siddik</surname><given-names>Z.H.</given-names></name></person-group><article-title>Gadolinium Texaphyrin (Gd-Tex)-Malonato-Platinum Conjugates: Synthesis Comparison with Carboplatin in Normal and Pt-Resistant Cell Lines</article-title><source>Dalton Trans.</source><year>2009</year><volume>48</volume><fpage>10834</fpage><lpage>10840</lpage><pub-id pub-id-type="doi">10.1039/b912089k</pub-id><pub-id pub-id-type="pmid">20023913</pub-id><pub-id pub-id-type="pmcid">PMC2862451</pub-id></element-citation></ref><ref id="B140-molecules-29-03453"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arambula</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Sessler</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Siddik</surname><given-names>Z.H.</given-names></name></person-group><article-title>Overcoming Biochemical Pharmacologic Mechanisms of Platinum Resistance with a Texaphyrin-Platinum Conjugate</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2011</year><volume>21</volume><fpage>1701</fpage><lpage>1705</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2011.01.092</pub-id><pub-id pub-id-type="pmid">21345675</pub-id><pub-id pub-id-type="pmcid">PMC3463136</pub-id></element-citation></ref><ref id="B141-molecules-29-03453"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arambula</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Sessler</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Siddik</surname><given-names>Z.H.</given-names></name></person-group><article-title>A Texaphyrin-Oxaliplatin Conjugate That Overcomes Both Pharmacologic and Molecular Mechanisms of Cisplatin Resistance in Cancer Cells</article-title><source>Medchemcomm</source><year>2012</year><volume>3</volume><fpage>1275</fpage><lpage>1281</lpage><pub-id pub-id-type="doi">10.1039/c2md20206a</pub-id><pub-id pub-id-type="pmid">23936624</pub-id><pub-id pub-id-type="pmcid">PMC3737007</pub-id></element-citation></ref><ref id="B142-molecules-29-03453"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thiabaud</surname><given-names>G.</given-names></name><name name-style="western"><surname>Arambula</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Siddik</surname><given-names>Z.H.</given-names></name><name name-style="western"><surname>Sessler</surname><given-names>J.L.</given-names></name></person-group><article-title>Photoinduced Reduction of Pt(IV) within an Anti-Proliferative Pt(IV)-Texaphyrin Conjugate</article-title><source>Chemistry</source><year>2014</year><volume>20</volume><fpage>8942</fpage><lpage>8947</lpage><pub-id pub-id-type="doi">10.1002/chem.201403094</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/chem.201403094</pub-id><pub-id pub-id-type="pmid">24961491</pub-id><pub-id pub-id-type="pmcid">PMC4241752</pub-id></element-citation></ref><ref id="B143-molecules-29-03453"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thiabaud</surname><given-names>G.</given-names></name><name name-style="western"><surname>He</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shelton</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Baze</surname><given-names>W.B.</given-names></name><name name-style="western"><surname>Segura</surname><given-names>L.</given-names></name><name name-style="western"><surname>Alaniz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Munoz Macias</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lyness</surname><given-names>G.</given-names></name><name name-style="western"><surname>Watts</surname><given-names>A.B.</given-names></name><etal/></person-group><article-title>Oxaliplatin Pt(IV) Prodrugs Conjugated to Gadolinium-Texaphyrin as Potential Antitumor Agents</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2020</year><volume>117</volume><fpage>7021</fpage><lpage>7029</lpage><pub-id pub-id-type="doi">10.1073/pnas.1914911117</pub-id><pub-id pub-id-type="pmid">32179677</pub-id><pub-id pub-id-type="pmcid">PMC7132275</pub-id></element-citation></ref><ref id="B144-molecules-29-03453"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thiabaud</surname><given-names>G.</given-names></name><name name-style="western"><surname>McCall</surname><given-names>R.</given-names></name><name name-style="western"><surname>He</surname><given-names>G.</given-names></name><name name-style="western"><surname>Arambula</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Siddik</surname><given-names>Z.H.</given-names></name><name name-style="western"><surname>Sessler</surname><given-names>J.L.</given-names></name></person-group><article-title>Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator</article-title><source>Angew. Chem. Int. Ed.</source><year>2016</year><volume>128</volume><fpage>12816</fpage><lpage>12821</lpage><pub-id pub-id-type="doi">10.1002/ange.201604236</pub-id><pub-id pub-id-type="pmcid">PMC5039070</pub-id><pub-id pub-id-type="pmid">27377046</pub-id></element-citation></ref><ref id="B145-molecules-29-03453"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adams</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Meade</surname><given-names>T.J.</given-names></name></person-group><article-title>Gd(III)-Pt(IV) Theranostic Contrast Agents for Tandem MR Imaging and Chemotherapy</article-title><source>Chem. Sci.</source><year>2020</year><volume>11</volume><fpage>2524</fpage><lpage>2530</lpage><pub-id pub-id-type="doi">10.1039/C9SC05937G</pub-id><pub-id pub-id-type="pmid">34084418</pub-id><pub-id pub-id-type="pmcid">PMC8157322</pub-id></element-citation></ref><ref id="B146-molecules-29-03453"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adams</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Meade</surname><given-names>T.J.</given-names></name></person-group><article-title>Towards Imaging Pt Chemoresistance Using Gd(III)-Pt(II) Theranostic MR Contrast Agents</article-title><source>ChemMedChem</source><year>2021</year><volume>16</volume><fpage>3663</fpage><lpage>3671</lpage><pub-id pub-id-type="doi">10.1002/cmdc.202100389</pub-id><pub-id pub-id-type="pmid">34355523</pub-id><pub-id pub-id-type="pmcid">PMC8678168</pub-id></element-citation></ref><ref id="B147-molecules-29-03453"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dadwal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Baldi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Narang</surname><given-names>R.K.</given-names></name></person-group><article-title>Nanoparticles as Carriers for Drug Delivery in Cancer</article-title><source>Artif. Cells Nanomed. Biotechnol.</source><year>2018</year><volume>46</volume><fpage>295</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1080/21691401.2018.1457039</pub-id><pub-id pub-id-type="pmid">30043651</pub-id></element-citation></ref><ref id="B148-molecules-29-03453"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Jong</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Borm</surname><given-names>P.J.A.</given-names></name></person-group><article-title>Drug Delivery and Nanoparticles: Applications and Hazards</article-title><source>Int. J. Nanomed.</source><year>2008</year><volume>3</volume><fpage>133</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.2147/IJN.S596</pub-id><pub-id pub-id-type="pmid">18686775</pub-id><pub-id pub-id-type="pmcid">PMC2527668</pub-id></element-citation></ref><ref id="B149-molecules-29-03453"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maeda</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Matsumura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hori</surname><given-names>K.</given-names></name></person-group><article-title>Tumor Vascular Permeability and the EPR Effect in Macromolecular Therapeutics: A Review</article-title><source>J. Control. Release</source><year>2000</year><volume>65</volume><fpage>271</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1016/S0168-3659(99)00248-5</pub-id><pub-id pub-id-type="pmid">10699287</pub-id></element-citation></ref><ref id="B150-molecules-29-03453"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsumura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kataoka</surname><given-names>K.</given-names></name></person-group><article-title>Preclinical and Clinical Studies of Anticancer Agent-Incorporating Polymer Micelles</article-title><source>Cancer Sci.</source><year>2009</year><volume>100</volume><fpage>572</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.2009.01103.x</pub-id><pub-id pub-id-type="pmid">19462526</pub-id><pub-id pub-id-type="pmcid">PMC11158079</pub-id></element-citation></ref><ref id="B151-molecules-29-03453"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalyane</surname><given-names>D.</given-names></name><name name-style="western"><surname>Raval</surname><given-names>N.</given-names></name><name name-style="western"><surname>Maheshwari</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tambe</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kalia</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tekade</surname><given-names>R.K.</given-names></name></person-group><article-title>Employment of Enhanced Permeability and Retention Effect (EPR): Nanoparticle-Based Precision Tools for Targeting of Therapeutic and Diagnostic Agent in Cancer</article-title><source>Mater. Sci. Eng. C</source><year>2019</year><volume>98</volume><fpage>1252</fpage><lpage>1276</lpage><pub-id pub-id-type="doi">10.1016/j.msec.2019.01.066</pub-id><pub-id pub-id-type="pmid">30813007</pub-id></element-citation></ref><ref id="B152-molecules-29-03453"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ganesan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name></person-group><article-title>Targeting Engineered Nanoparticles for Breast Cancer Therapy</article-title><source>Pharmaceutics</source><year>2021</year><volume>13</volume><elocation-id>1829</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics13111829</pub-id><pub-id pub-id-type="pmid">34834243</pub-id><pub-id pub-id-type="pmcid">PMC8623926</pub-id></element-citation></ref><ref id="B153-molecules-29-03453"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Navya</surname><given-names>P.N.</given-names></name><name name-style="western"><surname>Kaphle</surname><given-names>A.</given-names></name><name name-style="western"><surname>Srinivas</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Bhargava</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Rotello</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Daima</surname><given-names>H.K.</given-names></name></person-group><article-title>Current Trends and Challenges in Cancer Management and Therapy Using Designer Nanomaterials</article-title><source>Nano Converg.</source><year>2019</year><volume>6</volume><fpage>23</fpage><pub-id pub-id-type="doi">10.1186/s40580-019-0193-2</pub-id><pub-id pub-id-type="pmid">31304563</pub-id><pub-id pub-id-type="pmcid">PMC6626766</pub-id></element-citation></ref><ref id="B154-molecules-29-03453"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumari</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>B.</given-names></name><name name-style="western"><surname>Biswas</surname><given-names>S.</given-names></name></person-group><article-title>Nanocarriers for Cancer-Targeted Drug Delivery</article-title><source>J. Drug Target.</source><year>2016</year><volume>24</volume><fpage>179</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.3109/1061186X.2015.1051049</pub-id><pub-id pub-id-type="pmid">26061298</pub-id></element-citation></ref><ref id="B155-molecules-29-03453"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Bardhan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Stanton-Maxey</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Badve</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nakshatri</surname><given-names>H.</given-names></name><name name-style="western"><surname>Stantz</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>N.</given-names></name><name name-style="western"><surname>Halas</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Clare</surname><given-names>S.E.</given-names></name></person-group><article-title>Delivery of Nanoparticles to Brain Metastases of Breast Cancer Using a Cellular Trojan Horse</article-title><source>Cancer Nanotechnol.</source><year>2012</year><volume>3</volume><fpage>47</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1007/s12645-012-0029-9</pub-id><pub-id pub-id-type="pmid">23205151</pub-id><pub-id pub-id-type="pmcid">PMC3505533</pub-id></element-citation></ref><ref id="B156-molecules-29-03453"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Y.</given-names></name></person-group><article-title>Gold Nanoparticles Enhance Cisplatin Delivery and Potentiate Chemotherapy by Decompressing Colorectal Cancer Vessels</article-title><source>Int. J. Nanomed.</source><year>2018</year><volume>13</volume><fpage>6207</fpage><lpage>6221</lpage><pub-id pub-id-type="doi">10.2147/IJN.S176928</pub-id><pub-id pub-id-type="pmcid">PMC6188185</pub-id><pub-id pub-id-type="pmid">30349245</pub-id></element-citation></ref><ref id="B157-molecules-29-03453"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Varache</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bezverkhyy</surname><given-names>I.</given-names></name><name name-style="western"><surname>Weber</surname><given-names>G.</given-names></name><name name-style="western"><surname>Saviot</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chassagnon</surname><given-names>R.</given-names></name><name name-style="western"><surname>Baras</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bouyer</surname><given-names>F.</given-names></name></person-group><article-title>Loading of Cisplatin into Mesoporous Silica Nanoparticles: Effect of Surface Functionalization</article-title><source>Langmuir</source><year>2019</year><volume>35</volume><fpage>8984</fpage><lpage>8995</lpage><pub-id pub-id-type="doi">10.1021/acs.langmuir.9b00954</pub-id><pub-id pub-id-type="pmid">31244247</pub-id></element-citation></ref><ref id="B158-molecules-29-03453"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cabral</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nishiyama</surname><given-names>N.</given-names></name><name name-style="western"><surname>Okazaki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Koyama</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kataoka</surname><given-names>K.</given-names></name></person-group><article-title>Preparation and Biological Properties of Dichloro (1,2-Diaminocyclohexane) Platinum(II) (DACHPt)-Loaded Polymeric Micelles</article-title><source>J. Control. Release</source><year>2005</year><volume>101</volume><fpage>223</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2004.08.022</pub-id><pub-id pub-id-type="pmid">15588907</pub-id></element-citation></ref><ref id="B159-molecules-29-03453"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jokerst</surname><given-names>J.V.</given-names></name><name name-style="western"><surname>Lobovkina</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zare</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Gambhir</surname><given-names>S.S.</given-names></name></person-group><article-title>Nanoparticle PEGylation for Imaging and Therapy</article-title><source>Nanomedicine</source><year>2011</year><volume>6</volume><fpage>715</fpage><lpage>728</lpage><pub-id pub-id-type="doi">10.2217/nnm.11.19</pub-id><pub-id pub-id-type="pmid">21718180</pub-id><pub-id pub-id-type="pmcid">PMC3217316</pub-id></element-citation></ref><ref id="B160-molecules-29-03453"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCarthy</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Weissleder</surname><given-names>R.</given-names></name></person-group><article-title>Multifunctional Magnetic Nanoparticles for Targeted Imaging and Therapy</article-title><source>Adv. Drug Deliv. Rev.</source><year>2008</year><volume>60</volume><fpage>1241</fpage><lpage>1251</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2008.03.014</pub-id><pub-id pub-id-type="pmid">18508157</pub-id><pub-id pub-id-type="pmcid">PMC2583936</pub-id></element-citation></ref><ref id="B161-molecules-29-03453"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kato</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hamaguchi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yasui</surname><given-names>H.</given-names></name><name name-style="western"><surname>Okusaka</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ueno</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shirao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shimada</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nakahama</surname><given-names>H.</given-names></name><name name-style="western"><surname>Muro</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Phase I Study of NK105, a Paclitaxel-Incorporating Micellar Nanoparticle, in Patients with Advanced Cancer</article-title><source>J. Clin. Oncol.</source><year>2006</year><volume>24</volume><fpage>2018</fpage><pub-id pub-id-type="doi">10.1200/jco.2006.24.18_suppl.2018</pub-id><pub-id pub-id-type="pmcid">PMC2360299</pub-id><pub-id pub-id-type="pmid">17595665</pub-id></element-citation></ref><ref id="B162-molecules-29-03453"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Plummer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Adam</surname><given-names>J.</given-names></name><name name-style="western"><surname>Eatock</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Boddy</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>R.</given-names></name><name name-style="western"><surname>Matsumura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Calvert</surname><given-names>H.</given-names></name></person-group><article-title>Phase I and Pharmacokinetic Study of NC-6004, a New Platinum Entity of Cisplatin-Conjugated Polymer Forming Micelles</article-title><source>J. Clin. Oncol.</source><year>2008</year><volume>26</volume><fpage>2573</fpage><pub-id pub-id-type="doi">10.1200/jco.2008.26.15_suppl.2573</pub-id></element-citation></ref><ref id="B163-molecules-29-03453"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anelli</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Lattuada</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lorusso</surname><given-names>V.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tournier</surname><given-names>H.</given-names></name><name name-style="western"><surname>Uggeri</surname><given-names>F.</given-names></name></person-group><article-title>Mixed Micelles Containing Lipophilic Gadolinium Complexes as MRA Contrast Agents</article-title><source>Magn. Reson. Mater. Phys. Biol. Med.</source><year>2001</year><volume>12</volume><fpage>114</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1007/BF02668092</pub-id><pub-id pub-id-type="pmid">11390266</pub-id></element-citation></ref><ref id="B164-molecules-29-03453"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Padmanabhan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Guly&#225;s</surname><given-names>B.Z.</given-names></name></person-group><article-title>Gadolinium(III) Based Nanoparticles for: T1-Weighted Magnetic Resonance Imaging Probes</article-title><source>RSC Adv.</source><year>2016</year><volume>6</volume><fpage>60945</fpage><lpage>60966</lpage><pub-id pub-id-type="doi">10.1039/C6RA07782J</pub-id></element-citation></ref><ref id="B165-molecules-29-03453"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghezzi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pescina</surname><given-names>S.</given-names></name><name name-style="western"><surname>Padula</surname><given-names>C.</given-names></name><name name-style="western"><surname>Santi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Del Favero</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cant&#249;</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nicoli</surname><given-names>S.</given-names></name></person-group><article-title>Polymeric Micelles in Drug Delivery: An Insight of the Techniques for Their Characterization and Assessment in Biorelevant Conditions</article-title><source>J. Control. Release</source><year>2021</year><volume>332</volume><fpage>312</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2021.02.031</pub-id><pub-id pub-id-type="pmid">33652113</pub-id></element-citation></ref><ref id="B166-molecules-29-03453"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nishiyama</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kataoka</surname><given-names>K.</given-names></name></person-group><article-title>Current State, Achievements, and Future Prospects of Polymeric Micelles as Nanocarriers for Drug and Gene Delivery</article-title><source>Pharmacol. Ther.</source><year>2006</year><volume>112</volume><fpage>630</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2006.05.006</pub-id><pub-id pub-id-type="pmid">16815554</pub-id></element-citation></ref><ref id="B167-molecules-29-03453"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vinh</surname><given-names>N.Q.</given-names></name><name name-style="western"><surname>Naka</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cabral</surname><given-names>H.</given-names></name><name name-style="western"><surname>Murayama</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kaida</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kataoka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Morikawa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tani</surname><given-names>T.</given-names></name></person-group><article-title>MRI-Detectable Polymeric Micelles Incorporating Platinum Anticancer Drugs Enhance Survival in an Advanced Hepatocellular Carcinoma Model</article-title><source>Int. J. Nanomed.</source><year>2015</year><volume>10</volume><fpage>4137</fpage><lpage>4147</lpage><pub-id pub-id-type="doi">10.2147/IJN.S81339</pub-id><pub-id pub-id-type="pmcid">PMC4487238</pub-id><pub-id pub-id-type="pmid">26203241</pub-id></element-citation></ref><ref id="B168-molecules-29-03453"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Devaraj</surname><given-names>S.</given-names></name><name name-style="western"><surname>Munichandraiah</surname><given-names>N.</given-names></name></person-group><article-title>Effect of Crystallographic Structure of MnO<sub>2</sub> on Its Electrochemical Capacitance Properties</article-title><source>J. Phys. Chem. C</source><year>2008</year><volume>112</volume><fpage>4406</fpage><lpage>4417</lpage><pub-id pub-id-type="doi">10.1021/jp7108785</pub-id></element-citation></ref><ref id="B169-molecules-29-03453"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>D.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name></person-group><article-title>Manganese Dioxide Nanosheets-Based Redox/PH-Responsive Drug Delivery System for Cancer Theranostic Application</article-title><source>Int. J. Nanomed.</source><year>2016</year><volume>11</volume><fpage>1759</fpage><lpage>1778</lpage><pub-id pub-id-type="doi">10.2147/IJN.S98832</pub-id><pub-id pub-id-type="pmcid">PMC4857809</pub-id><pub-id pub-id-type="pmid">27199556</pub-id></element-citation></ref><ref id="B170-molecules-29-03453"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ba&#241;obre-L&#243;pez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Garc&#237;a-Hevia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cerqueira</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Rivadulla</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gallo</surname><given-names>J.</given-names></name></person-group><article-title>Tunable Performance of Manganese Oxide Nanostructures as MRI Contrast Agents</article-title><source>Chem. Eur. J.</source><year>2018</year><volume>24</volume><fpage>1295</fpage><lpage>1303</lpage><pub-id pub-id-type="doi">10.1002/chem.201704861</pub-id><pub-id pub-id-type="pmid">29178467</pub-id></element-citation></ref><ref id="B171-molecules-29-03453"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brito</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ruggiero</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Price</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>da Costa Silva</surname><given-names>M.</given-names></name><name name-style="western"><surname>Genicio</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Tyurina</surname><given-names>O.</given-names></name><name name-style="western"><surname>Rosecker</surname><given-names>V.</given-names></name><name name-style="western"><surname>Eykyn</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Ba&#241;obre-L&#243;pez</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Redox Double-Switch Cancer Theranostics through Pt(Iv) Functionalised Manganese Dioxide Nanostructures</article-title><source>Nanoscale</source><year>2023</year><volume>15</volume><fpage>10763</fpage><lpage>10775</lpage><pub-id pub-id-type="doi">10.1039/D3NR00076A</pub-id><pub-id pub-id-type="pmid">37325846</pub-id><pub-id pub-id-type="pmcid">PMC10311465</pub-id></element-citation></ref><ref id="B172-molecules-29-03453"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>Y.</given-names></name></person-group><article-title>A Novel Manganese Dioxide-Based Drug Delivery Strategy via in Situ Coating &#947;-Polyglutamic Acid/Cisplatin for Intelligent Anticancer Therapy</article-title><source>J. Mater. Chem. B</source><year>2023</year><volume>11</volume><fpage>667</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1039/D2TB01659A</pub-id><pub-id pub-id-type="pmid">36541339</pub-id></element-citation></ref><ref id="B173-molecules-29-03453"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grllrs</surname><given-names>P.</given-names></name><name name-style="western"><surname>Koenigi</surname><given-names>S.H.</given-names></name></person-group><article-title>Transverse Relaxation of Solvent Protons Induced by Magnetized Spheres: Application to Feffitin, Erythrocytes, and Magnetite</article-title><source>Magn. Reson. Med.</source><year>1987</year><volume>5</volume><fpage>323</fpage><lpage>345</lpage><pub-id pub-id-type="pmid">2824967</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mrm.1910050404</pub-id></element-citation></ref><ref id="B174-molecules-29-03453"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Manganese-Deposited Iron Oxide Promotes Tumor-Responsive Ferroptosis That Synergizes the Apoptosis of Cisplatin</article-title><source>Theranostics</source><year>2021</year><volume>11</volume><fpage>5418</fpage><lpage>5429</lpage><pub-id pub-id-type="doi">10.7150/thno.53346</pub-id><pub-id pub-id-type="pmid">33859755</pub-id><pub-id pub-id-type="pmcid">PMC8039957</pub-id></element-citation></ref><ref id="B175-molecules-29-03453"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Z.</given-names></name></person-group><article-title>Detecting and Delivering Platinum Anticancer Drugs Using Fluorescent Maghemite Nanoparticles</article-title><source>Chem. Commun.</source><year>2013</year><volume>49</volume><fpage>2786</fpage><lpage>2788</lpage><pub-id pub-id-type="doi">10.1039/c3cc39059d</pub-id><pub-id pub-id-type="pmid">23439956</pub-id></element-citation></ref><ref id="B176-molecules-29-03453"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Y.</given-names></name></person-group><article-title>Multifunctional Porous Iron Oxide Nanoagents for MRI and Photothermal/Chemo Synergistic Therapy</article-title><source>Bioconjug. Chem.</source><year>2018</year><volume>29</volume><fpage>1283</fpage><lpage>1290</lpage><pub-id pub-id-type="doi">10.1021/acs.bioconjchem.8b00052</pub-id><pub-id pub-id-type="pmid">29402074</pub-id></element-citation></ref><ref id="B177-molecules-29-03453"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xing</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Z.</given-names></name></person-group><article-title>Superparamagnetic Magnetite Nanocrystal Clusters as Potential Magnetic Carriers for the Delivery of Platinum Anticancer Drugs</article-title><source>J. Mater. Chem.</source><year>2011</year><volume>21</volume><fpage>11142</fpage><lpage>11149</lpage><pub-id pub-id-type="doi">10.1039/c1jm11369k</pub-id></element-citation></ref><ref id="B178-molecules-29-03453"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.M.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name></person-group><article-title>Glutathione Boosting the Cytotoxicity of a Magnetic Platinum(Iv) Nano-Prodrug in Tumor Cells</article-title><source>Chem. Sci.</source><year>2016</year><volume>7</volume><fpage>2864</fpage><lpage>2869</lpage><pub-id pub-id-type="doi">10.1039/C5SC04049C</pub-id><pub-id pub-id-type="pmid">30090279</pub-id><pub-id pub-id-type="pmcid">PMC6054038</pub-id></element-citation></ref><ref id="B179-molecules-29-03453"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mukherjee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Patra</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dash</surname><given-names>T.K.</given-names></name><name name-style="western"><surname>Chakraborty</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bhattacharyya</surname><given-names>R.</given-names></name><name name-style="western"><surname>Senapati</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shunmugam</surname><given-names>R.</given-names></name></person-group><article-title>Design and Synthesis of a Dual Imageable Theranostic Platinum Prodrug for Efficient Cancer Therapy</article-title><source>Polym. Chem.</source><year>2019</year><volume>10</volume><fpage>3066</fpage><lpage>3078</lpage><pub-id pub-id-type="doi">10.1039/C8PY01535J</pub-id></element-citation></ref><ref id="B180-molecules-29-03453"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Harriss</surname><given-names>B.I.</given-names></name><name name-style="western"><surname>Phinikaridou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lacerda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ramniceanu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Doan</surname><given-names>B.T.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Lo</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Botnar</surname><given-names>R.M.</given-names></name><etal/></person-group><article-title>Gadolinium and Platinum in Tandem: Real-Time Multi-Modal Monitoring of Drug Delivery by Mri and Fluorescence Imaging</article-title><source>Nanotheranostics</source><year>2017</year><volume>1</volume><fpage>186</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.7150/ntno.18619</pub-id><pub-id pub-id-type="pmid">29071187</pub-id><pub-id pub-id-type="pmcid">PMC5646715</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="molecules-29-03453-f001" orientation="portrait"><label>Figure 1</label><caption><p>Mechanism of action of cisplatin (created with <uri>BioRender.com</uri>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-29-03453-g001.jpg"/></fig><fig position="float" id="molecules-29-03453-f002" orientation="portrait"><label>Figure 2</label><caption><p>Platinum drugs in clinical use with their respective approval years.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-29-03453-g002.jpg"/></fig><fig position="float" id="molecules-29-03453-f003" orientation="portrait"><label>Figure 3</label><caption><p>Structure of Pt(IV) compounds tetraplatin, iproplatin and satraplatin.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-29-03453-g003.jpg"/></fig><fig position="float" id="molecules-29-03453-f004" orientation="portrait"><label>Figure 4</label><caption><p>Basic principles of optical fluorescence molecular imaging. Following administration of the fluorophore, the subject is illuminated with excitation light (&#955;<sub>1</sub>). This excites the fluorophore, causing it to emit light (&#955;<sub>2</sub>), which is then captured by a CCD camera within IVIS Lumina LT in vivo imaging system, processed, and converted into an image (created with <uri>BioRender.com</uri>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-29-03453-g004.jpg"/></fig><fig position="float" id="molecules-29-03453-f005" orientation="portrait"><label>Figure 5</label><caption><p>Chemical structures of the different fluorophore-cisplatin analogues: FDDP (<bold>1</bold>), CFDA-Pt (<bold>2</bold>), DNP-Pt (<bold>3</bold>), BODIPY-Pt (<bold>4</bold>&#8211;<bold>6</bold>), CP-11 (<bold>7</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-29-03453-g005.jpg"/></fig><fig position="float" id="molecules-29-03453-f006" orientation="portrait"><label>Figure 6</label><caption><p>Chemical structures of different exogeneous fluorescent probes.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-29-03453-g006.jpg"/></fig><fig position="float" id="molecules-29-03453-f007" orientation="portrait"><label>Figure 7</label><caption><p>Chemical structures of the different Pt(IV)-fluorescent scaffolds: Pt(IV) (FITC)<sub>2</sub> (<bold>8</bold>), Pt(IV) FL<sub>2</sub> (<bold>9</bold>), Pt(IV) prodrug-AIE conjugate (<bold>10</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-29-03453-g007.jpg"/></fig><fig position="float" id="molecules-29-03453-f008" orientation="portrait"><label>Figure 8</label><caption><p>Schematic illustration of AuNCs-based theranostic platform. The star symbol corresponds to Pt(IV)-cisplatin based scaffold and the wavy lines to HOOC&#8211;PEG&#8211;FA compound (created with <uri>BioRender.com</uri>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-29-03453-g008.jpg"/></fig><fig position="float" id="molecules-29-03453-f009" orientation="portrait"><label>Figure 9</label><caption><p>Structures of (<bold>a</bold>) Pt(II)metallacycle, (<bold>b</bold>) NIR(II) molecular dye and (<bold>c</bold>) representation of the nanoplatform (created with <uri>BioRender.com</uri>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-29-03453-g009.jpg"/></fig><fig position="float" id="molecules-29-03453-f010" orientation="portrait"><label>Figure 10</label><caption><p>Chemical structures of BODIPY-based NIR imaging probes (<bold>11</bold> and <bold>12</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-29-03453-g010.jpg"/></fig><fig position="float" id="molecules-29-03453-f011" orientation="portrait"><label>Figure 11</label><caption><p>Schematic representation of the basic principles of PET (created with <uri>BioRender.com</uri>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-29-03453-g011.jpg"/></fig><fig position="float" id="molecules-29-03453-f012" orientation="portrait"><label>Figure 12</label><caption><p>Chemical structures of <sup>191</sup>Pt-CDDP (<bold>13</bold>), <sup>195m</sup>Pt-CDDP (CISSPECT<sup>&#174;</sup>), (<bold>14</bold>), <sup>195m</sup>Pt-CP (<bold>15</bold>), <sup>18</sup>F-FCP (<bold>16</bold>) and <sup>13</sup>N-CDDP (<bold>17</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-29-03453-g012.jpg"/></fig><fig position="float" id="molecules-29-03453-f013" orientation="portrait"><label>Figure 13</label><caption><p>Chemical structure of <sup>195m</sup>Pt-biphosphonate (<sup>195m</sup>Pt-BP) compound (<bold>18</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-29-03453-g013.jpg"/></fig><fig position="float" id="molecules-29-03453-f014" orientation="portrait"><label>Figure 14</label><caption><p>Chemical structures of [<sup>64</sup>Cu]Cu-NOTA-TP (<bold>19</bold>), [<sup>64</sup>Cu]Cu-NOTA-C3-TP (<bold>20</bold>), Pt(II)salpen-<sup>111</sup>In (<bold>21</bold>) and Pt-succ-DFO-<sup>68</sup>Ga (<bold>22</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-29-03453-g014.jpg"/></fig><fig position="float" id="molecules-29-03453-f015" orientation="portrait"><label>Figure 15</label><caption><p>Representation of the basic principles of MRI (created with <uri>BioRender.com</uri>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-29-03453-g015.jpg"/></fig><fig position="float" id="molecules-29-03453-f016" orientation="portrait"><label>Figure 16</label><caption><p>Structure of Pt (II)-based Gd-DTPA conjugate (<bold>23</bold>), Pt (II)-based Gd&#8211;DOTA conjugate (<bold>24</bold>) and Pt (II)-based Gd&#8211;DTPA complexes <bold>25</bold> and <bold>26</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-29-03453-g016.jpg"/></fig><fig position="float" id="molecules-29-03453-f017" orientation="portrait"><label>Figure 17</label><caption><p>Structure of Motexafin-Gadolinium MGd and Pt (II)-based Motexafin-Gadolinium conjugates <bold>27</bold> and <bold>28</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-29-03453-g017.jpg"/></fig><fig position="float" id="molecules-29-03453-f018" orientation="portrait"><label>Figure 18</label><caption><p>Structure of Pt (II)-based Texaphyrinmalonate conjugates cisTEX (<bold>29</bold>) and oxaliTEX (<bold>30</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-29-03453-g018.jpg"/></fig><fig position="float" id="molecules-29-03453-f019" orientation="portrait"><label>Figure 19</label><caption><p>Structure of first generation of Pt (II)-based texaphyrinmalonate conjugates <bold>31</bold> and <bold>32</bold> and second generation of Pt (IV)-based texaphyrin <bold>33</bold>&#8211;<bold>36</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-29-03453-g019.jpg"/></fig><fig position="float" id="molecules-29-03453-f020" orientation="portrait"><label>Figure 20</label><caption><p>Structure of Pt (IV)-based Gd (III) conjugates as theranostic agents with Gd(III) MRI contrast agent in axial position of cisplatin <bold>37</bold> and carboplatin <bold>38</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-29-03453-g020.jpg"/></fig><fig position="float" id="molecules-29-03453-f021" orientation="portrait"><label>Figure 21</label><caption><p>Synthetic view of the structure of Gd&#8211;DTPA/DACHPt-loaded micelles and the consequently releasing of Pt and Gd complexes from the micelles (created with <uri>BioRender.com</uri>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-29-03453-g021.jpg"/></fig><fig position="float" id="molecules-29-03453-f022" orientation="portrait"><label>Figure 22</label><caption><p>Schematic procedure of Pt/Gd<sup>3+</sup>-loaded DOTA micelles (created with <uri>BioRender.com</uri>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-29-03453-g022.jpg"/></fig><fig position="float" id="molecules-29-03453-f023" orientation="portrait"><label>Figure 23</label><caption><p>Schematic illustration of preparation of MnO<sub>2</sub>/HA/cDDP nanosheets (created with <uri>BioRender.com</uri>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-29-03453-g023.jpg"/></fig><fig position="float" id="molecules-29-03453-f024" orientation="portrait"><label>Figure 24</label><caption><p>Schematic diagram of the preparation process and controlled drug release of PGA/CDDP@MnO<sub>2</sub> NPs (created with <uri>BioRender.com</uri>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-29-03453-g024.jpg"/></fig><fig position="float" id="molecules-29-03453-f025" orientation="portrait"><label>Figure 25</label><caption><p>Structure of conjugate CMDP&#8211;CMC&#8211;SPMNC magnetic drug carrier (created with <uri>BioRender.com</uri>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-29-03453-g025.jpg"/></fig><fig position="float" id="molecules-29-03453-f026" orientation="portrait"><label>Figure 26</label><caption><p>Scheme of the preparation of magnetic Pt-FMO nanoparticles (created with <uri>BioRender.com</uri>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-29-03453-g026.jpg"/></fig><table-wrap position="float" id="molecules-29-03453-t001" orientation="portrait"><object-id pub-id-type="pii">molecules-29-03453-t001_Table 1</object-id><label>Table 1</label><caption><p>Molecular mechanisms of cisplatin resistance.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Molecular<break/>Mechanism</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Factor (Function)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Preclinical Evidence</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical Evidence</th></tr></thead><tbody><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Pre-target resistance</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reduced<break/>uptake</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CTR1<break/>(plasma membrane copper transporter)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Knockdown of CTR1 reduces cisplatin uptake (80%) in both yeast and mouse embryonic fibroblasts [<xref rid="B15-molecules-29-03453" ref-type="bibr">15</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NSCLC tumors with undetectable CTR1 expression exhibit reduced intratumorally platinum concentration [<xref rid="B5-molecules-29-03453" ref-type="bibr">5</xref>].</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased <break/>efflux</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ATP7A/ATP7B (copper P-type ATPases involved in the regulation of ion homeostasis).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Overexpression of ATP7B in human oral squamous cells resulted in cisplatin resistance [<xref rid="B16-molecules-29-03453" ref-type="bibr">16</xref>].<break/>Human ovarian carcinoma cells with ATP7A overexpression show higher resistance to cisplatin, carboplatin and oxaliplatin [<xref rid="B8-molecules-29-03453" ref-type="bibr">8</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Elevated expression of ATP7A is associated with reduced clinical outcome for patients with ovarian cancer [<xref rid="B7-molecules-29-03453" ref-type="bibr">7</xref>].<break/>High ATP7B expression in ovarian carcinoma correlates with poor clinical outcomes in cisplatin-based chemotherapy-treated patients [<xref rid="B17-molecules-29-03453" ref-type="bibr">17</xref>].</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased <break/>inactivation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GSH/&#947;-GCS/GST</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cisplatin resistant cells often exhibit elevated levels of GSH, &#947;-GCS and GST [<xref rid="B9-molecules-29-03453" ref-type="bibr">9</xref>,<xref rid="B10-molecules-29-03453" ref-type="bibr">10</xref>,<xref rid="B11-molecules-29-03453" ref-type="bibr">11</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No conclusive clinical evidence.</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">On-target resistance</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nucleotide<break/>excision <break/>repair (NER)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ERCC1 <break/>(single-strand <break/>endonuclease)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased ERCC1 expression is associated with cisplatin resistance in human hepatocellular carcinoma and human cervical tumor cell lines [<xref rid="B18-molecules-29-03453" ref-type="bibr">18</xref>,<xref rid="B19-molecules-29-03453" ref-type="bibr">19</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Positive ERCC1 expression and cisplatin clinical resistance in non-small cell lung, ovarian cancer and human hepatocellular carcinoma [<xref rid="B18-molecules-29-03453" ref-type="bibr">18</xref>,<xref rid="B20-molecules-29-03453" ref-type="bibr">20</xref>,<xref rid="B21-molecules-29-03453" ref-type="bibr">21</xref>].</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA mismatch repair (MMR)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MLH1<break/>(protein that initiates DNA repair)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8211;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MLH1 deficiency is correlated with cisplatin resistance in esophageal cancer [<xref rid="B22-molecules-29-03453" ref-type="bibr">22</xref>].<break/>Low MLH1 expression was associated with improved prognosis in ovarian cancer [<xref rid="B23-molecules-29-03453" ref-type="bibr">23</xref>].</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NER, MMR and base <break/>excision <break/>repair</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HMGB1<break/>(protein involved in transcriptional regulation, DNA replication and repair)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Higher HMGB1 expression was associated with higher cisplatin resistance in lung adenocarcinoma cell line [<xref rid="B24-molecules-29-03453" ref-type="bibr">24</xref>].<break/>HMGB1-induced cell autophagy contributes to cisplatin resistance in cervical cancer cells [<xref rid="B25-molecules-29-03453" ref-type="bibr">25</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HMGB1 overexpression significantly promoted cisplatin resistance of NSCLC in vitro and in vivo [<xref rid="B26-molecules-29-03453" ref-type="bibr">26</xref>].<break/>Positive HMGB1 expression is strongly associated with cisplatin resistance in gastric cancer patients [<xref rid="B27-molecules-29-03453" ref-type="bibr">27</xref>].</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Post-target resistance</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8211;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TP53<break/>(tumor-suppressive protein that controls DNA repair and <break/>apoptosis in response to stress).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Full knock-out of TP53 in human testicular cancer-derived embryonal carcinoma cell line resulted in higher cisplatin resistance [<xref rid="B28-molecules-29-03453" ref-type="bibr">28</xref>,<xref rid="B29-molecules-29-03453" ref-type="bibr">29</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NSCLC patients harboring wild-type TP53 are associated with longer survival after cisplatin-based chemotherapy than patients with TP53 mutations [<xref rid="B30-molecules-29-03453" ref-type="bibr">30</xref>].</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Off-target resistance</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Autophagy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8211;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ovarian and lung cancer cells showed cisplatin-induced autophagy [<xref rid="B31-molecules-29-03453" ref-type="bibr">31</xref>,<xref rid="B32-molecules-29-03453" ref-type="bibr">32</xref>,<xref rid="B33-molecules-29-03453" ref-type="bibr">33</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No data reported.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8211;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ERBB2/HER-2<break/>(Oncogenic EGKR-like receptor that is overactivated in different types of cancer).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HER2 protein is overexpressed in cisplatin-resistant gastric cancer cells [<xref rid="B34-molecules-29-03453" ref-type="bibr">34</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High expression of HER2 is correlated with cisplatin resistance in NSCLC patients [<xref rid="B35-molecules-29-03453" ref-type="bibr">35</xref>].</td></tr></tbody></table></table-wrap><table-wrap position="float" id="molecules-29-03453-t002" orientation="portrait"><object-id pub-id-type="pii">molecules-29-03453-t002_Table 2</object-id><label>Table 2</label><caption><p>Example of imaging techniques used in theranostics [<xref rid="B45-molecules-29-03453" ref-type="bibr">45</xref>,<xref rid="B46-molecules-29-03453" ref-type="bibr">46</xref>].</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Imaging Method</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Imaging Time</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Main Purpose</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Benefits</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Limitations</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fluorescence</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sec-Min</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monitoring tumor response to treatment, metastatic spread; imaging gene expression and protein&#8211;protein interaction.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Relativity non-invasive and cheap.<break/>Easy labeling with many <break/>fluorescent molecules<break/>available.<break/>High sensitivity.<break/>No ionizing radiation.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Limited clinical applications.<break/>Potential incompatibility and toxicity of fluorescent probes.<break/>Limited wavelength range (700&#8211;900 nm).<break/>Limited tissue penetration (&#8804;2 cm).</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PET</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Min</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pharmacodynamics, pathophysiology, <break/>pharmacokinetics.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High sensitivity.<break/>Functional imaging is <break/>feasible.<break/>Fully quantitative.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Poor spatial resolution.<break/>Requires use of ionizing radiation. <break/>Limited accessibility.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SPECT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Min</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pharmacodynamics, pathophysiology, <break/>pharmacokinetics</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High sensitivity.<break/>Quantitative.<break/>High versatility.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Requires use of ionizing radiation.<break/>Poor spatial resolution.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MRI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Min-hours</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pharmacodynamics, pathophysiology,<break/>pharmacokinetics, anatomy.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Good spatial resolution.<break/>No ionizing radiation.<break/>Several contrast agents and nanodevices are widely used for clinical imaging.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Poor sensitivity.<break/>Difficult real-time imaging.<break/>High dosage of contrast agent (potential toxicity and accumulation).</td></tr></tbody></table></table-wrap><table-wrap position="float" id="molecules-29-03453-t004" orientation="portrait"><object-id pub-id-type="pii">molecules-29-03453-t004_Table 4</object-id><label>Table 4</label><caption><p>Characteristics of main Pt radionuclides.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Radionuclide</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Half-Life (Days)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Energies (keV)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Decay Mode</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Method of <break/>Production</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1"><sup>191</sup>Pt</td><td align="center" valign="middle" rowspan="1" colspan="1">2.86</td><td align="center" valign="middle" rowspan="1" colspan="1">539</td><td align="center" valign="middle" rowspan="1" colspan="1">EC <sup>1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1"><sup>191</sup>Ir (d,2n)<sup>191</sup>Pt</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><sup>193m</sup>Pt</td><td align="center" valign="middle" rowspan="1" colspan="1">4.33</td><td align="center" valign="middle" rowspan="1" colspan="1">66&#8211;77</td><td align="center" valign="middle" rowspan="1" colspan="1">IT <sup>2</sup> (100%)<break/>Auger electrons.</td><td align="center" valign="middle" rowspan="1" colspan="1"><sup>193</sup>Ir(d,2n)<sup>193m</sup>Pt</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><sup>195m</sup>Pt</td><td align="center" valign="middle" rowspan="1" colspan="1">4.02</td><td align="center" valign="middle" rowspan="1" colspan="1">66&#8211;77, 99, 129</td><td align="center" valign="middle" rowspan="1" colspan="1">IT (100%)<break/>Auger electrons.</td><td align="center" valign="middle" rowspan="1" colspan="1"><sup>194</sup>Pt(n,&#947;)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><sup>197</sup>Pt</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.83</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">77, 191</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#946;<sup>&#8722;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><sup>196</sup>Pt(n,&#947;)</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> EC = electron capture. <sup>2</sup> IT = isomeric transition.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="molecules-29-03453-t005" orientation="portrait"><object-id pub-id-type="pii">molecules-29-03453-t005_Table 5</object-id><label>Table 5</label><caption><p>Selected radionuclides used in PET and SPECT, their production mode and decay properties [<xref rid="B106-molecules-29-03453" ref-type="bibr">106</xref>].</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Radionuclide</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Half-Life</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">E<sub>max</sub> (keV)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Radiation</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Production</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Production<break/>Reaction</th></tr></thead><tbody><tr><td colspan="6" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">PET radionuclides</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><sup>13</sup>N</td><td align="center" valign="middle" rowspan="1" colspan="1">10 min</td><td align="center" valign="middle" rowspan="1" colspan="1">1199</td><td align="center" valign="middle" rowspan="1" colspan="1">&#946;+ (100%)</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyclotron</td><td align="center" valign="middle" rowspan="1" colspan="1"><sup>16</sup>O(p,&#945;)<sup>13</sup>N</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><sup>18</sup>F</td><td align="center" valign="middle" rowspan="1" colspan="1">110 min</td><td align="center" valign="middle" rowspan="1" colspan="1">634</td><td align="center" valign="middle" rowspan="1" colspan="1">&#946;+ (97%)</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyclotron</td><td align="center" valign="middle" rowspan="1" colspan="1"><sup>18</sup>O(p,n)<sup>18</sup>F</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><sup>64</sup>Cu</td><td align="center" valign="middle" rowspan="1" colspan="1">12.8 h</td><td align="center" valign="middle" rowspan="1" colspan="1">656</td><td align="center" valign="middle" rowspan="1" colspan="1">&#946;+ (18%)</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyclotron</td><td align="center" valign="middle" rowspan="1" colspan="1"><sup>64</sup>Ni(p,n)<sup>64</sup>Cu</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><sup>68</sup>Ga</td><td align="center" valign="middle" rowspan="1" colspan="1">67.6 min</td><td align="center" valign="middle" rowspan="1" colspan="1">1900</td><td align="center" valign="middle" rowspan="1" colspan="1">&#946;+ (89%)</td><td align="center" valign="middle" rowspan="1" colspan="1">Generator</td><td align="center" valign="middle" rowspan="1" colspan="1"><sup>68</sup>Ge &#8594; <sup>68</sup>Ga + &#946;<sup>&#8722;</sup></td></tr><tr><td colspan="6" align="center" valign="middle" rowspan="1">SPECT radionuclides</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><sup>99m</sup>Tc</td><td align="center" valign="middle" rowspan="1" colspan="1">6.0 h</td><td align="center" valign="middle" rowspan="1" colspan="1">141</td><td align="center" valign="middle" rowspan="1" colspan="1">&#947;</td><td align="center" valign="middle" rowspan="1" colspan="1">Generator</td><td align="center" valign="middle" rowspan="1" colspan="1"><sup>99</sup>Mo &#8594; <sup>99m</sup>Tc</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><sup>111</sup>In</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67.9 h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">245, 172</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#947;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cyclotron</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><sup>112</sup>Cd (p, 2n)<sup>111</sup>In</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>